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Low-Cost, Commercial Scale Production of Sofosbuvir
Abstract
Recent advances in antiviral therapeutics have produced highly effective small molecule drugs to treat
Hepatitis C, a deadly infection of the liver. Sofosbuvir, a hepatitis C drug developed by Gilead Sciences, is a
breakthrough treatment due to its low side effects and high cure rate. However, the cost of treatment is
extraordinarily high, priced at $84,000 per treatment in the US. In response to backlash regarding the cost
barriers in developing countries, Gilead has reached licensing agreements with generic pharmaceutical
companies to produce the drug for markets in low-income countries such as India, Kenya, and Cuba among
others. The report describes a cost-effective, commercial scale process design for the production of sofosbuvir.
The proposed production facility is designed to deliver 350,000 kg/year of the active pharmaceutical
ingredient, enough to treat 10 million patients per year. The production will be completed over one hundred
batches, requiring operation of 120 days/year. Assuming an 11-year period of operation, detailed economic
analysis suggests that this is a profitable venture with an IRR of 67.7% and a NPV of $1.2 billion USD.
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University of Pennsylvania
Department of Chemical and Biomolecular Engineering
220 South 33rd Street 
Philadelphia, PA 19104 
April 18th, 2017
Dear Dr. John Crocker and Professor Bruce Vrana:
Enclosed is our proposal for the process design and financial performance of the low-cost 
production of sofosbuvir, a Hepatitis C drug patented by Gilead Sciences. The goal of this 
proposal is to design a process that would offer sofosbuvir at a cost significantly lower than the 
current price of $84,000 per treatment. The process design scales up reactions as outlined by 
patents submitted by Jiangsu Hanson Pharma Group in 2016 and Medivir in 2015. In order to 
meet the projected annual demand for 10 million patients worldwide, it is recommended that 100
batches per year be produced, with each batch generating 3,500 kilograms of sofosbuvir.
This report contains analysis of the market for sofosbuvir in the developing world, which 
defends our estimation of a 100 million patient market. This process requires an initial capital 
investment of $27 million and an annual operating cost of $568 million. Assuming the current 
market price of starting materials and utilities, the drug can be produced at a cost of $1,434/kg. If 
the drug is sold at $100 for a 12-week course of treatment, then the internal rate of return is 
projected to be 67.7%, making this a profitable venture after ten years of operation. 
After thorough consideration, we submit this report for review with recommendations to 
build the facility to produce sofosbuvir to treat patients with Hepatitis C in low-income countries. 
Sincerely,
_____________________________
Joseph Solomon
_____________________________
Jake Hsu
_____________________________
Cynthia Tong
_____________________________
Ryan Bliss
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Section 4 - Abstract 
 Recent advances in antiviral therapeutics have produced highly effective small molecule 
drugs to treat Hepatitis C, a deadly infection of the liver. Sofosbuvir, a hepatitis C drug 
developed by Gilead Sciences, is a breakthrough treatment due to its low side effects and high 
cure rate. However, the cost of treatment is extraordinarily high, priced at $84,000 per treatment 
in the US. In response to backlash regarding the cost barriers in developing countries, Gilead has 
reached licensing agreements with generic pharmaceutical companies to produce the drug for 
markets in low-income countries such as India, Kenya, and Cuba among others. 
 The report describes a cost-effective, commercial scale process design for the production 
of sofosbuvir. The proposed production facility is designed to deliver 350,000 kg/year of the 
active pharmaceutical ingredient, enough to treat 10 million patients per year. The production 
will be completed over one hundred batches, requiring operation of 120 days/year. Assuming an 
11-year period of operation, detailed economic analysis suggests that this is a profitable venture 
with an IRR of 67.7% and a NPV of $1.2 billion USD.  
 
 
 
 
 
 
 
Keywords: sofosbuvir, hepatitis C, liver, drug production  
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Section 5 - Introduction and Objective Time Chart 
5.1 Introduction 
Hepatitis C is an infection of the liver that affects over 130 million people worldwide. 
While some patients do not exhibit symptoms, chronic infection can lead to severe liver damage, 
and there are approximately 700,000 deaths worldwide because of hepatitis-related 
complications each year5-1. The latency period of Hepatitis C Virus (HCV) is very long, and it 
can take several years for a HCV infection to become life-threatening in the form of 
hepatocellular carcinoma (liver cancer) or cirrhosis5-2. As a result, many patients will wait for 
medication to become more affordable. Recent advances in antiviral medications have produced 
anti-retroviral molecules that can eliminate the virus in infected patients, providing a much-
needed cure for this condition. 
Sovaldi (sofosbuvir) is a nucleotide analog drug produced by Gilead Sciences, which 
received FDA approval in 2013 for the treatment of HCV. Sovaldi is prescribed as a once-daily 
oral tablet for patients of all stages of HCV. A full course of treatment consists of 12-weeks of 
sofosbuvir (400mg) and a second-line antiviral. This treatment demonstrated cure rates as high as 
97% in clinical trials. The World Health Organization (WHO) has included sofosbuvir in its List 
of Essential Medicines. Compared to previous HCV treatments, sofosbuvir is a breakthrough due 
to its once daily dosing, oral administration, low side effects, minimal drug-drug interactions, 
and high virologic response rates in patients with unfavorable baseline characteristics. Most 
patients treated with sofosbuvir show no signs of the HCV after three months5-4.  
7
 
 
 
 
Figure 5-1 Sofosbuvir (PSI-7977) Molecular Structure 
The molecule is chiral about the phosphate group, as indicated by the green highlighted 
group in Figure 5-1. PSI-7977 is the S-enantiomer, which is more actively metabolized. Its 
isomer PSI-7976 is metabolized with the same pathway. PSI-7977 has an EC90 of 0.28μM 
whereas PS-7976 has an EC90 of 2.96 μM, indicating that PSI-7977 is roughly 10 times more 
active. To prevent dosage issues, sofosbuvir is enantiomerically pure, consisting of only the PSI-
7977 isomer. The phosphate group connects a modified uridine group (yellow) and a modified L-
alanine group (blue). 
 
Figure 5-2 Metabolism of Sofosbuvir (PSI-7977) Prodrug into Biologically Active PSI-7409 
HCV uses NS5B polymerase to replicate its viral RNA. NS5B is a reverse transcriptase, 
so it is a valuable antiviral target because reverse transcription is not used for any other function 
outside of viral replication. Sofosbuvir enters the body as a prodrug and is phosphorylated twice 
to become the active metabolite PSI-7409, as shown in Figure 5-2 above. The active metabolite 
then mimics uridine nucleotides and binds competitively with the NS5B polymerase to terminate 
the viral RNA chain. This inhibits HCV-RNA synthesis with minimal side effects, as the drug 
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does not bind with other substrates, given that reverse polymerase is not indigenous to the human 
body5-5.  
However, Sovaldi is one of the most expensive medications in the world. Currently, a 12-
week course of treatment costs $84,000 in the US, making it the most expensive drug of 2016 5-6. 
The high price point in the United States and other first world markets is driven by the need to 
recuperate the costs of research and development, which were reported to be roughly $400 
million. Given the average success rate of approximately 20% for R&D projects at 
pharmaceutical companies, the total costs to recuperate were approximately $2 billion. Currently, 
Gilead is aware that developing countries are unable to afford sofosbuvir at the price point 
previously discussed; however, HCV is a global humanitarian issue, and there is more to be 
discussed aside only from the high cost of the drug in developed countries. If Gilead could be 
reimbursed the costs of R&D, it is possible that the cost of the drug could drop in the developed 
world and the developing world, allowing for the global eradication of the deadly HCV. For 
instance, if Gilead were reimbursed by international governments or humanitarian aid 
organizations, the global cost of life-saving sofosbuvir could fall. While this discussion is beyond 
the scope of the design project, it is worth noting that the global eradication of a disease that 
claims the lives of millions annually is entirely feasible.  
In response to this backlash, Gilead has reached licensing agreements with 
pharmaceutical companies to sell sofosbuvir at generic prices in 101 specified developing 
countries. The patent covers many developing countries with high incidence of HCV, but 
deliberately excludes middle income countries such as China and Brazil, which each have 
millions of Hepatitis C patients. Mylan, Cipla, and Natco Pharma have all acquired licenses to 
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manufacture the generic drug5-4. This project assumes operation as one of these generic 
companies.  
We have been tasked with designing a process to produce sofosbuvir at a significantly 
reduced price. The goal is to provide the 12-week course of treatment for less than $100. This 
target is supported by the analysis of Andrew Hill and his group in the UK, who claim that 
sofosbuvir be produced for a price of $101 for a 12-week course of treatment5-8. The 
manufacturing facility will operate for ten years, as Gilead’s patent period on sofosbuvir will end 
in 20285-9 and thus the licensing agreement will end.  
5.2 Objective Time Chart 
 The goal of this project is to create a production process of sofosbuvir that is both 
affordable for patients in developing countries who need the drug and financially feasible for the 
drug manufacturer. The scope of this project includes analyzing the most profitable chemical 
routes to synthesize sofosbuvir, modeling unit operations to determine equipment needs, and 
costing all of the resources required in the process. As a general target, it must be profitable to 
sell the active pharmaceutical ingredient (API) for less than $3,000 per kilogram. Project leaders 
are Joseph Solomon, Cynthia Tong, Jake Hsu, and Ryan Bliss.  
Deliverable Description Date Accomplished 
Determine Chemical 
Synthesis Pathway 
Read patent literature and discuss with 
consultants to determine the most 
efficient, cost-efficient process 
February 10 
Model Process Steps in 
ASPEN 
Determine the equipment specifications 
to perform necessary reactions and 
separations with appropriate utility 
demands. 
March 15 
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Schedule Operations in 
SUPERPRO 
Model equipment operations in 
SUPERPRO and determine the 
scheduling of shifts 
April 2 
Determine Utility 
Requirements Needed 
Size equipment (reactor vessels, 
distillation columns) and determine the 
heating and cooling costs. 
April 4 
Complete Financial 
Analysis 
Calculate fixed and variable costs for the 
process and determine NPV and ROI 
April 8 
Complete Report  April 14 
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Section 6 - Innovation Map 
The low-cost process proposed in this report will yield a product that is bioequivalent to 
the API in Gilead Science’s branded drug Sovaldi. As shown in the Innovation Map (Figure 6-1) 
below, sofosbuvir products (Sovaldi, Harvoni, Epclusa) and the new generation of oral HCV 
drugs (Daklinza, Zepatier, and Viekira) are significantly differentiated from the previous 
generation pegylated-interferon (Peg-INF) and ribavirin (RBV) treatments in that they are highly 
effective, easily administered, and lead to few side-effects. The key attribute that differentiates 
sofosbuvir drugs and other HCV drugs is that it is approved for multiple genotypes of HCV. This 
makes sofosbuvir an ideal treatment for HCV patients in developing countries because HCV 
genotypes vary greatly between geographic regions. More detailed explanation of the market 
analysis can be found in Section 7.  
In terms of manufacturing process, many patented syntheses were considered. All 
synthesis patents considered required the expensive molecule 2’-deoxy-2’-fluoro-2’-
methyluridine (methyluridine). Patents were screened based on a variety of factors, the most 
important of which were final yield and complexity of intermediate. Between the first two 
processes shown in Figure 6-1, the first synthesis was chosen because of its significantly higher 
yield. Between the first and third processes, the first was chosen because of the more 
straightforward synthesis of the intermediate. Detailed explanation of the process selection and 
design is presented in Section 16. 
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Figure 6-1 Innovation Map  
  
14
 
 
 
Section 7 - Market and Competitive Analysis 
7.1 Hepatitis C Market Analysis 
 
Figure 7-1 Hepatitis C Genotypes by Geography7-1 
Treating HCV is uniquely challenging due to the high rates of mutation within the virus. 
Significantly differentiated viruses are categorized under separate genotypes. Currently, there are 
six genotypes of HCV enumerated 1 through 6. Each genotype may contain further sub-types. 
Genotype profiles can vary dramatically across geographic regions. In North America and 
Europe, genotype 1 is the most commonly observed among HCV patients for all genotypes, 
whereas India has high prevalence of genotype 3 and Africa has high prevalence of genotype 4.  
HCV treatment can be further complicated by advanced disease progression into liver 
cirrhosis, simultaneous infection by multiple genotypes, and cross-infection with HCV and HIV. 
In later stages of HCV, characterized by liver cirrhosis, patients experience lower cure rates. For 
example, among patients treated with Daklinza, those who suffered from cirrhosis were cured at 
a rate of 58%, whereas those who did not were cured at a rate of 98%. Patients who have 
15
 
 
 
multiple infections are often treated more aggressively with one or two additional antivirals. 
Overall, the global Hepatitis C market is fragmented by genotype and cross infection.  
7.2 Pharmaceutical Hepatitis C Treatment Options 
7.2.1 Pegylated-Interferon and Ribavirin 
Before effective oral treatments of HCV became available, the preferred course of 
treatment was a combination therapy of pegylated-interferon and ribavirin. The combined 
treatment had a cure rate of 45% in genotype 1 and 80% in genotypes 2 and 37-2.  
Pegylated-interferon (Peg-INF) mimics a protein in the body to fight off infection. It is 
typically delivered as a weekly injection, which must be administered by a doctor. This is not 
particularly desirable or convenient for patients because it creates barriers to treatment. Peg-INF 
can also lead to serious side effects such as fever, nausea, , and even autoimmune disorders. Peg-
INF is most commonly prescribed in a combination treatment with RBV; however, it can also be 
used in combination with sofosbuvir. The use of Peg-INF has decreased in recent years more 
approved treatments have become available.   
Ribavirin (RBV)7-3 is an oral antiviral drug approved in 1998 for use in HCV 
combination treatments. The mechanisms of RBV are not well documented because of 
challenges involved in developing an in vivo HCV model; however, it is believed that RBV 
interferes with the replication of viral DNA and RNA. By itself, RBV has shown to have no 
effect on viral replication, so it is never used as a stand-alone treatment. RBV is currently 
marketed under several generic brands, making it a popular second-line antiviral.   
7.2.2 New Oral Hepatitis C Treatments on the Market 
As antiviral research matured, more pill-based treatments were approved by the FDA and 
became available on the market. These treatments were a significant improvement from the 
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previous generation of peg-INF and RBV treatments because the oral forms were easier to take 
and were associated with less severe side effects. The most well known of these HCV antivirals 
was sofosbuvir; however, there are several other notable drugs that serve a sizeable portion of the 
global HCV market.  
Daklinza (daclatasvir)7-4, developed by Bristol-Myers Squibb, is an inhibitor for the 
NS5A replication complex. It was first approved by the FDA in July 2015 for the treatment of 
genotypes 1 and 3 in combination with sofosbuvir. It has occasionally been used to treat 
genotypes 2 and 4. Daklinza is taken in the form of a once-daily oral tablet with 98% efficacy 
when used as a first line treatment. 
In January 2016, Merck entered the HCV market with its own drug, Zepatier 
(elbasvir/grazoprevir)7-5. Zepatier is an oral first-line treatment for patients with genotypes 1 
through 4. It can be administered with or without RBV in combination. After 12 weeks of 
treatment, patients were cured with over 97% success. 
Viekira Pak/Viekira XR (ombitasvir/paritaprevir/ritonavir/dasabuvir)7-6 was 
developed by Abbvie in December 2014 for patients with genotype 1. Viekira Pak is taken as 
two tablets: the first containing ombitasvir/paritaprevir/ritonavir, and the second containing 
dasabuvir. Abbvie followed up with Viekira XR, a single tablet version of Viekira Pak in July 
2016. Among patients with genotype 1 without cirrhosis, Viekira Pak has a cure rate of 97% 
after a 12-week course of treatment.  
7.2.3 Gilead Sciences Hepatitis C Portfolio 
Gilead’s blockbuster drug, Sovaldi (sofosbuvir)7-7, changed the market of HCV 
treatments when it was approved in December of 2013. Its active drug, sofosbuvir, is a 
polymerase inhibitor that prevents the virus from replicating. It is taken as a daily oral tablet to 
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treat genotypes 1 through 4. Compared to its predecessors, Sovaldi boasted high cure rates as 
well as a wide viability; however, taking Sovaldi required combination treatments with peg-INF 
or RBV, which could be inconvenient.  
Harvoni (sofosbuvir/ledipasvir)7-8 was approved to Gilead’s HCV portfolio in October 
2014. At the time of approval, it was the first single pill treatment for patients with genotype 1. 
Unlike Sovaldi or Zepatier, Harvoni did not require co-administration with RBV or a second 
anti-viral. In phase 3 trials, 94% of patients treated with Harvoni were completely cured after 12 
weeks.  
Epclusa (sofosbuvir/velpatasvir)7-9 was approved in June 2016 as the first oral tablet that 
could be used to treat all genotypes of HCV. Epclusa’s treatment flexibility extends not only to 
genotypes but also to later stage patients with liver cirrhosis and patients with multiple 
infections. Among patients without cirrhosis, 98% were cured from HCF after 12-weeks of 
treatment with Epclusa. Epclusa used in combination with RBV resulted in similar cure rates 
among patients with cirrhosis.  
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7.3 Competitive Analysis 
 
Figure 7-2 Global Hepatitis C Pharmaceutical Sales in 2016 Listed by Commercial Drug 
Name and Company7-10, 11,12,13,14 
Although there are many options for HCV patients on the market, Gilead’s set of 
sofosbuvir-based drugs are the clear market leaders. Currently, these drugs are considered the 
recommended first-line treatment for HCV patients of all genotypes and at all stages of 
progression. In 2016, Gilead Sciences held 79.8% of the HCV pharmaceutical market (Figure 7-
2). Epclusa, Gilead’s new combination drug, which launched mid-year 2016, is poised to take an 
even greater share of the market in 2017. Thus, demand for sofosbuvir will remain high. 
However, this is mainly the case in the developed world, because branded HCV drugs are 
unaffordable to patients in developing countries. Due to patent restrictions, patients with HCV in 
developing countries were previously limited to Peg-INF and RBV treatments. The new 
sofosbuvir licensing agreements will drastically change the HCV market in developing countries. 
Though Gilead’s second-line antivirals ledipasvir and velpatasvir are protected under patent, 
sofosbuvir can be prescribed with ribavirin with similarly high efficacy. Given the restrictions 
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placed on the sofosbuvir licensing, sofosbuvir + ribavirin combination treatment is the best 
option for HCV patients in developing countries7-7.  
 Under the terms of Gilead’s generic licensing, generic manufacturers are able to produce 
and distribute sofosbuvir among 101 developing countries listed below in Table 7-1. These 
countries contain a large majority of HCV-infected individuals, totaling roughly 100 million 
patients. Thus, it is reasonable to estimate a maximum capacity of 10 million treatments 
produced per year over the next 12 years, while sofosbuvir is still on patent. Clinically, this will 
slow the spread of HCV in the most vulnerable populations. Financially, these large quantities of 
production will provide significant savings via the economies of scale. Once sofosbuvir comes 
off patent in 2028, this process will have had a significant advantage over new entrants in terms 
of brand recognition and optimization.  
Table 7-1 Developing countries eligible for distribution of generic sofosbuvir product 7-15 
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Section 8 - Customer Requirements 
 The project is to design a process that will produce sofosbuvir at the commercial scale in 
India. The identified customers are patients with chronic Hepatitis C infections. To meet the 
demands of over 100 million patients in developing countries covered by the licensing 
agreement, the manufacturing output must be 350,000 kg per year. The cost of the drug must be 
no greater than $100 USD for a 35 gram, 12-week course of treatment. If the cost of the drug is 
too high, then patients who need this drug will not be able to afford treatment. Additionally, the 
process must produce the drug according to good manufacturing practices (GMP) standards, 
such as maintaining batch integrity and using high-purity raw materials. Ultimately, the finished 
drug product consists of both sofosbuvir and ribavarinas as a combination treatment, so the 
project must include both molecules. These customer requirements are classified as fitness-to-
standard (FTS). 
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Section 9 - Critical-to-Quality Variables 
 Though this proposal focuses heavily on the process design aspect of sofosbuvir 
production, patient experience has also been seriously considered. Resources will be allocated to 
reducing barriers to patient access by maintaining low prices and optimizing distribution. High 
standards will be enforced to guarantee a high quality product by stringent quality control and 
precise dosing.  
 As mentioned previously, the main consideration for this project is price. The goal is to 
provide the drug at a price that is affordable to treat any patient. Because, the equipment units are 
designed around a specific patent, the process itself cannot be drastically changed. With this in 
mind, the team will be constantly monitoring the prices of starting prices. Procurement will seek 
to purchase the materials at cheaper prices as long as the same level of quality can be guaranteed. 
This is particularly true for methyluridine; currently, there are vendors in China who are offering 
the intermediate for sale at about $200 per kilogram. If this product can be verified for its purity, 
further price reductions may be available.   
One important factor to our product is the purity of the sofosbuvir API. In order to 
guarantee patient safety, it is crucial that the purification process removes all undesirable 
contaminants, DCM, EA, and acetone in particular. According to the FDA, DCM is classified as 
a class 2 impurity, meaning that it has inherent toxicity and should be limited. The concentration 
limit for DCM is 600 ppm or 6 mg/day. EA and acetone are considered class 3 impurities, 
meaning they are less toxic and are not known to be human health hazards. Class 3 impurities are 
limited to less than 50 mg/day.9-1 To enforce these safety standards, strict quality control will be 
conducted with each batch.  
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 To prevent toxicity, each pill will be precisely dosed for 400 mg of sofosbuvir or 600 mg 
of ribavirin, the recommended daily dose for an adult being treated with the sofosbuvir + 
ribavirin combination.9-2 Each pill will be formulated with distinct labels to avoid confusion. 
This will allow patients to easily keep track of their medication and avoid over-dosing. 
Furthermore, pills will be pressed with patient consumption in mind. Pills will be design to be as 
small as possible to be easily swallowed. Due to the language barriers that may exist, labels will 
be rigorously translated to enforce clarity and consistency. 
 Finally, the drug will be distributed with the geographic spread of our patients in 
consideration. Rather than focusing our efforts in distribution to individual pharmacies, it will 
instead be sold to national health agencies in the licensed developing countries or to international 
humanitarian non-profit organizations. These organizations have pre-established distribution 
channels, which will shorten the time to delivery.  
 
 
 
 
 
 
 
 
 
 
 
Endnotes 
 
9-1: US Department of Health and Human Services Food and Drug Administration (2012). 
Guidance for Industry: Q3C Tables and List. Retrieved from 
https://www.fda.gov/downloads/drugs/guidances/ucm073395.pdf. 
9-2: Zeuzem, Stefan (2014). Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. N Engl J Med 
2014; 370: DOI: 10.1056/NEJMoa1316145  
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Section 10 - Product Concepts 
Currently, Gilead owns the only patent for a HCV treatment drug sofosbuvir. Gilead’s 
brand name drug, Sovaldi, is sold in wealthier countries as are most, if not all, of their 
competitors in the Hepatitis C industry. For the purposes of the design project, our team is 
developing a generic, low-cost alternative to brand name drugs available via a license of the 
patent by Gilead for use in India. In that regard, there are no alternatives to product design, as the 
drug is protected by patent and non-generic drugs are cost prohibitive in developing countries.  
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Section 11 - Superior Product Concepts 
As previously discussed, for the purposes of the design project, our team is developing a 
generic, low-cost alternative to brand name drugs available via a license of the patent by Gilead 
for use in India. In that regard, there are no alternatives to product design, as the drug is 
protected by patent and non-generic drugs are price prohibitive in developing countries.  
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Section 12 - Competitive Patent Analysis 
As previously discussed, for the purposes of the design project, our team is developing a 
generic, low-cost alternative to brand name drugs available via a license of the patent by Gilead 
for use in India. In that regard, there is no competitive patent analysis, as our team is assuming 
that we are licensing the patent of Gilead Sciences in a market without brand-name competition.  
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Section 13 - Preliminary Process Synthesis 
During the process synthesis analysis, various process flow diagrams were evaluated 
based on multiple patents, consultant recommendations, industrial scaling considerations and 
scheduling considerations. Each week, the product synthesis process was altered to minimize the 
cost of production of sofosbuvir and maintain a reasonably straightforward synthesis process. 
Initial assumptions were made regarding the scheduling, design and flow of the process so that 
our team could proceed accordingly. Subsequently, thorough patent analysis was performed to 
determine the optimal industrial synthesis route for sofosbuvir. Finally, synthesis processes were 
developed, altered and corrected throughout the term with the guidance of industrial consultants, 
external consultants, and close patent analysis.  
The challenges throughout the semester were the scaling lab scale processes into 
industrial units. Our team concluded, among many other decisions discussed below, that 
chromatography and rotary evaporation were not viable at the industrial scale; industrial 
processes instead use large-scale liquid-liquid extraction and flash evaporation, respectively, in 
place of those two lab-scale processes. Flash evaporation vessels were modeled either as vacuum 
evaporation vessels or as distillation towers with multiple trays, operated at the ambient 
temperature vapor pressure of the solvent to avoid damage of the API. Furthermore, our group 
considered the process by which the soluble product would be purified and dried, deciding that 
the most relevant industrial scale analog of the lab scale process was a liquid- liquid extraction in 
a large, agitated wash vessel followed by drying in an anhydrous sodium sulfate packed bed. 
More complex process revisions are discussed herein.  The overall goals of the process design 
were to find a synthesis route with a reasonable cost of raw materials and to scale the process 
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from lab-scale design in patents to an industrial-scale analog. The flow diagrams are available in 
Section 15 and the final processes are discussed in detail in Section 16. 
13.1 Initial Considerations 
The majority of early stage synthesis route prediction was born from exhaustive patent 
study. Most patents were extremely vague, as are their nature, which made the process of 
determining exact synthesis routes difficult initially. At the recommendation of industrial 
consultants and Dr. Crocker, it was determined that an appropriate route for patent “translation” 
was to choose R groups or solvents based on cost of raw materials, cost of removal and safety if 
the patent mentioned multiple R groups and solvents. Furthermore, the consultants recommended 
that our group should attempt to start with the lab scale process for the synthesis in the patents 
since there is often times an industrial scale parallel process. The obvious first step and goal was, 
then, to determine the process and/or synthesis route for producing sofosbuvir before discussing 
equipment in detail.  
Our group concluded that it was safe to assume the use of a batch process since 
pharmaceutical standards require traceable batches the event of a contamination. Due to the 
chirality requirements of the sofosbuvir molecule, stereospecific and non-stereospecific 
processes were both considered. It was concluded that it is preferable to purchase the feedstock 
with the chiral center enantiomerically pure rather than separating after the reaction. Our group 
determined that the cost of R- and S- separation is prohibitive, so only stereospecific reactions 
were considered.  
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13.2 Synthesis Route Determination 
 Initial synthesis route determination was based on patents provided during the initial 
project proposal phase. Most patents were too vague regarding the synthesis route for sofosbuvir, 
mentioning only general routes between compounds of various R groups and chiral centers. 
Patent authors aim for their intellectual property to be as widely applicable as possible and 
purposefully neglect to identify specific solvents and functional groups. Our team decided to 
choose unspecified components based on cost and safety. In most cases, the pharmaceutical 
patents referenced to peer-reviewed papers where the synthesis process was more coherently 
outlined, so our team pivoted towards the peer-reviewed papers mentioned in the patents.  
 An article published in the Journal of Medicinal Chemistry, Discovery of a Nucleotide 
Prodrug for the Treatment of Hepatitis C by researchers Michael Sofia et al. was the first to be 
thoroughly reviewed for the process synthesis. The article detailed a synthesis route to obtain a 
family of molecules that could be directly converted to sofosbuvir. The paper discussed 3 major 
syntheses: a synthesis to produce methyluridine, a synthesis to produce an intermediate product, 
and the reaction of those two products to create a molecule in the family of molecules that could 
directly be translated to sofosbuvir. It is important to mention that the paper does not explicitly 
discuss the synthesis of the sofosbuvir as the final product, but does discuss the yields associated 
with the direct route synthesis from each of the molecules in the family of molecules described 
previously. Figure 13-1 presents an overview of the synthesis route described by the paper; the 
reaction pathway featured the use an amino acid ester (compound 9) and dichlorophosphate 
(compound 10) to create an intermediate product (compound 11), which would then react with a 
methyluridine (compound 5) to create one of many molecules that could be converted to 
sofosbuvir directly. Reactions a and b are conducted in the DCM as described in the figure.13-1
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The paper determined that molecule 14, which has a structure similar to the final product 
in Figure 13-1, resulted in the best yield of the sofosbuvir. However, the paper revealed that the 
yields from each of the direct route molecules (compounds 12-49) were all fairly low, ranging 
from 10-25% yield of sofosbuvir. The overall synthesis from starting materials to sofosbuvir had 
a yield of 3%. This low yield concerned our group, but industrial consultants remarked that 
yields as low as 3% could be used in industry as long as the costs associated with that low of a 
yield are reasonable. Our team decided to move forward with an in depth analysis of this 
process.13-1 
 In order to determine the viability of the process described in the Sofia article, the raw 
material costs were analyzed to determine whether or not it would be possible to synthesize 
sofosbuvir for the target price. Raw materials 9 and 10 in Figure 13-1, amino acid ester and 
dichlorophosphate, were searched for on various chemical supplier websites in order to find a 
reasonable price point. Our team sought to find all raw materials for a total below $1,000 per 
kilogram of sofosbuvir product in order to obtain our objective price point. Preliminary research 
determined that the amino acid ester and dichlorophosphate were both reasonably priced and 
could be obtained for a price point well below the threshold of $1,000 per kilogram. However, 
our team determined that the price of methyluridine (compound 5) was constraining with a price 
point as high as $4000 per kilogram. This high price led our team to analyze the various 
processes described in the Sofia et al. article for the synthesis of methyluridine, but we soon 
determined that, again, the raw material costs for those syntheses were also quite cost 
prohibitive.  
Our team, concerned by the high price point of this raw material, reached out to external 
industry experts to determine if an alternative synthesis of methyluridine was possible or a more 
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reasonable price was obtainable.  Professor of Chemistry and Pharmaceutical Sciences at 
Howard University Joseph Fortunak advised our team that most companies currently producing 
sofosbuvir in India buy methyluridine directly from chemical manufacturers in China for prices 
much less than what our group was being quoted. Professor Fortunak recommended that we 
research the import-export data between China and India to find the realistic price for which we 
could purchase the methyluridine as a manufacturer in India. After researching import-export 
data between India and China, our team discovered that the imported methyluridine was much 
less cost prohibitive than previously thought, averaging $888 per kilogram in 2016. Our team 
also discovered that prices for our other raw materials were also less than previously estimated; 
all prices are discussed in the Section 14. After realizing the less prohibitive costs of the raw 
materials, the synthesis described by Sofia was reevaluated for its cost efficiency. While the 
costs of raw materials did decrease, the yield (3%), which had previously not been evaluated, 
proved to make the process impractical, as the total cost to obtain the necessary amount of 
sofosbuvir was well above the stated goal. Furthermore, many of the patents that referenced the 
Sofia et al. article mentioned chromatography separation of the final product and various 
intermediate products during the process. However, in meetings with industrial consultants our 
team was advised that chromatography processes are generally converted to adsorption towers. 
In order to determine the size of the adsorption tower needed, it was necessary to determine 
either the isotherm associated with the adsorption products or determine the mass or volume of 
silica gel used at the laboratory scale in order to scale the procedure up. Shorthand calculations 
revealed that the size of the tower would be too large to be reasonably affordable. The size and 
cost of the tower, together with the cost prohibitive yield of reaction and the industrial consultant 
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indication that adsorption is a rare industrial process led our group to decide to find a new 
synthesis route for sofosbuvir. 
For help with the patent search, our team reached out to the University of Pennsylvania 
Chemistry department. Dan Wu recommended that our team use Reaxys, a chemistry synthesis 
software.  Reaxys is a search tool that retrieves reaction data from journal literature and 
published patents. Given a compound it summarizes the reactions in which the compound was 
synthesized or reacted. These hits could be sorted based on yield. Starting with sofosbuvir as the 
end product, our team used Reaxys to back-synthesize until we reached starting molecules that 
could be purchased at reasonable prices. Synthesis reactions were selected in favor of high yields 
and simple intermediates. Reactions that included heavy metals were deliberately excluded 
because they would be difficult to remove in separation steps. Figure 13-2 displays the synthesis 
process determined using Reaxys to arrive at the final product sofosbuvir. Three total reactions 
are used each with yields ranging from 50 to 97%. With the higher overall yields, it was 
reasonable to assume the purchase of methyluridine given the prices from import data.  
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 Reaction 3, the reaction furthest left in Figure 13-2, starts with raw materials isopropanol 
(IPA) and L-alanine to arrive at L-alanine isopropyl ester with an 87% yield. The L-alanine 
isopropyl ester from reaction 3 is then reacted with 2-chloro-6-hydroxypyridine and phenyl 
dichlorophosphate to yield Intermediate A1 with a 97% yield. Intermediate A1 is then reacted 
with methyluridine in reaction 1 to synthesize sofosbuvir. This reaction has a 50% yield, which is 
much higher than those seen in previous papers. The reactions featured many other solvents and 
catalysts that also factored into the costs associated with the process. Reaction 3 used IPA and 
thionyl chloride; reaction 2 uses the solvents dichloromethane (DCM) and N, N-diisopropyl 
ethylamine (DIEA); reaction 1 was catalyzed with zinc chloride in DIEA and tetrahydrofuran 
(THF). Additional washing buffers and drying agents were used to purify the product stream. 
These included ethyl acetate, ammonium chloride solution, salt water, hydrochloric acid, sodium 
carbonate/bicarbonate buffer and sodium sulfate. After researching the raw material costs via 
import data, the total cost for the synthesis was determined to be below the threshold. With the 
synthesis steps now reasonably determined for the process, it was possible to begin analysis of 
process equipment, timing and planning. 
13.3 Process Development 
 For the purposes of flowsheet preparation, preliminary syntheses can be discussed on a 
reaction-by-reaction basis. As discussed above, the reaction synthesis selected for the process 
features three primary reactions. A key assumption our team made was that the reaction rates, 
volumes and order of reactions from the patents were directly scalable to the industrial scale. For 
simplicity, each reaction and its iterations will be discussed individually to highlight the changes 
made in each reaction more clearly and concisely.  
13.3.1 Reaction 3 - Process 100 
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 Reaction 3, herein Process 100, was developed from a patent by Medivir (Appendix A-2), 
which accounted for the described of L-alanine isopropyl ester.13-2 The reaction required a 
dropwise addition of thionyl chloride to a suspension of L-alanine in IPA, which was stirred 
overnight at room temperature to yield L-alanine isopropyl ester. After the reaction step, the 
patent states that the product was “concentrated,” which our team interpreted to be a 
crystallization to yield solid L-alanine isopropyl ester.  
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Process 100, visualized in Figure 13-3, used a single reaction vessel for the combination 
and reaction of the three raw material feeds, L-alanine, IPA and thionyl chloride. Those three 
raw materials were added to a reaction vessel according to the rates prescribed in the patent, by 
scaling based on the time of addition. After the appropriate reaction time, the product was 
removed from the system and crystallized to remove the main product as well as the mother-
liquor waste.  
Revisions were made to Process 100 and visualized in Figure 13-4. After discussing with 
industrial consultants and Dr. Crocker, our team revised our interpretation of the concentration 
step. Concentration is typically used in the final step of the process, not in intermediate reactions. 
The separation method by which the product was removed in Process 100 was changed to reflect 
the aforementioned conclusions. Given the aqueous suspension of product, it seemed prudent to 
use ultrafiltration to remove the suspended particulates from the solution for subsequent use. 
Furthermore, our team decided to add a storage tank to the process to regulate the addition of 
product to the next process, as the rate of ultrafiltration could be quite low.  
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 After refining Process 100, visualized in Figure 13-4, our team discussed the new 
separation process with industrial consultants; our team concluded that ultrafiltration is 
extremely rare at the industrial scale, and is infeasible given the massive scale with which our 
process is operating. Given the total volume of the reaction, it is highly unlikely the time needed 
for ultrafiltration would be reasonable for the production time discussed for the entire supply of 
sofosbuvir. This was supported by the fact that solids are difficult to transfer from one process to 
the next, so a concentrated suspension of L-alanine isopropyl ester would be more convenient for 
the subsequent process. 
After reviewing patent language, Process 100 was again revised, visualized in Figure 13-
5; it was decided that rotary evaporation used at the bench scale could also be used at the 
industrial scale and was certainly more feasible than the use of ultrafiltration. Process 100 was 
revised to include a rotary evaporator, but other vessels remained the same.  
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After the third revision, Figure 13-5, our team reached out to Natalie Eyke, a chemical 
engineer at Merck with experience in small-molecules. Natalie advised our team that lab scale 
rotary evaporation is perhaps better adapted as a flash distillation to quickly remove solvent. 
Because IPA is relatively volatile, the solvent would be heated and removed from the solution 
resulting in a concentrated L-alanine isopropyl ester solution. However, our team was concerned 
that excessive heating could damage the product. The flash vessel was designed to operate as an 
evaporator unit, running at the vapor pressure of IPA at room temperature rather than using the 
vapor temperature at atmospheric pressure. The flash vessel design was incorporated in the 
subsequent flow diagram (Figure 13-6).  
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Figure 13-6 depicts the last iteration before the finalized flow diagram for Process 100 
was generated. In discussions with industrial consultants following the selection of the flash 
vessel, concerns regarding the collection, potential re-use, sale or wasting of the evaporated 
solvent arose. In order to return the distillate to the waste vessel or to the process, it had to be 
condensed back to a liquid state. Pharmaceutical processes rarely re-use solvents, as it interferes 
with batch integrity and introduces potential impurities to the process. In order to reduce the 
volume of waste or to sell the waste to a distributor who might purify it, our team decided to 
consider the use of a distillation column with multiple trays and a condenser and reboiler, to 
maximize the purity of IPA in the waste streams, as other liquids, namely unreacted thionyl 
chloride and side products, would be present in the stream. Furthermore, the low vapor pressure 
of IPA (0.04 bar) was a safety concern. These considerations are included in the final process 
flow diagram, presented in Section 15 and discussed in detail in Section 16.  
13.3.2 Reaction 2 - Process 200 
Reaction 2, herein Process 200, was developed from a patent by Jiangsu Hanson Pharma 
Group (Appendix A-3), which described for the production of Intermediate A1. The reaction 
required the addition of DCM, which would act as the main solvent in the process, to a vessel 
(V200A). Under nitrogen protection at -50° C, phenyl dichlorophosphate and DIEA were added 
and stirred before the L-alanine isopropyl ester from Process 100 was added. The solution 
reacted over 3-4 hours. In a separate reaction vessel (V200B) DCM was charged into the vessel 
before 2-hydroxy, 6-chloropyridine and DIEA were added. The mixture was stirred for 1-2 
hours. After the contents of V200B were fully reacted, the contents of V200B were added to 
V200A to react for 6 hours. After the process was completed, the product was washed with a 
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combination of water and salt water to remove leftover reactants and then dried via anhydrous 
sodium sulfate. Intermediate A1 was then concentrated for use in Process 300. 
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Process 200, presented in Figure 13-7, initially featured the addition of V200B reactants 
to an independent vessel (Vessel 200B) to produce Intermediate A2. Meanwhile, V200A 
reactants were loaded into Vessel 200A and reacted the prescribed amount of time before the 
products of reaction V200B were added to V200A. After several hours of reaction, the final 
product is washed with cycles of salt water and dried with anhydrous sodium sulfate in vessel 
V200A before the final product was removed for crystallization.   
Revisions were made to the process, visualized in Figure 13-8, mainly to the separation methods 
and reaction vessel scheme. Conversations with industry consultants centered around the method 
by which the reaction vessels were used and ordered for the most efficient reaction process. The 
patent calls for a 2:1 volume ratio of V200A and V200B to create Intermediate A1, and it 
became clear that the volume required for Vessel 200A would be far too large, especially after 
wash steps. Because the wash steps effectively doubled the volume, the reactor would require 
double the original working capacity. Furthermore, our team found that washing in the same 
vessel could affect batch integrity, because the step would create a bottleneck and there would be 
no clean-in-place operation. Finally, as previously discussed for Process 100, crystallization is 
normally not used for intermediate products. 
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In order to account for the considerable volume required for the DCM, our team decided 
that running two reaction vessels in parallel was best, as it would allow for the bulk pricing and 
purchase of reactors of similar volume. L-alanine isopropyl ester from Process 100 is split evenly 
between the two reaction vessels and even quantities of the phenyl dichlorophosphate are reacted 
in the Vessel to yield Intermediate A2, which leaves in stream S3 in Figure 13-8. 
Simultaneously, 6-chloro, 2-hydroxypyridine is mixed with DCM and DIEA in Vessel 200B. 
During the development of the process in Superpro, it was clear that the scheduling of Process 
200 was bottlenecked about the mixing occurring in Vessel 200B due to a long waiting period 
for Vessel 200A to load its product into Vessel 200C. In order to remove this bottleneck, a 
storage tank was added to the process to allow for cleaning- and sterilizing- in-place to take place 
before the next batch, which decreased the turnaround time. The products of both reactions are 
fed to a third reactor (V200C) to remove the bottleneck. Our team reasoned that without the third 
reaction vessel (V200C) the production timeframe might not be feasible, so the added costs of 
the vessel were necessary and acceptable. After the reaction was completed, industrial 
consultants suggested flash vaporizing off a significant portion of the DCM, which was simply a 
solvent in the process, to reduce the volume of product that would need be washed and reduce 
the volume of the wash vessel. After evaporating off a portion of the DCM, the product solution 
was charged to a wash vessel and washed with the two cycles of water and one cycle of salt 
water. Water was removed from the washed solution using sodium sulfate. Finally, rotary 
evaporation was used to concentrate the product, as we thought at the time that rotary 
evaporation was the best method of concentration. The concentrated Intermediate A1 was then 
fed to Process 300 for the final synthesis of sofosbuvir.  
51
While Figure 13-8 made substantial progress for the process design of Process 200, our 
team made further considerations to refine the process, shown in Figure 13-9. As previously 
discussed for Process 100, Natalie Eyke our team that flash vessels are a better interpretation of 
rotary evaporation at the industrial scale. Taking into consideration the heat sensitivity of 
intermediate A1, the new flash vessel, as well as the flash vessel already involved in the process, 
was designed to flash the DCM at its vapor pressure at room temperature. The vapor pressure of 
DCM at ambient conditions is 0.54 bar, which is a reasonable operating condition for the flash 
vessels. Waste considerations were made for the process and the process flow diagram was 
revised to reflect solvent flash and condensation. Furthermore, industrial consultants revised a 
suggestion made in previous meetings regarding the flow rate between vessels. Previously, our 
team had been operating under the suggestion that vessels of 100 m3 could be filled within about 
an hour, a flow rate of approximately 1500 L/min. After consideration, our team revised this 
assumption, realizing that 1500 L/min was actually quite. While possible if a large enough pump 
was used, our team decided to proceed with a lower flow rate of precisely 500 L/min. After 
investigating the effects this flow rate change had on the flow rate, it became clear that Reaction 
Vessel 200B, now renamed to V202, would no longer cause a bottleneck if the storage tank were 
not employed. Since the storage tank was now unnecessary to prevent a bottleneck in V202, our 
team decided to remove the tank to reduce equipment costs. To simplify process scheduling, 
parallel reaction vessels were removed. 
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Figure 13-9 represents the last iteration before the finalized flow diagram for Process 200 
was generated. While the process visualized in Figure 13-9 is reasonable, our team made 
additional revisions to address various aspects of the process. The reactor volumes of V201 and 
V203 would be too large to be reasonably purchased. Furthermore, our team determined that it 
was most likely that the anhydrous sodium sulfate drying was down outside the wash vessel, 
perhaps in a packed bed. These considerations are included in the final process flow diagram, 
presented in Section 15 and discussed in detail in Section 16.  
13.3.3 Reaction 1 - Process 300 
Reaction 1, herein Process 300, was developed from the same patent by Jiangsu Hanson 
Pharma Group (Appendix A-3), describing the synthesis of the final product, sofosbuvir. The 
patent called for the addition of solvent THF to the previously synthesized Intermediate A1. 
Once suspended, reactants methyluridine and DIEA were added to the reaction vessel along with 
a catalyst, zinc chloride. Under nitrogen protection, the reactor was heated to 60°C and the 
reaction proceeded for 15-40 hours. After reaction, the product stream was mixed with ethyl 
acetate and washed with various washing solvents: saturated ammonium chloride solution, 0.5 M 
hydrochloric acid, sodium carbonate/bicarbonate buffer, and saturated salt water. After the wash, 
water is removed from the organic phase by passing the solution over anhydrous sodium sulfate. 
The water-removed solution is concentrated and then crystallized using acetone and DCM. The 
initial process is visualized in Figure 13-10. 
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Similar to Process 200, the patent was initially interpreted to perform the reaction and 
wash steps within the same vessel, but this assumption was eventually ruled out, as it is would 
create a bottleneck and require excessively large reaction vessels; revisions for Process 300 were 
made in Figure 13-11. Again, our team was concerned that the massive wash volume required 
for the process would be too cumbersome for a reaction vessel and would be better suited for an 
independent wash vessel. The patent uses the vacuum evaporation to yield the “oily” product 
before crystallization to yield the nearly pure sofosbuvir. Process 300 was revised to include a 
separate wash vessel as well as a vacuum evaporation unit to reduce the volume of the solvent 
before crystallizing the final product. These changes are reflected in Figure 13-11. 
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In subsequent meetings with industrial consultants, it became clear that the method by 
which solvents and products were dried with sodium sulfate was inherently different than our 
process reflected. Our process added the sodium sulfate to the wash vessel, when for practical 
purposes the product is run over a bed or through cartridges of sodium sulfate to remove water. 
After preliminary costing, it was clear that sodium sulfate cartridges would be cost prohibitive, 
and that using a necessary amount of sodium sulfate and then refreshing it after each batch with 
nitrogen purging would be more acceptable. Furthermore, Process 300 also changed in its 
volume reduction step, using the same method as Processes 100 and 200 wherein a flash vessel 
was used rather than rotary evaporation. The flash vessel was designed to run at ambient 
temperature and a pressure well below ambient, nearly 0.1 bar, the vapor pressure of the main 
solvents. Furthermore, a condenser was added after the flash unit to condense the solvent being 
vaporized for re-sale or disposal; these changes are reflected in Figure 13-12. 
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Figure 13-12 represents the last iteration before the finalized flow diagram for Process 
300 was generated. In subsequent meetings, our team determined that the vacuum like pressure 
necessary in the flash vessel, was too low to be safely and economically operated; the use of a 
distillation column, much like Process 100, was considered. We reached out to Dr. Igor 
Dubovyk, a medical chemist at Pharmacyclics for better interpretation of the wash steps. 
Furthermore, the size and behavior of the crystallization unit were clarified with regards to the 
patent, as many consultants remarked that given the large volume of solvent remaining, it might 
be possible that the patent was referring to a centrifugal crystallization. These considerations are 
included in the final process flow diagram, presented in Section 15 and discussed in detail in 
Section 16.  
 
 
 
 
Endnotes 
 
13-1: Ross, B. S., Reddy, P. G., Zhang, H., Rachakonda, S., & Sofia, M. J. (2011). Synthesis of 
Diastereomerically Pure Nucleotide Phosphoramidates. The Journal of Organic 
Chemistry,76(20), 8311-8319. doi:10.1021/jo201492m 
13-2: Medivir, A. (2015). Global Patent No. WO2015/56213. Geneva, Switzerland: The World 
Intellectual Property Organization (WIPO). Synthesis of l-alanine isopropyl ester. 
13-3: Jiangsu Hanson Pharma Group Co., Ltd. (2015). P.R.C. Patent No. CN105461773. Beijing, 
China: State Intellectual Property Office of the People's Republic of China (SIPO). 
Synthesis of Intermediate A1 and Sofosbuvir. 
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Section 14 - Assembly of Database 
The database of chemicals used throughout the process can be found in Appendix M as 
MSDS sheets. Reactants are listed in Appendix M-1 in alphabetical order; solvents, wash salts, 
desiccant, and catalysts are listed in Appendix M-2 in alphabetical order. The chemicals 
considered hazardous in this process are THF and ethyl acetate, both of which are highly 
flammable in the presence of oxygen. Prices for all chemicals are given in Table 14-1. Because 
of the large quantities needed for each batch, it was not feasible to obtain quotes from specialized 
chemical companies such as Sigma Aldrich. For entries that are sourced from “India 
Import/Export Data,” the average recent import price of chemicals into India were used as the 
component price per kilogram14-1. This data can be found in Appendix G. Other vendors were 
found using Alibaba, which is a major exporter of pharmaceutical chemicals to India.  
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Table 14-1 Summary of Raw Material Prices and Vendor Sources 
Component Price ($/kg) Source 
L-Alanine hydrochloride $4.34 India Import/Export Data 
Isopropanol $0.96 Qingdao HanHaiDa Import And Export Co., Ltd. 
Thionyl chloride $0.64 India Import/Export Data 
Phenyl dichlorophosphate $8.67 Haihang Industry (Jinan) Co., Ltd. 
Dichloromethane $0.42 Taizhou Ruibai Chemical Co., Ltd. 
N,N-Diisopropylethylamine $5.47 India Import/Export Data 
2-Chloro-6-hydroxypyridine $5.00 Jinan Finer Chemical Co., Ltd. 
Saturated Salt Water $0.01 India Import/Export Data 
Anhydrous sodium sulfate $0.10 India Import/Export Data 
2’-deoxy-2’-fluoro-2’-methyluridine $500-888 India Import/Export Data 
Zinc Chloride $0.90 Taian Health Chemical Co., Ltd. 
Ethyl Acetate $0.30 Shanghai Polymet Commodities Ltd. 
Water for Injection $0.12 India Import/Export Data 
Ammonium chloride $0.14 Dahua Group Dalian Guanlin International Trade 
Co., Ltd. 
Hydrochloric Acid 0.5M $0.15 India Import/Export Data 
Sodium Carbonate $0.20 India Import/Export Data 
Sodium Bicarbonate $0.22 Tianjin Huge Roc Enterprises Co., Ltd. 
Sodium Chloride $0.38 India Import/Export Data 
Acetone $0.60 India Import/Export Data 
Nitrogen $0.11 India Import/Export Data 
Ethylene Glycol $1.05 Indiamart 
Propane $0.40 India Import/Export Data 
Ribavarin $44.18 India Import/Export Data 
 
 
Endnotes 
 
14-1: Info Drive India (2016). Import export data, export import data from customs. Retrieved 
from infodriveindia.com 
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Section 15 - Process Flow Diagram and Material Balances 
15.1 Process Flow Diagrams  
1 5 . 1 . 1  Re a ct io n St ep s  a nd  S yn t he si s 
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1 5 .1 .2  Process 1 00 
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1 5 . 1 . 3  Pr o ce s  2 0 0 
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15.2 Material Balances 
Material Balances were calculated for each of the reactor units and summarized below. 
For Process 100, the synthesis of L-alanine isopropyl ester hydrochloride and its side products 
are summarized in Table 15-2. The synthesis is assumed to go to completion because the reaction 
and wash yield (87%) is rather high. Thus, it is reasonable to assume that any side products are 
negligible. The same assumption is extended to Process 200, whose reactions are summarized in 
Tables 15-2, 15-3, and 15-4. Though Process 300 has significantly lower yield (49%), the 
reaction step is assumed to reach completion because Intermediate A1 is fed in extreme excess.  
Table 15-1 Synthesis of L-alanine isopropyl ester hydrochloride in reactor V101 
Reaction 1: C3H7NO2 • HCl (L-alanine hydrochloride) + C3H7OH (Isopropanol) → C6H13NO2 • 
HCl (L-alanine isopropyl ester hydrochloride) + HOH 
Reaction 2: HOH + SOCl2 → 2HCl + SO2 
Stream Number 1 2 3 4 
Stream Description L-Alanine In IPA In Thionyl 
Chloride In 
Reactor V102 
Out 
Total Mass (kg) 4569 100108 8653 113330 
Component Mass (kg) 
L-Alanine 4569 0 0 590 
Isopropanol 0 100108 0 98205 
Thionyl Chloride 0 0 8653 4883 
L-Alanine Isopropyl Ester 
Hydrochloride 
0 0 0 5313 
HCl 0 0 0 2311 
SO2 0 0 0 2029 
In - Out    0 
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Table 15-2 Synthesis of Intermediate A2 in reactor V201 
Reaction: C6H13NO2 • HCl (L-alanine isopropyl ester hydrochloride) + C6H5PO2Cl2 (Phenyl 
dichlorophosphate)→ C12H17ClNO4P (A2) + 2HCl 
Stream Number 8 9 10 11 12 
Stream Description DCM In Phenyl In L-AIE In DIEA In Reactor V201 
Out 
Total Mass (kg) 149335 6634 5313 8041 169323 
Component Mass (kg) 
DCM 149335 0 0 0 149335 
Phenyl Dichlorophosphate 0 6634 0 0 0 
L-Alanine Isopropyl Ester 
hydrochloride 
0 0 5313 0 42 
DIEA 0 0 0 8041 8041 
Intermediate A2 0 0 0 0 9612 
HCl 0 0 0 0 2293 
In - Out     0 
 
Table 15-3 Dissolution of 2-chloro, 6-hydroxypyridine in reactor V202 
Stream Number 13 14 15 16 
Stream Description Pyridine In DCM In DIEA In Reactor V202 
Out 
Total Mass (kg) 3705 76391 4021 84116 
Component Mass (kg) 
DCM 0 76391 0 76391 
DIEA 0 0 4021 4021 
2-Chloro, 6-Hydroxypyridine 3705 0 0 3705 
In - Out    0 
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Table 15-4 Synthesis of Intermediate A1 in reactor V203 
Reaction: C12H17ClNO4P (A2) + C5H4ClNO (2-chloro, 6-hydroxypyridine) → C17H20ClN2O5P 
(A1) + HCl 
Stream Number 12 16 17 
Stream Description Reactor 1 out Reactor 2 
out 
Reactor 3 out 
Total Mass (kg) 169323 84116 253440 
Component Mass (kg) 
DCM 149335 76391 225726 
L-Alanine Isopropyl Ester hydrochloride 42 0 42 
DIEA 8041 4021 12062 
Intermediate A2 9612 0 870 
HCl 2293 0 3336 
Hydroxypyridine 0 3705 0 
Intermediate A1 0 0 11405 
In - Out   0 
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Table 15-5 Synthesis of sofosbuvir in reactor V301 
Reaction: C17H20ClN2O5P (A1) + C10H13FN2O5 (methyluridine) → C22H29FN3O9P (sofosbuvir) + 
C5H4ClNO (2-chloro, 6-hydroxypyridine) 
Stream Number 30 31 32 33 34 35 
Stream Description M-uridine 
In 
Int A1 In ZnCl2 In THF In DIEA In Reactor Out 
Total Mass (kg) 3640 11143 2884 49778 2730 70174 
Component Mass (kg) 
Methyluridine 3640 0 0 0 0 0 
Intermediate A1 0 11143 0 0 0 5565 
Zinc Chloride 0 0 2884 0 0 2884 
THF 0 0 0 49778 0 49778 
DIEA 0 0 0 0 2730 2730 
Sofosbuvir 0 0 0 0 0 7405 
Pyridine 0 0 0 0 0 1812 
In - Out      0 
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Section 16 - Process Description 
In order to provide a much more cost-effective alternative to brand name Hepatitis C 
drugs, it was necessary to analyze various synthesis routes and methods to limit costs. Patent 
analysis, chemical synthesis route determination and raw material costing was a majority of 
process development, with the raw materials often being the key cost contributor on a per batch 
basis. Once a legitimate synthesis route was determined, it was necessary to recreate the often 
lab scale development processes on a commercial scale. Iteration of process steps, reaction 
routes, separation techniques and drying methods was necessary to develop an acceptable, 
commercial-scale process for the production of affordable sofosbuvir.  
16.1 Chemical Synthesis 
 The synthesis of sofosbuvir was generated from an exhaustive patent analysis and search, 
described in detail in Section 13.2. Figure 15-1 visualizes the final, overall synthesis route for 
sofosbuvir, separated into four reactions carried out in three reaction processes. IPA, is used as a 
solvent for L-alanine hydrochloride, the salt of L-alanine ester. IPA is fed in excess to maximize 
the reaction yield, with the majority of the solvent left unreacted and distilled after the reaction 
step. The reaction is carried out in Process 100, discussed in Section 16.2, and yields, at 87%, L-
alanine isopropyl ester for use in subsequent reactions.  
 The product of the first reaction, L-alanine isopropyl ester, is added to a reaction vessel in 
Process 200 with various solvents, including mainly DCM, and main reactant phenyl 
dichlorophosphate, fed in excess. The reaction yields phenyl(isopropoxy-L-alanine) 
phosphorochloridate, herein Intermediate A2, which is then added to a separate reaction vessel to 
a solution containing main reactant 2-chloro, 6-hydroxypyridine, which is suspended in DCM 
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from a previous reaction step. The two reactants yield a reactive intermediary referred to in the 
patent as Intermediate A1. The overall yield of the three reactions, all carried out in Process 200, 
is 97% and the Intermediate is fed to subsequent processes. 
The most specialized chemical in the synthesis is used in the final reaction to produce 
sofosbuvir. The reactive Intermediate A1 is added to a reaction vessel with solvent THF with 
main reactant methyluridine.  These two reactants yield sofosbuvir at 47% overall, the lowest of 
all yields, yet most efficient of all patents analyzed. Each of the reactions involves a complex 
series of separations, washes and drying phases, which are all discussed in detail in the 
remainder of Section 16. 
16.2 Process 100 
Process 100, whose development is discussed in detail in Section 13.3.1, was developed 
from a patent by Medivir, which accounted for the production of L-alanine isopropyl ester. The 
patent calls for the dropwise addition of thionyl chloride at 0°C to a suspension of L-alanine 
hydrochloride dissolved in IPA which is to be stirred overnight. Process 100, visualized in Figure 
15-2, demonstrates three main vessel procedures. A heat exchanger, V101, is used to cool inlet 
thionyl chloride from ambient temperature to the prescribed 0°C for dropwise addition to the 
reaction vessel, V102. The heat exchanger is operated with coolant ethylene glycol, which is 
cooled between batches in a refrigerated chiller unit to -10°C. All three solvents are charged with 
pumps at 500 L/min into two parallel reaction vessels for the overnight reaction time, which was 
assumed to be 16 hours. All pumping speeds are maintained at 500 L/min unless otherwise 
noted. After the reaction is complete, the product is pumped continuously into a distillation 
column, V103, where the main solvent, IPA, is removed from the product L-alanine isopropyl 
ester; the distillation process was modeled in ASPEN using RADFRAC. The use of multiple 
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trays in the column allows for a purer overhead product of waste IPA. The purer IPA facilitates 
its resale to distributors for little or no cost, as it is then easily repurposed as pure IPA. 
Pharmaceutical processes do not recycle solvents or reagents, as this does not maintain batch 
integrity. The addition of trays to the column was non-cost prohibitive, so the generation of a 
pure overhead was a reasonable consideration; the overhead IPA is condensed using propane 
coolant again with a chiller unit cooled between batches. After distillation removes most of the 
solvent, the product, suspended in some IPA, is pumped into Process 200 for further synthesis. 
After each vessel is used, it is cleaned in place before the next batch begins. Vessel details and 
specifications can be found in Sections 18 and 19. 
16.3 Process 200 
 Process 200, whose development is discussed in detail in Section 13.3.2, was established 
from a patent by Jiangsu Hanson Pharma Group Co, which described the production of 
Intermediate A1. The Process, which is visualized in Figure 15-3, features a series of vessel 
procedures to produce the final reactive intermediary, Intermediate A1, for the production of 
sofosbuvir. In two reaction vessels in parallel, V201, DCM is added under nitrogen protection 
and cooled to -50°C using liquid propane in cooling coils. The liquid propane coils are chilled 
between batches using a refrigerated chiller unit, as are all other coolants in Process 200. Phenyl 
dichlorophosphate, the main reactant in V201, is added and stirred for 15 minutes before the 
product of Process 100, L-alanine isopropyl ester, is added. While the L-alanine isopropyl ester 
is suspended in some remaining IPA, IPA and DCM are miscible and, thus, IPA was assumed to 
be an inert. All additional flow rates are 500 L/min unless otherwise noted and all materials are 
charged with pumps to avoid any inconsistency with gravity pumping. DIEA is added at a flow 
rate of 133 L/min, a scaling factor from the patent which called for dropwise addition. After the 
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addition of DIEA, the vessel temperature raises to around -5°C over the course of 3-4 hours. As 
the first reaction vessel, V201, begins its initial cooling step to -50°C, a second reaction vessel, 
V202 is loaded with DCM and 2-chloro, 6-hydroxypyridine under nitrogen protection and cooled 
to -10°C using liquid propane in coils. Again, DIEA is added to the vessel at a slower flow rate 
to account for lab-scale dropwise addition with constant stirring throughout its addition. After the 
addition of DIEA, the vessel temperature rises to approximately 0°C over the course of 1.5 
hours, as the reaction is exothermic. Once V201 reached its ending temperature of -5°C, the 
contents of V201, which is run in parallel, were pumped to a third vessel, V203, which is also 
run in parallel. V203 is held at 0°C using liquid brine in coils while the contents of V202 are 
split evenly and pumped into V203 over the course of 15 minutes. Again, brine is chilled 
between batches in a refrigerated chiller unit. Once the addition of V202 contents is complete, 
V203 is stirred for six hours while the contents equilibrate to room temperature. A consideration 
made during the revisions of Process 200 was the possibility of a runaway chemical reaction, as 
each of the three reaction steps are significantly exothermic, raising 5-10°C every hour. To 
account for the possibility of a runaway chemical reaction, two runaway reaction vessels were 
attached to the 5 total reaction vessels with multiple pumps such that if the vessels began 
overheating, their contents could be emptied and quenched with utility water to avoid a highly 
exothermic meltdown. 
 After the reaction in V203 is complete, the contents of the parallel reactors are pumped 
into an evaporation vessel, V204, at a flow rate of 500 L/min. The evaporation vessel operates a 
de-facto flash vessel, though it serves to vaporize DCM at its ambient vapor pressure 
isothermally to avoid heating damage of the active. The vessel operates at 0.5 bar, just below the 
vapor pressure of DCM at ambient temperature. The evaporation serves two main purposes: it 
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drastically reduces the wash volume needed in subsequent procedures and it increases the overall 
evaporation of DCM in the process that would otherwise be fed to Process 300. V204 evaporates 
71% of DCM, which is then condensed using a heat exchanger, V208, operating with chilled 
propane at -100°C. This propane is, similarly, refrigerated on a batch-by-batch basis in a chiller 
unit, with a sufficient flow rate and inlet temperature to completely condense the evaporated 
DCM, which can then be disposed of more affordably.  
The now more concentrated product stream enters a wash vessel, V205, where it is 
washed two times with a pure water stream and one time with a salt water stream. The water and 
brine are up to 3x more polar than DCM16-1, allowing for the removal of any polar impurities in 
the product as well as the removal of some DCM from the product stream. The washing agents 
are added to the vessel and mixed thoroughly before being removed with some amount of 
impurities, which call for their safe disposal, a consideration discussed in Section 23.1. After the 
various wash cycles, the product is pumped into a packed bed of drying agent sodium sulfate, 
V206. ASPEN simulations, in Appendix I, revealed that approximately 2% of water from the 
washes remains in the DCM and Intermediate A1 product stream. At an absorption ratio of 1.2 g 
water:1 g sodium sulfate, approximately 2,400 kg of sodium sulfate packing was required. The 
bed size was calculated with a void fraction of 0.55, as recommended by industrial consultants, 
as well as the consideration that sodium sulfate expands as it absorbs water. After the product 
drying is complete and the water is removed, the bed is emptied and replaced with fresh sodium 
sulfate, maintaining batch integrity and actually lower the cost of cleaning and sodium sulfate 
drying costs. The now “dry” product stream is pumped into a second evaporator vessel, V207 
with similar operating conditions and stream results as V204. Again, 71% of DCM is evaporated, 
resulting in an overall volume reduction of 92% of the original solvent feed. The vapor overhead 
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is, again, condensed in heat exchanger V208 while the final product stream, which is the 
synthesized Intermediate A1 in a remaining volume of DCM, is pumped into Process 300. After 
each vessel is used, it is cleaned in place before the next batch begins. The specifications, sizes 
and number of all equipment in Process 200 can be found in Sections 18 and 19.   
16.4 Process 300 
 Process 300, whose development is discussed in detail in Section 13.3.1, was 
developedfrom a patent by Jiangsu Hanson Pharma Group (Appendix A-4), which accounted for 
the production of the final product, sofosbuvir. Under nitrogen protection, a reaction vessel, 
V301, is charged, again at a constant pump flow rate of 500 L/min, with methyluridine, THF, 
DIEA and zinc chloride. The vessel is then sparged with nitrogen to remove any oxygen that 
may have been introduced during the process and Intermediate A1 is added to the vessel from 
Process 200, along with some leftover DCM; however, DCM and THF are miscible and DCM is 
even used in a later process step, so its presence was acceptable. The contents of the vessel are 
then heated to 60°C and reacted over “15-40 hours”, per the patent; our team decided to react the 
contents for an overnight duration, 16 hours. After the reaction in V301 is complete the contents 
are split and transferred to a wash vessel, since the 1:1 wash volume would require a single 
vessel too large for practical purposes. The wash vessel, V302, is run in parallel and requires 
various washing agents added sequentially. Ethyl acetate (EA) is added to the product stream. 
EA and THF are miscible, but sofosubvir is more soluble in EA. Saturated ammonium chloride 
solution creates a phase separation with the EA phase containing sofosbuvir, and draws out 
DIEA. HCl is used to remove the zinc chloride catalyst and any remaining DIEA completely. 
Sodium carbonate and bicarbonate buffer is added to neutralize the HCl remaining in the   rganic 
phase. Finally, the solution is washed with saturated salt water as a preliminary drying step to 
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remove water from the organic phase.  These washes are performed as liquid- liquid extractions 
in the wash vessel.  
 The wash product is then pumped through a sodium sulfate packed bed, V303, much like 
Process 200. The two packed beds are similar in size and amount of packing material required, 
and like the packed bed in Process 200, V303 also uses fresh sodium sulfate for each batch. For 
both packed bed units V206 and V303, the Ergun equation was used to determine the pressure 
drop in the packed bed to determine the energy requirement of pumps into and out of the vessel. 
The dried product stream is subsequently pumped into a distillation column, V304, for reasons 
similar to Process 100, in that the vapor pressure of the main solvent, EA, is far too low for an 
evaporator vessel, but the recovery of solvent is still highly important to the procedure. The 
distillation process will occur continuously, as the batch flows out of the packed bed, much like 
the operation of the evaporators and distillation columns previously used as well. The liquid 
overhead EA is condensed using liquid propane coolant, which is refrigerated between batches in 
a chiller unit, and collected for waste disposal and/or resale; the concentrated bottoms product 
stream enters a final mixing vessel, V305, where solvents DCM and acetone are charged to assist 
in crystallization. After the solvents and concentrated product are agitated in V305, the contents 
are pumped out at a very low flow rate, approximately 80 L/min, into the crystallizer unit, V306. 
This flow rate into the crystallizer was selected based on the rate at which the unit could perform 
a continuous crystallization, as scaling a crystallizer was more cost intensive than most other 
equipment. During scheduling, the flow rate into the crystallizer was changed such that the 
mixing vessel, V305, became the bottleneck, assuring that the flow rate in to V306 was as low as 
possible. The crystallizer operates continuously for about 20 hours with 4 hours of downtime 
between batches. Finally, the wet crystals are pumped to a tray drying unit, V308, where the wet 
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crystals are dried over 30 mins until the remaining EA, DCM and acetone, all of which are 
extremely volatile, evaporate. The total area of the trays will be 50 square feet, based on the flow 
rate of the crystallized product out. Furthermore, the mother liquor waste is collected and 
disposed of properly. Tray drying will yield the final product, sofosbuvir, in solid form, ready for 
encapsulation and long term storage for sale. The specifications, sizes and number of all 
equipment in the overall process can be found in Sections 18 and 19.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endnotes 
 
16-1: Louisiana State University (2010). Polarity Index. Retrieved from 
http://macro.lsu.edu/howto/solvents/Polarity%20index.htm. 
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Section 17 - Energy Balance and Utility Requirements 
For each batch of sofosbuvir, 197,000 kWh of energy are required. While this quantity 
appears to be a large amount, but the overall cost of energy utilities ($23,987 per batch) 
constitutes only a small portion of the total cost of sofosbuvir. Electricity was estimated to cost 
roughly $0.07 per kWh as noted in Table 17-1 of the Product and Process Design Principles 
textbook by Dr. Seider (Appendix F-1). This was a reasonable estimate for cost of electricity in 
India as it is consistent with the prices of $0.08 surveyed by Ovo Energy17-1. Furthermore, to 
encourage industry in India, the government will subsidize energy, so the cost could conceivably 
be lower than $0.07. The other major cost is for the regeneration of coolant, which is used in the 
condensers. These costs are interpolated from the data provided in Appendix F-1. More detailed 
breakdowns of the energy utilities for each individual process stage can be found in Tables 17.1-
3 below.  
Table 17-1 Utility Costs Per Equipment in Process 100 
Unit Function 
Energy 
Requirement 
(kWh/Batch) Cost ($/Batch) 
V101 - SOCl2 Heat Exchanger Cooling 61 $19.70 
V102 - Screw Conveyor Transport 1 $0.06 
V102 - Reaction Vessel Stirring 92 $6.46 
V103 - Distillation Column Heating 44,181 $3,092.69 
Cooling 44,236 $7,154.96 
Pumping Transport 3 $0.23 
Process 100 Total  88,574 $10,274.11 
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Table 17-2 Utility Costs Per Equipment in Process 200 
Unit Function 
Energy 
Requirement 
(kWh/Batch) 
Cost 
($/Batch) 
V201 - Screw Conveyor Transport 1 $0.06 
V201 - Reaction Vessel Cooling 3,833 $1,705.07 
Stirring 35 $2.47 
V202 - Screw Conveyor Transport 1 $0.06 
V202 - Reaction Vessel Cooling 894 $289.35 
Stirring 18 $1.23 
V203 - Reaction Vessel Cooling 230 $47.50 
Stirring 68 $4.76 
V204 - Flash Heating 13,280 $929.60 
V205 - Wash Vessel Stirring 227 $15.88 
Salt Water Tank Stirring 16 $1.10 
V207 - Flash Heating 3,867 $270.69 
V208 - Condenser Cooling 18,284 $2,957.43 
Total Pumping Transport 16 $1.10 
Process 200 Total 40,770 $6,226.31 
Table 17-3 Utility Costs Per Equipment in Process 300 
Unit Function 
Energy 
Requirement 
(kWh/Batch) 
Cost 
($/Batch) 
V301 - Screw Conveyor Transport 2 $0.13 
V301 - Reaction Vessel Heating 5,180 $362.57 
V301 - Reaction Vessel Stirring 90 $6.29 
Buffer Tanks (Combined) Stirring 27 $1.88 
V302 - Wash Vessel Stirring 113 $7.94 
V304 - Distillation Reboiler Heating 30,397 $2,127.81 
V304 - Distillation Condenser Cooling 30,533 $4,938.58 
V305 - Mixing Vessel Stirring 181 $12.67 
V305 - Crystallizer Heating 384 $26.88 
Total Pumping Transport 22 $1.51 
Process 300 Total 66,928 $7,486.26 
Overall Total 196,273 $23,986.68 
80
 
 
 
 
Figure 17-1 Percentage of total energy requirement (192,912 kWh per batch) broken down 
by section of process 
 
Figure 17-2 Percentage of total energy requirement (192,812 kWh per batch) broken down 
by energy use 
17.1 Heating Utilities 
Distillation columns and flash vessels were modeled in Aspen Plus using the RADFRAC 
and Flash2 units respectively (Appendix F). Overall, separation vessels require 91,700 kWh to 
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induce the separation. All heating will be accomplished using electricity, which costs $0.07 per 
kWh. As a result, it will cost $6,421 per day to heat the distillation columns and flash vessels.  
In V301, reaction to synthesize sofosbuvir occurs at 55°C and is operated overnight. 
Based on Aspen HeatEx calculations, 5,180 kWh of heating is required to increase the 
temperature of the vessel from 25°C to 55°C and to maintain that temperature over 16 hours. At 
a cost of $0.07 per kWh, V301 costs $363 per day.  
For both evaporation and reaction, electricity was used as the heating mechanism instead 
of steam utility, because it is both cheaper and enables better control of the temperature 
fluctuation. A thermocouple installed in the vessel provides feedback to a PID controller that will 
maintain the temperature the distillation column and the flash vessel as solvent is removed.  
17.2 Cooling Utilities 
The largest energy requirement is regenerating coolant for the condensers and cooling the 
reactors. Cooling energy duties were simulated with Aspen Plus for the relevant solvents. 
Condenser heat duties were modeled using RADFRAC for the V103 and V304 distillation 
columns and using HeatX after the flash vessel V207. All condenser units were designed for total 
condenser, so the distillate stream can be stored and disposed. Based on the amount and final 
temperature of cooling necessary, either ethylene glycol or propane was selected to be the 
refrigerant (Appendix F-2).  
Reactor V201 containing DCM was cooled to -50°C before the start of the reaction to 
prevent side reactions. Since the final temperature is low, propane was selected as the refrigerant. 
The heat capacity of propane (98 J/mol-K) is comparable to that of DCM (102 J/mol-K), so it 
can be used without creating a pinch point. To cool the DCM from 25°C to -50°C, 3,833 kWh 
would be removed via propane. To accomplish this cooling, the process requires a utility of 
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154,682 kg of propane refrigerated to -100°C, pumped through the system at 708 L/min for a 
total cooling time of 3.8 hours. The utility cost of refrigerating propane to -100°C is $10 per ton-
day, yielding a total cost of $1,705 per day for cooling in reactor V201 (Appendix F-1).  
Reactor V202 is cooled to -10°C prior to operation. Assuming that the 2-Chloro-6-
hydroxypyridine does not affect the heat capacity of the DCM solvent, 894 kWh of cooling is 
required to cool the DCM solution from 25°C to -10°C. To cool V202, 26,249 kg of propane 
refrigerant are cooled by the propane chiller to -100°C. Propane is pumped through the cooling 
jacket over the course of 4.9 hours. Refrigerating propane to -10°C costs $10 per ton-day, 
yielding a total cost of $289 per day for cooling V202.  
Reactor V203 is cooled from room temperature to 0°C and maintained at the temperature 
while transferring in the contents of reaction vessel V201. To accomplish this cooling, 230 kWh 
of energy is removed via chilled brine over 15 minutes. Refrigerating brine to -18°C costs 
$2.25per ton-day, yielding a total cost of $47.50 per day for the cooling of V203.  
For reactors V201, V202, and V203, a thermocouple inside the reactor will detect 
temperature as the system cools. When the setpoint temperature is reached, the response with 
shut the valve for incoming refrigerant. This will prevent the waste of refrigerant used to cool the 
reactor below the setpoint or maintain the temperature once equilibrium is reached.  
17.3 Pumps and Screw Conveyors 
Pumps used for charging starting materials and transferring materials from one reactor to 
the next were modeled in Aspen Plus using the Pipe and Pump units. Flow calculations followed 
the following assumptions. Solvents flowed at 500 L/minute through stainless steel tubing with 
inner diameter of 0.15 meters. Since most tanks are roughly one story tall, the pipe had a length 
of 20 meters and an elevation change of 3 meters. Thus, the pump needed to compensate for 
83
 
 
 
roughly 0.3 bars of pressure drop. This amounted to 0.431 kW per hour (Appendix F-3). Because 
the energy utility of pumps was so small, pump utilities were combined for each step of the 
process. Out of 197,800 kWh of energy required per batch, only 41 kWh was needed for 
pumping all the fluids.  
Transport of the solid materials L-alanine, phenyl dichlorophosphate, 6-chloro-2-
hydroxypyridine, and methyluridine were done via screw conveyor. Screw conveyors allow for 
controlled transport of the solid reactants. The energy utility of the twin screw conveyor was 
estimated using Appendix F-3 referenced from the Journal of Agricultural Science. At a rotation 
speed of 600 rpm and 12 mm of clearance, the conveyor would require 0.451 kW of power to 
transport solids. Altogether the screw conveyors require 5 kWh of electricity per batch. The total 
energy of transport is 46 kWh per batch, which is only 0.02% of the total energy utilities.  
17.4 Agitators 
Agitator requirements were estimated by the Agitator 
Power Calculator by CheCalc17-2. Calculations for the reactors 
were modeled a pitched blade agitator with 0.3 D/T ratio at a 
scale of 4. D/T ratio, the ratio between the agitator diameter 
and the tank diameter, typically ranges between 0.2 and 0.6. 
The scale of 4 was chosen because the organic solvents have 
similar viscosities and specific gravities. In comparison, the 
wash vessels (V205 and V302) were modeled with a scale of 8, 
because they require high velocities to mix the two immiscible fluids completely before 
separation occurs. The power of reactor agitators was roughly 10 kWh, whereas the power of 
larger wash agitators was much higher at 40 kWh. A summary of the agitator power 
 
Figure 17-3 Dimensions of 
agitator with respect to the 
mixing vessel.  
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requirements are summarized in Table 17-4 presented below. The individual power requirement 
as solved by the program was multiplied with the operating time of the reactor to obtain the 
agitator energy utility.  
Table 17-4 Summary of Agitator Power Requirements 
 V101 V201 V202 V203 V301 
Batch Volume (m3) 100 85 85 125 80 
Fluid IPA DCM DCM DCM THF 
Density (kg/m3) 786 1330 1330 1330 889 
Dynamic Viscosity (cP) 2.04 0.413 0.413 0.413 0.48 
Diameter (m) 1.5 1.43 1.43 1.63 1.4 
Agitator Speed (rpm) 52.87 55.82 55.82 49.08 56.95 
Reynolds Number 773,362 6,123,009 6,123,009 6,962,981 3,451,020 
Power (kW) 5.77 8.82 8.82 11.33 5.62 
 
 
 
 
 
Endnotes 
17-1: OVO Energy (2016). Average electricity prices around the world: $/kWh. Retrieved from 
https://www.ovoenergy.com/guides/energy-guides/average-electricity-prices-kwh.html 
17-2: CheCalc (2015). Agitator Power: Calculates agitator speed and power requirement for a 
given reactor geometry and mixture properties. Retrieved from 
http://checalc.com/solved/agitator.html.  
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Section 18 - Equipment List and Description 
18.1 Equipment List 
Table 18-1 General Equipment 
Equipment 
Description 
Unit Number Number of Units Vendor 
Vessel Agitator V102/V201/V202/V203/V204/V3
01/V302/V307 
12 N/A 
Centrifugal Pumps S102/S103/S104/S105/S106 
S202/S203/S204/S205/S207/S208
/S209/S210/S211/S212/S213/S21
4/S215/S216 
S301/S303/S304/S306/S307/S308
/S309/S310/S311/S312/S313/S31
4/S315/S316/S317/S318/S319 
42 Flowserve 
Propane Chiller Chiller-Propane 1 Johnson 
Controls 
Screw Conveyer S101/S201/S206/S302/S305 5 N/A 
Table 18-2 Process 100 Equipment 
Equipment 
Description 
Unit Number Number of Units Vendor 
Heat Exchanger  V101 1 N/A 
100,000L Reaction 
Vessel 
V102 2 N/A 
Distillation Column V103 1 N/A 
Ethylene Glycol Chiller Chiller-EG 1 Johnson 
Controls 
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Table 18-3 Process 200 Equipment 
Equipment Description Unit Number Number of Units Vendor 
85,000 L Reaction Vessel V201 2 N/A 
85,000L Reaction Vessel V202 1 N/A 
140,000L Reaction Vessel V203 2 N/A 
Flash Vessel V204/V207 2 N/A 
400,000 L  
Wash Vessel 
V205 1 N/A 
Packed Bed Drying Vessel V206 1 N/A 
Condenser (Heat Exchanger) V208 1 N/A 
100,000L Runaway Reaction Vessel V209 2 N/A 
Brine Chiller  Chiller-Brine 1 Johnson Controls 
Table 18-4 Process 300 Equipment 
Equipment Description Unit Number Number of Units Vendor 
120,000L Reactor V301 1 N/A 
192,000L Wash Vessel V302 2 N/A 
60,000 L Packed Bed Drying Vessel V303 1 N/A 
Flash Vessel V304 1 N/A 
160,000L Mixing Vessel V305 1 1 
Crystallization Unit V306 1 Thermal Kinetics 
Dryer V307 1 N/A 
Belt Conveyer S320 1 N/A 
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18.2 Equipment Selection 
Equipment units were selected based on the maximum efficiency of the process with 
advice from industrial consultants as well as specific vendors. Units were chosen to comply with 
GMP production. 
18.3 Common Units 
Pumps 
Centrifugal pumps are used to transfer fluids throughout the process. In the reactor 
processes, the power of the pump is approximately 5 hp. The pumps operate at room temperature 
with a maximum flow rate of 500 L/min. The purchase cost of each pump is $4,936, as 
determined using the equipment costing spreadsheet. There are a total of 10 pumps for Process 
100, 22 pumps for Process 200, and 10 pumps for Process 300.   
Agitator 
The Agitator is a component of each reaction vessel and wash vessel. The vessel costs 
were determined separately, as the vessel costs were computed using the pressure vessel cost 
equations. The agitator is necessary to keep the reactor contents well mixed in terms of reactant 
concentration and temperature. The agitator power is 15 hp, and this was determined based on 
the volume of the reactor contents and the intensity of mixing necessary. The agitator cost was 
determined to be $19,216 using chapter 23 of Product and Process Design Principles18-1 .  
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Chiller (Ethylene Glycol/Brine/Propane) 
The chillers for each of the refrigerants are used to remove heat from the refrigerants so 
they can be used in heat exchange functions to cool the process. These chillers use water for 
cooling, and their refrigeration capability is evaluated in calculations shown in Appendix C. The 
costs for the ethylene glycol, brine, and propane chillers were determined to be $4,000, $26,200, 
and $378,500, respectively.  
Screw Conveyors S101/S201/S206/S302/S305 
Screw conveyors will be used to feed solid materials into reactor vessel, including 2’-
deoxy-2’-fluoro-2’-methyluridine and zinc chloride. Separate units will be used for each feed 
material to maintain GMP standards. The diameter of the conveyer will be 20 inches, and the 
length will be 30 feet. The purchase cost, as determined using Table 16.32 of Process Design 
Principles, is $15,748. 
18.4 Process 100 Equipment Description 
Heat Exchanger V101 
The heat exchanger is used to cool the thionyl chloride from ambient temperature (25°C) 
to 0°C before it enters the reaction vessel. Patent literature states that this step is necessary in 
producing the L-alanine isopropyl ester. This exchanger uses shell and tube geometry, and 
ethylene glycol as the coolant. The area of the exchanger is about 25 square meters, and the 
ethylene glycol exits the exchanger at 4.8°C. This heat exchanger will cost $36,110, as 
determined using the equipment costing spreadsheet. A pressure relief valve will be used to 
maintain safe operation. 
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Reaction Vessel V102 
The reaction vessel is used for the production of L-alanine isopropyl ester. The reaction 
vessel is charged with isopropyl alcohol, thionyl chloride, and L-alanine hydrochloride. The unit 
will be agitated at room temperature overnight to facilitate the reaction. The unit is made of 
stainless steel, and temperature and agitation are controlled with PID controls. The tank has a 
volume of 100,000L and a working volume of 75,000L. The cost is approximately $189,207, as 
determined using the equipment costing spreadsheet for a pressure vessel. 
Distillation Column V103 
The distillation column is used to concentrate the L-alanine isopropyl ester product from 
the unconsumed reactants and side products. The distillation column will have three stages, and 
will operate at reflux ratio of 3.0 and a bottoms-to-feed ratio of 0.04. The reboiler temperature 
will be kept low (46°C) to avoid degradation of the product. The column sizing was determined 
using chapter 13 of Process Design Principles (Seider, 2016). Calculations are shown in 
Appendix C. The column material will be stainless steel, and the purchase cost will be $249,823. 
18.5 Process 200 Equipment Description 
Reaction Vessel V201 
This reaction vessel will combine phenyl dichlorophosphate, DCM, DIEA, and the L-
alanine isopropyl ester from Process 100. The reaction vessel is made from stainless steel with a 
volume of 85,000L. In addition to jacketing for temperature control, there will be cooling coils to 
maintain the -50°C temperature necessary for the reaction. Additionally, a turbine agitator will 
be used to mix the reactor contents. The purchase cost of this reactor is $178,144. Two identical 
reactors will operate in parallel, and the reactants will be split evenly between the two vessels. 
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Reaction Vessel V202 
This reaction vessel will react 2-chloro-6-hydroxypyridine, DCM, DIEA to produce a 
reaction intermediate that is to be reacted with the products of V201. The reaction vessel is made 
from stainless steel with a volume of 85,000L, and is jacketed for temperature control. Using the 
equipment costing spreadsheet the estimated purchase cost is $178,144. 
Reaction Vessel V203 
This reaction vessel will combine the products of V201 and V202 to produce 
Intermediate A1. The reactor will be jacketed for temperature control, and the reactor volume 
will be 140,000L. Additionally, the vessel will have a agitation turbine to induce mixing. The 
material will be stainless steel, and the purchase cost is $222,075. 
Flash Vessel V204/V207 
The flash vessel will be used to remove DCM from the product stream of V203 to reduce 
the volume of product that enters the wash vessel. The vessel will operate at 25°C and 0.50 bar, 
and the material will be stainless steel. One flash vessel will be used immediately after 
completion of the reaction, and another identical flash vessel will operate after sodium sulfate 
drying. Using the equipment costing spreadsheet the purchase cost of the flash vessel is $55,007. 
Wash Vessel V205 
The wash vessel’s purpose is to add salt water to the product of V203. This process is 
necessary to purify the product intermediate A1. The vessel volume will be 400,000L and its 
material will be stainless steel. The washes will be performed at room temperature and ambient 
pressure, and thermal jacketing will be used for temperature control. Modeling the wash vessel 
as a pressure vessel, the estimated cost is $361,004. 
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Packed Bed Drying Vessel V206 
The packed bed drying vessel will use anhydrous sodium sulfate to selectively absorb 
water from the product mixture. Between batches, the resin will be removed and the vessel can 
be cleaned using clean-in-place procedures. The anhydrous sodium sulfate will need to be 
replaced for each new batch as the sodium sulfate has limited absorption capacity. The vessel 
material will be stainless steel, and the estimated purchase cost is $72,082. 
Condenser/Heat Exchanger V208 
A heat exchanger will operate using propane as the refrigerant to condense the distillate 
product of the flash vessel. The exchanger geometry will be shell and tube with 12 feet long 
tubes, and the material will be carbon steel and stainless steel. The total area of heat transfer is 
1614 ft2 and the purchase cost is $75,569. 
Runaway Reaction Vessel V209 
The runaway reaction vessel will be used as a safety measure because process 200 
involves exothermic reactions. The vessel will be filled with room temperature water. Reactor 
contents can be rapidly pumped into the runaway vessel in the event of a runaway reaction. The 
vessel material will be stainless steel and the volume is 100,000L. The purchase cost is 
$189,207. 
18.6 Process 300 Equipment Description 
Reaction Vessel V301 
This reaction vessel will react methyluridine, DIEA, and intermediate A1 to produce the 
final product, sofosbuvir. The reaction vessel will use both an outer temperature jacket and 
internal heating coils for temperature control as the reaction is performed at higher temperature 
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(55°C). The material will be stainless steel and it will have a volume of 120,000L. The purchase 
cost will be $193,445. 
Wash Vessel V302 
The wash vessel will use various buffers and salt solutions to wash the product of V301. 
This step is necessary to purify the final product sofosbuvir. The vessel volume required will be 
192,000L, and two vessels will be necessary per batch. Temperature control will not be 
necessary in this vessel. The material to be used is stainless steel, and the estimated cost of the 
vessel is $253,955.  
Packed Bed Drying Vessel V303 
Anhydrous sodium sulfate is used as a resin in a packed bed vessel to remove water from 
the organic phase after the wash. Sodium sulfate is a drying agent that will selectively absorb the 
water from the mixture, and this is part of the purification process. The purchase cost of the 
vessel is $48,091. 
Distillation Column V304 
A distillation column will be used to remove much of the solvent from the mixture 
leaving the drying vessel. Ethyl acetate will be removed in the distillate, while the product 
sofosbuvir will leave in the bottoms product. The column will operate at a reflux ratio of 3.0 and 
a bottoms-to-feed ratio of 0.085. The column will have two stages, and the column will operate 
at 0.15 bar. Stainless steel will be used as the material and the purchase cost of the column is 
$107,690. 
Mixing Vessel V305 
A mixing vessel will be used to mix acetone, DCM, and the bottoms product of the 
distillation column before feeding to the crystallization unit. The mixing vessel will agitate its 
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contents for 10 minutes before transferring the contents to the crystallizer. The vessel volume 
will be 160,000 L and the material will be stainless steel. The purchase cost was determined to 
be $237,160. 
Crystallization Unit V306 
A crystallization unit will be used to obtain the final product as crystals. A mixture of the 
product sofosbuvir, DCM, and acetone will be combined in the crystallizer. The crystallization 
unit will handle a flow rate of 5000L per hour. The cost is approximately $750,000 as 
determined by contacting the vendor directly. 
Drying Batch Tray V307 
A batch drying tray will be used to dry the final product after crystallization. The drying 
tray will use electrical heating to evaporate the remaining DCM from the sofosbuvir crystals. The 
tray will have an area of 50 square feet, and will operate at 39°C, the boiling temperature of 
DCM. The purchase cost is $17,301. 
Belt Conveyer S320 
A belt conveyer will be used to transport the solid sofosbuvir crystals from the 
crystallizer to the drying unit. The belt conveyer will have dimensions of 30 inches by 30 feet, 
and will operate only as the crystallizer produces sofosbuvir crystals. Using Table 16.32 of 
Process Design Principles, the purchase cost of the belt conveyer is $21,960. 
 
 
Endnotes 
Seider, W.D. (2016). Product and process design principles: synthesis, analysis and design. New 
York, NY: John Wiley & Sons. 
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Section 19 – Equipment Specification Sheets 
Heat Exchanger V101 
Description and Function: Heat exchanger uses ethylene glycol to cool thionyl chloride before it 
enters the reactor. Thionyl chloride is specified to enter the reactor at 0°C, so it must be cooled 
accordingly. For safety, the heat exchanger will have a pressure relief valve.  
Vendor: N/A 
Operation: Continuous 
Materials Handled:  
Input Flow Rate (L/min) Inlet Temperature (°C) Outlet Temperature 
(°C) 
Ethylene Glycol 500 -10 4.9 
Thionyl Chloride 500 25 0 
 
Characteristics: 
Material Carbon Steel 
Area 25 m2 
Heat Duty 73571 cal/s 
Tube length 12 feet 
Sterilization CIP 
Tube Outer Diameter 1.5 in 
Tubes 60 
 
Operating Conditions: 
Pressure 1.1 bar 
 
Purchase Cost: 
$36,110 
Reference Page: 
N/A  
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Reactor Vessel V102 
Description and Function: 100,000L reactor used to produce L-alanine isopropyl ester in the first 
synthesis step. The reactor vessel will be temperature controlled to maintain the reaction 
conditions described in the patent literature. All contents of the tank will be pumped to V102 for 
separation by distillation. For safety, a pressure relief valve will be incorporated. 
Vendor: N/A 
Operation: Batch 
Materials Handled (split in half across two identical vessels):  
Input Quantity (kg) 
L-alanine hydrochloride 4568 
Isopropyl Alcohol 99882 
Thionyl Chloride 8642 
 
Characteristics: 
Material Stainless steel 
Working Volume 100,000 L 
Total Volume 70,000 L 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$189,207 
Reference Page: 
N/A 
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Distillation Column V103 
Description and Function: Distillation column used to separate L-alanine isopropyl ester product 
from isopropyl alcohol and thionyl chloride. The column will operate with three trays with reflux 
ratio set to three and bottoms to feed ratio of 0.04. The bottoms product will be pumped to V103 
for storage. For safety, the column will have a pressure relief valve.  
 
Vendor: N/A 
Operation: Continuous 
Materials Handled:  
Input Quantity (kg) 
L-Alanine 295 
Isopropanol 49101 
Thionyl Chloride 2441 
L-Alanine Isopropyl Ester 2656 
HCl 1156 
SO2 1014 
 
Characteristics: 
Material Stainless steel 
Diameter 15 ft 
Height 31 ft 
Sterilization CIP 
Spacing between stages 24 in 
Tray Type Valve  
 
Operating Conditions: 
Reflux Ratio 3.0 
Stages 3 
Bottoms to feed Ratio 0.04 
Reboiler Temperature 320.8 K 
Condenser Temperature 295.8 K 
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Pressure 0.06 bar 
Foaming? No Foaming 
Purchase Cost: 
$249,823 
Reference Page: N/A 
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Ethylene Glycol Chiller 
Chiller-EG 
Description and Function: This chiller uses water cooling to absorb heat from the refrigerant, 
ethylene. The ethylene glycol is used as a refrigerant in V101. 
Vendor: Johnson Controls 
Operation: Continuous 
Materials Handled: 
Material Input (L) 
Ethylene Glycol 50,000 
 
Characteristics: 
Material Stainless Steel 
Power 10 tons 
 
Operating Conditions: 
Cooling Method Water 
Temperature -10°C 
 
Purchase Cost: 
$4,000 
Reference Page: 
N/A 
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Reaction Vessel V201 
Description and Function: 85,000L reactor used to produce a reaction intermediate in process 
200. The reactor vessel will be temperature and pressure controlled to maintain the reaction 
conditions described in the patent literature. Cooling will be provided using cooling coils with 
propane as the refrigerant. All contents of the reactor will be combined with the product of V202 
in a third reaction step in V203. To ensure safe operation, the vessel will have a pressure relief 
valve, and the vessel will be nitrogen padded to prevent side reactions with oxygen. 
 
Vendor: N/A 
Operation: Batch 
Materials Handled (split in half across two identical vessels): 
Input Quantity (kg) 
DCM 149,335.08 
Phenyl Dichlorophosphate 0 
L-Alanine Isopropyl Ester hydrochloride 42.02963693 
DIEA 8,041.12 
Intermediate A2 9612.172131 
HCl 2292.849779 
 
Characteristics: 
Material Stainless Steel 
Working Volume 60,000 L 
Total Volume 85,000 L 
Sterilization CIP 
 
Operating Conditions: 
Temperature -50 to -10°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$178,144 
Reference Page: 
N/A 
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Reaction Vessel V202 
Description and Function: 85,000L reactor used to produce a reaction intermediate in process 
200. The reactor vessel will be temperature and pressure controlled to maintain the reaction 
conditions described in the patent literature. Cooling will be provided using cooling coils with 
propane as the refrigerant. All contents of the reactor will be combined with the product of V201 
in a third reaction step in V203. To ensure safe operation, the vessel will have a pressure relief 
valve, and the vessel will be nitrogen padded to prevent side reactions with oxygen. 
 
Vendor: N/A 
Operation: Batch 
Materials Handled (split in half across two identical vessels): 
Input Quantity (kg) 
2-chloro-6-hydroxypyridine 3705 
DCM 76,342 
DIEA 4020 
 
Characteristics: 
Material Stainless Steel 
Working Volume 60,000 L 
Total Volume 85,000 L 
Sterilization CIP 
 
Operating Conditions: 
Temperature -10 to 0°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$178,144 
Reference Page: 
N/A 
  
101
 
 
 
Reaction Vessel V203 
Description and Function: 140,000L reactor used to produce intermediate A1 in process 200. The 
reactor vessel will be temperature and pressure controlled to maintain the reaction conditions 
described in the patent literature. The reactor vessel will be jacketed to provide the necessary 
cooling. All contents of the reactor will be sent to a flash vessel (V204) for purification of 
product. To ensure safe operation, the vessel will have a pressure relief valve, and the vessel will 
be nitrogen padded to prevent side reactions with oxygen. 
 
Vendor: N/A 
Operation: Batch 
Materials Handled (split in half across two identical vessels): 
Input Quantity (kg) 
V201 Product 171670 
V202 Product 84067 
 
Characteristics: 
Material Stainless Steel 
Working Volume 98,000 L 
Total Volume 140,000 L 
Sterilization CIP 
 
Operating Conditions: 
Temperature 0 - 25°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$222,075 
Reference Page: 
N/A 
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Flash Vessel V204 
Description and Function: Flash vessel to separate DCM from the product intermediate A1. Due 
to the relatively high vapor pressure of DCM at room temperature, the flash process does not 
manipulate temperature; only pressure is reduced in the flash vessel.  
Vendor: N/A 
Operation: Continuous 
Materials Handled: 
Input Quantity (kg) 
DCM 204886 
Intermediate A1 21481 
 
Characteristics: 
Material Stainless Steel 
Diameter 7 ft 
Length 22 ft 
Feed flow rate 500 L/min 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25°C 
Pressure 0.5 bar 
 
Purchase Cost: 
$55,007 
Reference Page: 
N/A 
  
103
 
 
 
Wash Vessel V205 
Description and Function: The wash vessel introduces saturated salt water to wash away polar 
impurities such as phenyl dichlorophosphate. The vessel has an agitator to improve mixing. 
Temperature control is not necessary in this step.   
Vendor: N/A 
Operation: Batch 
Materials Handled: 
Input Quantity (kg) 
DCM 58858 
Intermediate A1 21361 
Saturated Salt Water 201027  
 
Characteristics: 
Material Stainless Steel 
Total Volume 400,000 L 
Working Volume 280,000 L 
Feed flow rate 500 L/min 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$361,004 
Reference Page: 
N/A 
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Drying Packed Bed V206 
Description and Function: Packed bed with anhydrous sodium sulfate to remove water from the 
product mixture. The sodium sulfate selectively absorbs water in the mixture.  
Vendor: N/A 
Operation: Continuous 
Materials Handled: 
Input Quantity (kg) 
DCM 58858 
Intermediate A1 21361 
Saturated Salt Water 4026 
 
Characteristics: 
Material Stainless Steel 
Diameter 6ft 
Length 12.4ft 
Resin Anhydrous Sodium Sulfate 
Feed flow rate 500 L/min 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25°C 
Pressure 2.4 bar 
Void Fraction 0.55 
 
Purchase Cost: 
$72,082 
Reference Page: 
N/A 
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Flash Vessel V207 
Description and Function: Flash vessel to further remove DCM from Intermediate A1. The flash 
vessel will also be fed trace amounts of water that are not able to removed by sodium sulfate 
drying.  
Vendor: N/A 
Operation: Continuous 
Materials Handled: 
Input Quantity (kg) 
DCM 58858 
Intermediate A1 21361 
Saturated Salt Water 10             
 
Characteristics: 
Material Stainless Steel 
Diameter  7 
Length 22 
Feed flow rate 500 L/min 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25°C 
Pressure 0.5 bar 
 
Purchase Cost: 
$55,007 
Reference Page: 
N/A 
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Heat Exchanger (Cooling) V208 
Description and Function: This heat exchanger uses ethylene glycol to condense the distillate of 
V204 and V207. The distillate is mostly DCM, and condensing to liquid allows the material to be 
discarded as liquid organic waste.  
Vendor: N/A 
Operation: Batch 
Materials Handled: 
Input Inlet Flow rate (L/min) Inlet Temperature (°C) Outlet 
Temperature (°C) 
DCM 500 25 21 
Propane 500 -100 21 
 
Characteristics: 
Material Stainless Steel/Carbon Steel 
Area  1614 ft2 
Exchanger Design Shell and Tube 
Tube Length 20 ft 
Tube Outer Diameter 1.5 in 
Number of Tubes 206 
 
Operating Conditions: 
Pressure 0.5 bar 
 
Purchase Cost: 
$67,473 
Reference Page: 
N/A 
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Runaway Reaction Vessel V209 
Description and Function: This runaway reaction vessel is necessary to address safety concerns. 
Process 200 involves exothermic reactions that may release excessive heat in the event of a 
runaway reaction. This vessel will contain cold water that can absorb the energy release by the 
reaction, preventing a runaway reaction from causing damage to the process.   
Vendor: N/A 
Operation: Batch 
Materials Handled: 
Input Quantity (kg) 
Water 20,000 
V201 Contents 0-60,000 
 
Characteristics: 
Material Stainless Steel 
Volume 100,000L 
 
Operating Conditions: 
Temperature 25°C 
Pressure 0.5 bar 
 
Purchase Cost: 
$189,207 
Reference Page: 
N/A 
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Brine Chiller  
Chiller-Brine 
Description and Function: This chiller uses water cooling to absorb heat from the refrigerant, 
brine. The chiller operates continuously to cool the brine which is used as a refrigerant for V203.  
Vendor: Johnson Controls 
Operation: Continuous 
Materials Handled: 
Material Input (L) 
Brine 82000 
 
Characteristics: 
Material Stainless Steel 
Power 65 tons 
 
Operating Conditions: 
Cooling Method Water 
Temperature 0°C 
 
Purchase Cost: 
$26,158 
Reference Page: 
N/A 
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Reaction Vessel V301 
Description and Function: Reaction vessel to produce final product sofosbuvir. Reactor will 
operate at 55C for 16 hours. Reactor contents will be pumped to V302 for washing to purify 
product.  
Vendor: N/A 
Operation: Batch 
Materials Handled: 
Input Quantity (kg) 
2’-deoxy-2’-fluoro-2’-methyluridine 3639 
Intermediate A1 11142 
DIEA 2729 
Zinc Chloride 2883 
THF 49784 
 
Characteristics: 
Material Stainless Steel 
Working Volume 84,000 L 
Total Volume 120,000 L 
Sterilization CIP 
 
Operating Conditions: 
Temperature 55°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$193,445 
Reference Page: 
N/A 
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Wash Vessel V302 
Description and Function: Wash vessel introduces ethyl acetate, HCl, and saturated salt water to 
wash the product before further purification steps. The vessel will agitate contents to improve 
washing.  
Vendor: N/A 
Operation: Batch 
Materials Handled (split across two identical vessels): 
Input Quantity (kg) 
Sofosbuvir 3499 
THF 49784 
Ethyl Acetate 100466 
Saturated Salt Water 55993 
HCl 55993 
Ammonium Chloride 19597 
 
Characteristics: 
Material Stainless Steel 
Working Volume 140,000 L 
Total Volume 192,000 L 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$253,955 
Reference Page: 
N/A 
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Drying Packed Bed V303 
Description and Function: Packed bed uses anhydrous sodium sulfate to selectively absorb water 
and remove it from the product.  
Vendor: N/A 
Operation: Continuous 
Materials Handled: 
Input Quantity (kg) 
Sofosbuvir 3499 
THF 49784 
Ethyl Acetate 100466 
Saturated Salt Water 55993 
HCl 55993 
Ammonium Chloride 19597 
 
Characteristics: 
Material Stainless Steel 
Diameter 3.4 ft 
Length 13.6 ft 
Resin Sodium Sulfate 
Resin Mass 2100 kg 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25°C 
Pressure 2.4 bar 
 
Purchase Cost: 
$48,091 
Reference Page: 
N/A 
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Distillation Column V304 
Description and Function: Distillation column used to separate ethyl acetate from the sofosbuvir 
product. The column will operate with two stages with reflux ratio set to three and bottoms to 
feed ratio of 0.085. The distillate will be discarded as waste while the bottoms product will be 
further processed by crystallization. The column sizing calculation is shown in Appendix C.  
Vendor: N/A 
Operation: Continuous 
Materials Handled:  
Input Quantity (kg) 
Methyluridine 1587 
Intermediate A1 7997 
THF 27418 
Sofosbuvir 3684 
Ethyl Acetate 100452 
Water 2500 
 
Characteristics: 
Material Stainless steel 
Diameter 8 ft 
Height 29 ft 
Sterilization CIP 
Plate Spacing 24 in 
Operating Conditions: 
Reflux Ratio 3.0 
Stages 2 
Bottoms to feed Ratio 0.085 
Reboiler Temperature 310.8 K 
Condenser Temperature 293.9 K 
Pressure 0.159 bar 
Foaming? No Foaming 
 
Purchase Cost: 
$137,659 
Reference Page: N/A 
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Mixing Vessel V305 
Description and Function: Mixing vessel to combine acetone, DCM, and oily bottoms product of 
distillation column.   
Vendor: N/A  
Operation: Batch 
Materials Handled: 
Input Quantity (kg) 
Sofosbuvir 3499 
Acetone 8845 
DCM 70760 
Ethyl Acetate 10045 
 
Characteristics: 
Material Stainless Steel 
Sterilization CIP 
Working Volume 120,000 L 
Total Volume 160,000 L 
 
Operating Conditions: 
Temperature 25°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$237,160 
Reference Page: 
N/A 
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Crystallization Unit V306 
Description and Function: Crystallization unit introduces acetone and DCM to crystallize 
sofosbuvir as a purified final product.  
Vendor: Thermal Kinetics  
Operation: Batch 
Materials Handled: 
Input Quantity (kg) 
Sofosbuvir 3500 
Acetone 8845 
DCM 70760 
Ethyl Acetate 10045 
 
Characteristics: 
Material Stainless Steel 
Model Custom 
Sterilization CIP 
 
Operating Conditions: 
Temperature 25-30°C 
Flow Rate 5000L/hr 
Pressure 1.1 bar 
 
Purchase Cost: 
$750,000 
Reference Page: 
N/A 
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Batch Tray Dryer V308 
Description and Function: Drying equipment removes residual DCM from sofosbuvir crystals.  
Operation is at 39°C, the boiling point of DCM.  
Vendor: N/A  
Operation: Batch 
Materials Handled: 
Input Quantity (kg) 
Sofosbuvir 3500 
DCM 170 
 
Characteristics: 
Material Stainless Steel 
Sterilization CIP 
Area 50 ft2 
 
Operating Conditions: 
Temperature 39°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$17,301 
Reference Page: 
N/A 
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Belt Conveyer S320 
Description and Function: Belt conveyer is used as solids-handling equipment to transport solid 
sofosbuvir crystals, still wet with DCM, from the crystallizer to the dryer.   
Vendor: N/A  
Operation: Continuous 
Materials Handled: 
Input Quantity (kg) 
Sofosbuvir 3500 
DCM 170 
 
Characteristics: 
Material Stainless Steel 
Sterilization CIP 
Length 30 ft  
Width 30 in 
 
Operating Conditions: 
Temperature 35°C 
Pressure 1 bar 
 
Purchase Cost: 
$21,960 
Reference Page: 
N/A 
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Screw Conveyers 
Description and Function: The screw conveyer is used to add solid material to the reaction 
vessel, as solid materials cannot be transported by pressure-driven flow. The conveyer will 
handle crystalline solids and add them to V102, V202, and V301. Specifically, streams S101, 
S201, S206, S302, and S305 are transported using screw conveyers.  
Vendor: N/A 
Operation: Continuous 
Materials Handled:  
Input Mass (kg) 
2’-deoxy-2’-fluoro-2’-methyluridine 3639 
Zinc Chloride 2883 
Characteristics: 
Material Stainless Steel 
Conveyer Length 30 feet 
Conveyer Diameter 20 in 
Operating Conditions: 
Pressure 1.1 bar 
Temperature 25°C 
Purchase Cost: 
$11,902 
Reference Page: 
N/A 
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Centrifugal Pumps 
S101/S102/S103/S104/S105/S106 
S201/S202/S203/S204/S205/S206/S207/S208/S209/S210/S211/S212/S213/S214/S215/S216 
S301/S302/S303/S304/S305/S306/S307/S308/S309/S310/S311/S312/S313/S314/S315/S316/S31
7/S318/S319 
Description and Function: Pumps create a pressure drop across the length of a pipe to induce 
pressure-driven flow of material.    
Vendor: N/A 
Operation: Batch 
Characteristics: 
Material Ductile Iron 
Flow Rate 500 L/min 
 
Operating Conditions: 
Temperature 25°C 
Pressure Change 0.3-2 bar 
 
Purchase Cost: 
$4,936 per pump 
Reference Page: 
N/A 
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Agitator for Vessels 
V101/V201/V202/V203/V205/V301/V302/V305 
Description and Function: Agitator helps mix materials within reactors and wash vessels. 
Reaction vessels were priced using the pressure vessel model, so agitators are priced separately.   
Vendor: N/A 
Operation: Batch 
Characteristics: 
Material Stainless Steel 
Motor Hp 15 hp 
 
Operating Conditions: 
Temperature -50 to 25°C 
Pressure 1.1 bar 
 
Purchase Cost: 
$19,216 
Reference Page: 
N/A 
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Propane Chiller  
Chiller-Propane 
Description and Function: This chiller uses water cooling to absorb heat from the refrigerant, 
propane. The chiller operates continuously to cool the propane which is used as a refrigerant for 
V201, V202, and for the condensers of distillation columns V103 and V304.  
Vendor: Johnson Controls 
Operation: Continuous 
Materials Handled: 
Material Input (kg) 
Propane 1,546,400 
 
Characteristics: 
Material Stainless Steel 
Power 950 tons 
 
Operating Conditions: 
Cooling Method Water 
Temperature  -100°C 
 
Purchase Cost: 
$378,500 
Reference Page: 
N/A 
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Section 20 - Equipment Cost Summary 
This section contains tables of equipment cost summaries for each process (100, 200, 
300) including unit number, purchase cost of one unit, and the number of units needed. 
Equipment costing spreadsheets used to determine purchase costs are included in Appendix B. 
The crystallizer cost was determined by directly contacting the vendor. Additionally, equipment 
costs were rounded to the nearest $100 given the limited accuracy of equipment costing data. 
 
Table 20-1 General Equipment 
 
Equipment 
Description 
Unit Number Purchase Cost 
per Unit 
Number of 
Units 
Vendor 
Vessel Agitator  V101/V201/V202/V203/V301/
V304 
$19,200 12 N/A 
Centrifugal Pumps S101/S102/S103/S104/S105/S1
06 
 
S201/S202/S203/S204/S205/S2
06/S207/S208/S209/S210/S211/
S212/S213/S214/S215/S216 
 
S301/S302/S303/S304/S305/S3
06/S307/S308/S309/S310/S311/
S312/S313/S314/S315/S316/S3
17/S318/S319 
$5,000 42 Flowserve 
Propane Chiller Chiller-Propane $378,500 1 Johnson 
Controls 
Screw Conveyer S101/S201/S206/S302/S305 $15,800 5 N/A 
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Table 20-2 Process 100 Equipment 
Equipment Description Unit Number Purchase Cost 
per Unit 
Number of 
Units 
Vendor 
Heat Exchanger V101 $36,100 1 N/A 
100,000L Reaction Vessel V102 $189,200 2 N/A 
Distillation Column V103 $249,800 1 N/A 
Ethylene Glycol Chiller Chiller-EG $4,000 1 Johnson 
Controls 
 
Table 20-3 Process 200 Equipment 
Equipment Description Unit 
Number 
Purchase Cost 
per Unit 
Number of 
Units 
Vendor 
85,000 L Reaction Vessel V201 $178,200 2 N/A 
85,000L Reaction Vessel V202 
 
$178,200 1 N/A 
140,000L Reaction Vessel V203 $222,100 2 N/A 
Flash Vessel V204/V207 $55,000 2 N/A 
400,000 L Wash Vessel V205 $361,000 1 N/A 
Packed Bed Drying Vessel V206 $72,100 1 N/A 
Condenser (Heat Exchanger) V208 $67,500 1 N/A 
100,000L Runaway Reaction Vessel V209 $189,200 2 N/A 
Brine Chiller Chiller-Brine $26,200 1 Johnson 
Controls 
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Table 20-4 Process 300 Equipment 
Equipment Description Unit 
Number 
Purchase Cost 
per Unit 
Number of 
Units 
Vendor 
120,000L Reactor V301 $193,500 1 N/A 
192,000L Wash Vessel V302 $254,000 2 N/A 
Packed Bed Drying Vessel V303 $48,100 1 N/A 
Distillation Column V304 $137,700 1 N/A 
160,000L Mixing Vessel V305 $237,200 1 N/A 
Crystallization Unit V306 $750,000 1 Thermal 
Kinetics 
Drying Unit V307 $17,300 1 N/A 
Belt Conveyer S320 $22,000 1 N/A 
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Section 21 - Fixed Capital Investment 
This chapter describes the fixed capital investment, consisting of the equipment purchase 
and installation costs as well as the total permanent investment cost, which includes construction 
and plant startup.  To calculate costs, the Profitability Analysis-4.0.xls spreadsheet by Brian K. 
Downey (2008) was used. 
21.1 Equipment Costs 
21.1.1 Unit Bare Module Costs 
Purchase costs, as determined in Chapter 20, were used to calculate the bare module cost 
for each piece of equipment. The bare module cost for the entire process was then computed 
using the costs of individual pieces of equipment. The equipment cost is concentrated in 
Processes 200 and 300, which require several large reaction and wash vessels.  The total general 
equipment Bare Module Costs is $1,547,000, the total Process 100 Bare Module Costs is 
$2,732,000, the total Process 200 Bare Module Costs is $8,302,000, and the total Process 300 
Bare Module Costs is $6,387,000.  The Bare Module Factors and Costs are tabulated below in 
Tables 21.1, 21.2, 21.3, and 21.4.  The Total Bare Module cost is $18,976,000. 
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Table 21-1 General Equipment 
Equipment 
Description Unit Number 
Purchase 
Cost per 
Unit 
Number 
of Units 
Bare 
Module 
Factor 
Total Bare 
Module 
Cost 
Vendor 
Vessel 
Agitator $19,216 12 1.5 $345,900 N/A 
Centrifugal 
Pumps $4,936 42 3.3 $684,100 Flowserve 
Propane 
Chiller $378,500 1 3.17 $1,199,900 
Johnson 
Controls 
Screw 
Conveyer $15,748 5 2 $157,500 N/A 
Sprinklers 
V101/V201/V202/V20 
3/V301/V304 
S101/S102/S103/S104/
S105/S106 
S201/S202/S203/S204/
S205/S206/S207/S208/
S209/S210/S211/S212/
S213/S214/S215/S216 
S301/S302/S303/S304/
S305/S306/S307/S308/
S309/S310/S311/S312/
S313/S314/S315/S316/
S317/S318/S319 
Chiller-Propane 
S101/S201/S206/S302/
S305 
N/A $1.61/ft2 100,000 ft2 3.21 $517,000 N/A 
Total General Equipment Cost = $2,904,400 
126
Table 21-2 Process 100 Equipment 
Equipment 
Description 
Unit 
Number 
Purchase 
Cost per 
Unit 
Number of 
Units 
Bare 
Module 
Factor 
Total Bare 
Module Cost Vendor 
Heat 
Exchanger V101 $36,100 1 3.17 $114,500 N/A 
100,000L 
Reaction 
Vessel 
V102 $189,200 2 4.16 $1,574,200 N/A 
Distillation 
Column V103 $249,800 1 4.16 $1,039,300 N/A 
Ethylene 
Glycol 
Chiller 
Chiller-EG $4,000 1 3.21 $12,800 Johnson Controls 
Total Process 100 Equipment Cost = $2,741,000 
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Table 21-3 Process 200 Equipment 
Equipment 
Description 
Unit 
Number 
Purchase 
Cost per 
Unit 
Number of 
Units 
Bare 
Module 
Factor 
Total Bare 
Module Cost Vendor 
85,000 L 
Reaction 
Vessel 
V201 $178,144 2 4.16 $1,482,200 N/A 
85,000L 
Reaction 
Vessel 
V202 $178,144 1 4.16 $741,100 N/A 
140,000L 
Reaction 
Vessel 
V203 $222,075 2 4.16 $1,847,700 N/A 
Flash 
Vessel V204/V207 $55,007 2 4.16 $457,700 N/A 
400,000 L 
Wash 
Vessel 
V205 $361,004 1 4.16 $1,501,800 N/A 
Packed Bed 
Drying 
Vessel 
V206 $72,082 1 4.16 $299,900 N/A 
Condenser 
(Heat 
Exchanger) 
V208 $67,473 1 3.17 $213,900 N/A 
100,000L 
Runaway 
Reaction 
Vessel 
V209 $189,207 2 4.16 $1,574,200 N/A 
Brine 
Chiller Chiller-Brine $26,200 1 3.17 $83,100 
Johnson 
Controls 
Total Process 200 Equipment Cost = $8,201,600 
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Table 21-4 Process 300 Equipment 
Equipment 
Description 
Unit 
Number 
Purchase 
Cost per 
Unit 
Number of 
Units 
Bare 
Module 
Factor 
Total Bare 
Module Cost Vendor 
120,000L 
Reactor V301 $193,445 1 4.16 $804,700 N/A 
192,000L 
Wash Vessel V302 $253,955 2 4.16 $2,112,900 N/A 
Packed Bed 
Drying Vessel V303 $48,091 1 4.16 $200,100 N/A 
Distillation 
Column V304 $137,659 1 4.16 $572,700 N/A 
160,000L 
Mixing Vessel V305 $237,160 1 4.16 $986,600 N/A 
Crystallization 
Unit V306 $750,000 1 2.06 $1,545,000 
Thermal 
Kinetics 
Drying Unit V307 $17,301 1 2.06 $35,600 N/A 
Belt Conveyer S320 $21,960 1 1.61 $35,400 N/A 
Total Process 300 Equipment Cost = $6,293,000 
21.1.2 Bare Module Factor Assumptions 
Bare module factors were chosen for each type of equipment from Chapter 16 of Product 
and Process Design Principles21-1, except for screw conveyors and agitators, which were 
suggested by the faculty advisors.  Table 21-5 lists all the bare module factors used in the 
calculations in the previous section. 
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Table 21-5 Bare Module Factors 
Equipment Assumed Bare Module Factor 
Reactor Vessels, Wash Vessels, Mixing Vessels, Flash 
Columns, Distillation Columns, Packed Bed Columns 4.16 
Crystallization Units 2.06 
Drying Units 2.06 
Heat Exchangers (Shell and Tube) 3.17 
Centrifugal Pumps 3.30 
Belt Conveyors 1.61 
Screw Conveyors 2.00 
Vessel Agitators 1.50 
Sprinklers 3.21 
21.1.3 Other Material Costs 
In addition to raw materials, several chemicals are purchased only once at the onset of 
production.  Ethylene glycol, propane, and brine used as coolants, are refrigerated in-house after 
use.  The quantities required for each material were calculated for one batch of production, and 
the utilities required to refrigerate each coolant to a pre-determined temperature are included in 
Section 22. Table 21-6 shows the quantities and costs for these material purchases. The total cost 
for single-purchase materials is $577,000.  
Table 21-6 One-Time Material Purchase Costs 
Material Use Amount Required (kg) 
Price per 
kilogram Price ($) Vendor 
Ethylene 
Glycol V101 – Coolant 4,463 $2.50 $11,159 
Jiangsu Yida 
Chemical Co. 
Propane V103 – Coolant 649,088 $0.40 $259,635 Infodrive India 
Propane V201 – Coolant 154,682 $0.40 $61,873 Infodrive India 
Propane V202 – Coolant 26,249 $0.40 $10,500 Infodrive India 
Brine (WFI) V203 – Coolant 13,800 $0.12 $1,656 N/A 
Brine (Salt) V203 – Coolant 3,450 $0.38 $1,311 N/A 
Propane V208 – Coolant 128,309 $0.40 $51,324 Infodrive India 
Propane V304 – Coolant 448,020 $0.40 $179,208 Infodrive India 
Total One-Time Material Purchase Cost = $577,000 
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21.2 Permanent Investment Costs 
This section presents the plant investment costs relating to start-up, space requirements, 
and contractor fees.  These costs, as indicated by the profitability spreadsheet, are derived from 
the Total Bare Module cost and are shown below in Table 21-7.  The cost of site preparations is 
set at 5.0% of the Total Bare Module cost, the cost of service facilities is set at 5.0% of the Total 
Bare Module Cost, cost of contingencies and contractor fees is set at 18% of Bare Module Cost, 
the cost of land will be 2.0% of Bare Module Cost, and the cost of plant start-up is 2.0% of Bare 
Module Cost.  These values were chosen in accordance with guidelines from Product and 
Process Design Principles (Seider, et al.). 
Table 21-7 Total Permanent Investment Components  
Endnotes 
Seider, et al. (2016). Product and Process Design Principles. 
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Section 22 - Operating Costs 
The manufacturing process incurs $4,117,000 of costs per batch produced. These are 
broken down into variable material costs and energy costs, and fixed labor costs and material 
costs. The vast majority of operating costs come from material costs, particularly methyluridine. 
As production ramps up in moderate and cautious estimations, the fixed costs per batch factor 
less into the overall cost of sofosbuvir production.  
22.1 Variable Costs 
22.1.1 Variable Material Costs 
Due to the bulk quantities for raw materials required, raw material prices were obtained 
through Indian import/export data in 2016 (Appendix G). Assuming a batch size of 3,500 kg, the 
amount of each input was scaled up from the original patent. Calculations for each item can be 
found in Appendix L. These costs are summarized in Table 22-1 below in a per kilogram basis. 
Of the variable material costs, methyluridine is the most expensive, contributing $923 per kg of 
sofosbuvir produced. The variable raw material costs associated with the production of 
sofosbuvir also include consumed utilities water for injection (WFI) and anhydrous sodium 
sulfate. Water for injection, which is used for the washes, is purchased as a utility and purified on 
site. The cost for WFI includes both the cost of utility water and the costs incurred to purify it. 
Anhydrous sodium sulfate desiccant is considered a variable cost because the quantity is scaled 
according to the wash volumes. To maintain batch integrity, fresh anhydrous sodium sulfate is 
purchased for each batch.  
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Table 22-1 Variable Raw Material Costs per kilogram of Sofosbuvir 
Raw Material $/kg Sofosbuvir 
2-Chloro-6-hydroxypyridine $5.29 
2’-Deoxy-2’-fluoro-2’-methyluridine $923.41 
Acetone $0.95 
Ammonium chloride $0.76 
Anhydrous Sodium sulfate $0.14 
DCM $36.87 
DIEA $23.12 
Ethyl acetate $8.61 
Hydrochloric Acid 0.5 M $2.48 
Isopropanol $27.46 
L-Alanine - HCl $5.67 
Phenyl Dichlorophosphate $16.43 
Ribavirin $65.14 
Sodium Bicarbonate $0.14 
Sodium Carbonate $0.27 
Sodium Chloride $8.37 
THF $24.18 
Thionyl Chloride $1.58 
Water for Injection $12.65 
Zinc Chloride $0.74 
Total $1,164.26 
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22.1.2 Variable Energy Utility Costs 
Compared to raw material costs, the cost of energy utilities is significantly smaller, 
totaling $6.85 per kilogram of sofosbuvir produced. The variable energy costs are summarized in 
Table 22-2 below. The majority of utility costs are incurred when regenerating refrigerants used 
to cool reactors and condensers. More detailed analysis of the utility costs can be found in 
Section 17. 
Table 22-2 Variable Energy Costs per kilogram of Sofosbuvir 
Utility $/kg Sofosbuvir 
Cooling Refrigerants $4.89 
Electricity $1.96 
Total $6.85 
22.2 Fixed Costs 
22.2.1 Fixed Labor Costs 
The day-to-day operations of the plant are managed by local chemical engineers, 
chemical operators, and experienced chemical plant workers. Two chemical engineers, working 
during the day shift, will oversee the entire operation and ensure that all units are operating 
properly. Each of the three shifts will have two chemical operators to oversee key transfer steps 
and ensure optimal reaction conditions. Experienced chemical plant workers will be employed to 
load raw materials, carry out the transfer steps, perform cleaning operations, and conduct routine 
maintenance. For the daytime process, 25 plant workers, 2 chemical operators, and 2 chemical 
engineers will be hired for a total of 29 employees in the day shift. Because only several 
reactions operate overnight, fewer employees are required during each of the two night shifts. In 
each shift, 20 plant workers will be overseen by 2 chemical operators for a total of 22 employees 
134
 
 
 
per night-shift. Wages are obtained by considering the hourly wages of skilled chemical 
engineers22-1, chemical operators22-2, and plant workers22-3 in the US. These wages were 
multiplied by a factor of 0.138, the ratio between the minimum wage in India22-4 and the US, to 
account for the lower cost of living in India (Appendix D-1). Since the process is operated over a 
short period of time, employees would be expected to work overtime. The overtime rate is 25% 
more than the regular hourly rate. Night shift employees will earn 5% less than their daytime 
counterparts because they are less skilled. The total annual wages for employees of each position 
are calculated in Appendix D-2. Since these employees will only be working on this project for 
one third of the year, the ‘Total pay’ reflects the amount paid to employees of the position over 
the 4-month period. To evaluate the cost burden of wages, employee pay is calculated on a per 
batch basis. These figures are summarized in Table 22-3 below. For each batch of sofosbuvir 
produced, employees are paid $2,815.  
Table 22-3 Summary of labor costs normalized per batch 
Position 
Individual 
Pay ($/Batch) 
Number of 
employees 
Total Pay 
($/Batch) 
Chemical Engineer  $82  2 $164  
Chemical operator (day shift) $67  2 $134  
Plant worker (day) $36  25 $900  
Chemical operator (night shift) $65  4 $259  
Plant worker (night) $34  40 $1,358  
Total Wages   $2,815  
22.2.2 Fixed Material Costs 
Some raw materials are consumed on a per batch basis rather than proportionally with 
sofosbuvir produced. Sand, which is used to absorb and contain chemical spills, is purchased as a 
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safety precaution. Assuming a turnover for reused materials of once per 100 batches, the cost for 
replenishing sand amounts to $45 per batch. Nitrogen is used to clear out the tank and to prevent 
fires. For each batch, $16,427 of liquid nitrogen is needed to fill the head spaces of the reactors. 
The fixed costs of individual raw materials are tabulated below in Table 22-4.  
Table 22-4 Summary of fixed material costs 
Raw material 
Costs 
Total Cost 
($) 
Cost per Batch 
($) 
Nitrogen $1,642,672 $16,427 
Sand $4,547 $45 
Total $1,647,219 $16,472 
 
 
 
 
 
Endnotes 
22-1: PayScale Human Capital (2017). Chemical Engineer Salary. Retrieved from 
http://www.payscale.com/research/US/Job=Chemical_Engineer/Salary.  
22-2: PayScale Human Capital (2017). Chemical Operator Salary. Retrieved from 
http://www.payscale.com/research/US/Job=Chemical_Operator/Hourly_Rate. 
22-3: PayScale Human Capital (2017). Hourly Rate for Skill: Plant Maintenance. Retrieved from 
http://www.payscale.com/research/US/Skill=Plant_Maintenance/Hourly_Rate. 
22-4: Paycheck.in (2017). Minimum Wage in Delhi. Retrieved from 
http://www.paycheck.in/main/salary/minimumwages/delhi/minimum-wage- in-delhi-w-e-
f-march-3-2017-to-august-31-2017. 
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Section 23 - Other Important Considerations 
 During the development of a commercial-scale synthesis design for sofosbuvir, the 
crucial considerations revolved around the chemical synthesis steps, the process development, 
equipment needs and overall costs and profitability. However, in order to justify most of the 
above considerations, various important considerations are also taken into account that must be 
satisfied for justifiable project development. Some important considerations include the project 
impact on the environment, the control systems required at the plant, the safety employees and 
the surrounding community and the work and shift schedule. These less obvious considerations 
all had an impact on some crucial consideration made in the process and, as such, were explored 
in much finer detail. 
23.1 Environmental Considerations 
 Chemical processes produce a variety of chemicals and require a large amount of 
chemical inerts and unreacted chemicals; for the production of sofosbuvir, this was no exception. 
Each process previously discussed featured a significant amount of unreacted solvents, excess 
reactants and chemical inerts that had to be accounted for during and after the process. In order 
to limit and negate any impact the production had on the environment, various considerations 
were made to assure that the waste solvents and chemical inerts were safely handled and 
disposed. 
 Initial environmental considerations revolved around the selection of a safe metal catalyst 
for the reaction steps. Our team sought to avoid the use of heavy metal catalysts in any reaction 
step, which would have a significant positive impact on the environmental consciousness of the 
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process as a whole. In the end, a more organic, salt-like catalyst in zinc-chloride will be used in 
place of any toxic, heavy metals. 
 Perhaps the most prevalent issue in the process was the safe disposal of solvents and 
washing agents. Each process in the synthesis had waste considerations to be made in order to 
minimize impact on the environment. Process 100 required a significant volume of IPA, which 
was removed from the product stream after the reaction step. A distillation tower with a 
condenser was used for the solvent phase separation to minimize the escape of any gas phase 
solvent into the atmosphere. In order to minimize the amount of unreacted materials and 
chemical impurities in the outlet stream, multiple trays were added to the distillation column to 
increase the purity of the solvent waste stream, increasing the ability of the waste disposal 
services to re-use or re-purpose the IPA. Similar considerations were taken in Process 200, where 
solvent waste was flashed and condensed to remove a mostly pure solvent for proper disposal. 
Process 200 features two evaporation units, each of which condense their distillate streams to 
eliminate the potential for gas pollutant escaping to the atmosphere. These solvents will also be 
relatively pure, allowing for the purification and potential future re-use of those solvents rather 
than disposal. Furthermore, Process 200 will actively use and contaminate a large volume of both 
pure water and brine during wash processes. This wastewater will have to be disposed of through 
appropriate venues to avoid any possible water source contamination in the already contaminated 
waterways of India. Process 300 had waste considerations similar to Process 100, where the 
solvents, THF and ethyl acetate, were distilled to remove a nearly pure stream to increase the 
likelihood of reuse and minimize total waste. Furthermore, Process 300 will also feature a 
substantial use of water for wash cycles, which will result in significant wastewater disposal. 
Overall, major considerations were made with regards to the primary byproducts and waste 
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solvents the process would produce, aiming to minimize or eliminate their impact on the 
environment. 
23.2 Process Control 
 For any chemical production process, control systems must be in place to ensure the 
efficacy of the synthesis, the safety of employees as well as the stability of the reaction 
conditions. Among the many requirements for a successful chemical plant operation, there are 
several that require process control. These include safety, production specifications, 
environmental regulation, operational constraints and economics.23-1 The aforementioned 
requirements bring about the need for constant process monitoring, suppression of external 
disturbances on the process and assurance of process stability.  
Each vessel involved in the entire production process requires a control system to manage 
the external disturbances that could affect the system. For example, the heat exchanger for 
thionyl chloride cooling in Process 100, V101, should feature a feedback control loop, where the 
set-point value is an outlet temperature of 0°C and a feedback PID controller could increase or 
decrease the flow rate of coolant into the heat exchanger to influence the exit temperature of 
thionyl chloride into the reactor, V102. Furthermore, a feedback controller is used on the 
distillation condensers in V103 and V304 to control the concentration of the outlet solvent waste. 
If a supplier specified that they required a certain purity in order to purchase the waste solvent, a 
PID control system could vary the set-point and adjust the tray conditions and inlet flow rate to 
control the overhead solvent purity. Control systems could be similarly used for the heat 
exchanger in Process 200 as well as the reaction vessels in Processes 200 and 300, where vessel 
temperature is relevant to the reaction. Overall, it is crucial to maintain a system of process 
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controls, such that the required reaction conditions are met and to maintain overall control on the 
outlet conditions of waste products and sofosbuvir. 
23.3 Safety and Health Considerations 
 During the design of the process, various considerations were taken regarding the safety 
of both plant operators and the immediate community surrounding the plant. While the synthesis 
route was restrictive in terms of which chemicals could be used for the production of sofosbuvir, 
attention was still paid to the material safety of all the raw materials involved in the production 
process. Fire danger is associated with many of the solvents used in the process, namely acetone, 
EA, THF and IPA. In order to combat the risks of fire, our team projected the installation of a 
fire sprinklers in the entire facility. After reviewing the material safety data sheets, or MSDS, 
which can be seen in Appendix M, our team determined that water extinguishing of fires of all of 
the aforementioned solvents was appropriate. At a size of approximately 100,000 square feet, the 
cost of fire sprinkler installation for the entire facility is approximately $116,000.23-2 
Furthermore, various materials have a significant health hazard and caustic potential, namely 
HCl, NH4Cl, ZnCl, sodium sulfate, DCM, DIEA, thionyl chloride and THF. In order to combat 
the risks of possible leaks, 45 metric tons of sand were included in capital costs, enough sand to 
absorb a massive chemical spill of a main solvent in the process. If the sand were to be used at 
any point, the same quantity could be purchased again. The cost of sand was relatively cheap: 45 
metric tons totaling approximately $4500. Furthermore, it would be necessary to have strict 
oversight of any loading processes in which a hazardous material were being loaded or handled 
by operators. 
 During the process development, many safety considerations were made, especially with 
reaction vessels. For instance, the reactions taking place in Process 200 are all exothermic, which 
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could result in a runaway chemical reaction. Aside from the cooling coils in the tank that could 
be used to cool the vessels at any time with the constant volume of coolant, Process 200 also 
incorporates 2 runaway reaction vessels to quench a reaction if it becomes uncontrollable. Each 
of the 5 reaction vessels is connected to a runaway reaction vessel and the reactants could be re-
routed and quenched with water in the event of a runaway reaction. Along those same lines, 
considerations were made with regards to the nitrogen protection of reactions in Processes 200 
and 300. Our team made certain that reaction vessels would be sparged with nitrogen for any 
possible oxygen contamination, such as the introduction of new solvents during the process.  
 Aside from nitrogen protection of the reaction vessels, industrial consultants made safety 
recommendations regarding vessel transfers with nitrogen. Initially, our team considered 
nitrogen pumping between reaction vessels, but was advised by consultants that this type of 
pumping could have extreme hazards in situations where pressure was not constant in the 
process. In the event of a pressure difference between vessels, gaseous nitrogen could have an 
explosive blowback once the entire vessel were emptied, filling the contents of subsequent 
vessels rapidly and explosively. In order to avoid this hazard given the possible pressure 
variations from vessel to vessel before nitrogen caps and protection were in place, our team 
decided to simply use pumps to empty each vessel rather than using nitrogen. Furthermore, 
pressure release valves were accounted for on each reaction vessel and heat exchanger where any 
volatile solvent or coolant could be heated to its flash temperature and vaporize in the vessel. 
The emergency pressure release valve would release pressurized vapor in the event of an 
emergency pressure difference in the vessel. 
 A final safety consideration was made regarding the loading of solid powders into 
reaction vessels. In Process 300, two solid phase reactants, methyluridine and zinc chloride, are 
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loaded into the reactor as powder or fine particulates. Initially, the process was designed such 
that solid methyluridine powder was loaded into the vessel before THF solvent was added, but 
this raised concerns regarding the dust-up of the solid powder and its resulting flammability. In 
order to avoid this risk, our team revised the loading schedule, instead loading the liquid solvent 
THF before the solid powder methyluridine, reducing the risk of flammability by solid dust-up. 
 Overall, our team was able to take various safety and health hazards into consideration 
and work to mitigate risks. Installation of fire sprinklers, purchase of chemical spill absorbent, 
installation of runaway reactions vessels as well as changes made to process procedure should all 
noticeably reduce the risk of accidents. 
23.4 Work Scheduling and Shift Considerations 
 The initial design project proposal made two important assumptions regarding the work 
scheduling: important staff worked a standard 40 hour week and that projects of this magnitude 
are typically completed with 3-4 months, with the product being stored for the remainder of the 
production year. With these two considerations in mind, our team sought to determine if it was 
possible to satisfy both conditions and, if so, under what circumstances. Initial project scheduling 
based on Processes 100 and 200 found that it was possible to operate the system with skilled 
workers during a day shift for the major changeover operations and with a small night staff for 
overseeing overnight reactions. However, full development of Process 300 significantly changed 
both the bottleneck equipment as well as the bottleneck time, making the day shift unable to 
consistently cover the same tasks in each batch. Development of the full process Gantt chart, 
Figure 23-1, allowed for a more exact analysis of the process scheduling.  
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Figure 23-1 Gantt Chart with Shift Allocations. Four separate batches are shown along 
with independent day and night shifts in blue and red, respectively. Batch time is 4.1 days 
and cycle time is 1.16 days. 
During discussions with industrial consultants, it became clear that highly skilled 
chemical engineers would work a day shift in a standard 40-hour week, and our team did its best 
to schedule the day shifts such that the skilled workers were present during important processes. 
For the purposes of the entire process, it was decided that the most important processes to 
oversee were the crystallization and distillation steps in Process 300, though many other 
processes could be overseen by a skilled chemical engineer. Furthermore, our team took into 
consideration which processes were the most labor intensive and would most significantly 
benefit from the skilled day workers being present. The wash steps in both Processes 200 and 
300, each of which had the most moving parts, appeared to be the optimal candidates for day 
time shifts. Unfortunately, size constraints on the crystallization unit required a significant 
loading time and crystallization time, creating a bottleneck in the process that was an uneven 
multiple of the 8-hour day our team was attempting to plan. A brief sensitivity analysis as well as 
a discussion with industrial consultants revealed that scheduling a larger night staff was much 
more conducive to profitability than purchasing a larger crystallization unit. Furthermore, in 
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order to complete the drug production within the planned 4 month time window, it was necessary 
to schedule shifts during all 7 days of the week. With all these considerations taken into place, 
our team decided to move forward with the work schedule presented in Figure 23-1.  
The work schedule will feature three 8-hour shifts. The 8-hour day shift is run with 
skilled workers and experienced chemical engineers. The two 8-hour night shifts, are run by two 
skilled chemical operators and less skilled plant workers. At any given time, the maximum 
number of processes occurring during a day shift will be 14, as seen on day 4 in Figure 23-1. 
Similarly, the night shift will operate up to 11 processes at once and 14 in a single shift. Using 
the advice of industrial consultants, it is wise to overestimate the amount of plant workers 
needed. With this advice in mind, our team determined that the work schedule would follow the 
following pattern: the day shift would employ 29 workers: 2 skilled chemical operators, 2 
experienced chemical engineers and 25 skilled plant workers; similarly, the night shifts would 
each employ 22 workers: 2 skilled chemical operators and 20 plant workers. Using published 
information regarding average salary for chemical plant operators, workers and engineers, our 
team arrived at the average hourly wage for each type of employee; these calculations are 
available in Appendix D. For the entire 4-month production process, the total labor costs will be 
approximately $281,500. On a per batch basis, this labor cost is $2,815 per batch, which is a 
small fraction of total costs per batch compared to raw materials and utilities.  
The original design goals were to orient the work shifts around a standard 40 hour work 
week, while completing the production of sofosbuvir in a 4-month production schedule. Our 
team determined that, given the reaction times involved in the process, it would be infeasible to 
complete the production of the drug in the 4 month window while also maintaining a standard 40 
hour work week. Simple cost analysis determined that the cost of labor in India was sufficiently 
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low to justify working more hours per week to complete the production on schedule. The total 
labor costs even with overtime and around-the-clock wages considered is a small fraction of the 
total costs and sales for the project, which justified the labor schedule proposed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endnotes 
 
23-1: Stephanopoulos, G. (2015). Chemical process control: an introduction to theory and 
practice. Noida, India: Pearson India Education Services. 
23-2: Cost Helper. (2015). How Much Do Fire Sprinklers Cost? Retrieved from 
http://home.costhelper.com/fire-sprinkler.html  
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Section 24 - Profitability Analysis 
Hepatitis C is a virus that affects 130 million people worldwide, predominantly in 
developing countries in Africa and East Asia. It claims 700,000 lives each year, and four million 
people are diagnosed with HCV each year.24-1,24-2 To combat this global epidemic, this proposal 
set out to produce Gilead’s highly successful sofosbuvir at an affordable price, while generating 
enough profit to sustain operation. The target customers of this facility are the 100 million people 
infected with HCV across the countries to which we may sell, per Gilead’s low-cost production 
license.24-3 As demonstrated in the following section, the project is highly successful, with room 
for production expansion to treat the entire affected population. The net present value (NPV) was 
calculated to be $1.22B, and the internal rate of return (IRR) was calculated to be 67.7%. As 
initial investment sums to below $100MM, accounting for working capital and ignoring tax 
benefits, the project shows promise to fully cure or drastically reduce the presence of HCV in the 
global population.  
Various factors were analyzed for their effect on financial performance, such as 
prominent material costs. Additionally, the feasibility of increased production was assessed to 
130 million affected globally, as well as those who are newly diagnosed each year. The 
Profitability Analysis-4.0.xls spreadsheet by Brian K. Downey was used to calculate economic 
performance of the plant. Data were gathered using Aspen, SuperPro, research, and suggestions 
from faculty advisors and industrial consultants. 
24.1 Model Assumptions 
The effective tax rate was assumed to be 34.61%, and the cost of capital, effectively the 
discount rate, was assumed to be 15% and remain constant for all years of interest.24-4, 24-5 The 
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plant will occupy a space previously used for pharmaceutical manufacturing, thus start-up and 
construction costs were assumed to be relatively low. Leasing costs were based off the average 
rate for commercial property in Mumbai, a popular city for pharmaceutical manufacturing, at 
$1.64/ft2.24-6 Equipment costs were calculated via the procedure given by Seider, et al. rather 
than by the Aspen Process Economic Analyzer (APEA) methods.24-7 Equipment was depreciated 
on a five-year schedule. All other factors were left at the default options as specified by the 
profitability spreadsheet.  
As discussed in Section 16, sofosbuvir is administered in combination with RBV, in a 
ratio of 400 mg sofosbuvir/600 mg RBV. In addition to raw materials used in the synthesis 
process, RBV was purchased and combined with the produced sofosbuvir for formulation. The 
cost of tablet formulation and packaging was estimated at 20% of the cost to produce the drug, 
per data from Hill et al.24-8 In the base assumption model, it was assumed that roughly 95% of 
the volume of organic solvents could be removed with minimal contamination via distillation, 
and the remaining impure 5% would be collected by a paid waste disposal service. Calculations 
shown in Appendix N show that the value from the resale of pure solvents was roughly enough 
to compensate for the cost to dispose of the impure 5%, for a net zero cost of organic material 
disposal. Water-based solvents, however, were fully contaminated and required paid disposal, 
also shown in Appendix N. Section 24.3.4 explores the case where the distillate streams are not 
pure enough for resale and thus 100% of the organic solvents must be disposed. Lastly, negative 
taxable income in Year 1 led to a positive tax bill; however, as we are operating as a component 
of a large pharmaceutical company, it is expected that this negative income would be used to 
offset income in another business division and provide a tax benefit. 
24.2 Profitability Measures 
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The entire project has an 11-year schedule: ten years of operation, with all product from 
one year sold in the following year, and all construction and capital costs occurring in Year 1. 
The plant does not operate in Year 11, but the inventory generated in Year 10 is sold. During 
Years 1-10, the plant is run for 120 consecutive days to produce 100 batches/year of sofosbuvir, 
and labor and variable costs are limited to this period. The relative brevity of operation facilitates 
increased production or compensation for lost batches simply by running the plant for extra days. 
Sales are timed each year in line with production such that there is always a 50-batch stock 
reserve in the event of plant shutdown or lost product. If production is disrupted, as discussed in 
Section 24.3.5, operation can be extended past the 120-day mark to compensate for any lost 
product. The plant operation period of 10 years was assumed based on calculations performed in 
Appendix E, and various production schedules, as shown in Section 24.3.2, were created to 
model distribution. Given HCV’s long latency period, producing 10 million batches of 
sofosbuvir over 10 years will avoid the deaths of many who are currently infected. 
  
Figure 24-1: Cash Flows and Cumulative NPV vs. Year of Operation 
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In the base case scenario, IRR was calculated to be 67.7%, and NPV was calculated to be 
$1.22B, using a discount rate of 15%. The project NPV surpasses the revenue potential of 
$1.05B, demonstrating that sofosbuvir can be sold profitably at a much lower cost than originally 
marketed. Figure 24-1 shows the project cash flows, and Input and Cost Summary data are 
tabulated in Appendix L. The substantial profit margin causes the project to reach positive NPV 
in Year 3 and grow steadily through Year 11. Various internal cost benchmarks were set to 
ensure profitability; while variable costs were high, all individual costs fell at or well below these 
benchmarks. The target for total raw material costs and utilities was less than 50% of revenues to 
allocate enough of the budget to equipment and personnel costs. The intended limit for raw 
material costs was $1/g or $1,000/kg of sofosbuvir but was narrowly missed due to the high cost 
of methyluridine. The raw material costs were $1,170/kg of sofosbuvir or 39% of revenues, 
comprised primarily of methyluridine which cost $925/kg of sofosbuvir. The high cost associated 
with methyluridine is discussed in Section 24.3.3. Utility costs of $264/kg of sofosbuvir, 
composed primarily of the $239/kg formulation cost, brought the variable costs to 47.8% of 
revenues. Individual material costs can be found in Section 14. Capital investment costs were a 
concern in the early stages of the design due to the large vessel volumes required to produce such 
a large amount of sofosbuvir. Ultimately, these costs added up to less 10% of revenues. Despite 
the need for round-the-clock operators, personnel costs stayed below 1% of revenues, as hourly 
wages in India are relatively low. Low labor costs were countered by relatively high corporate 
taxes, comparable to those in the US, that accounted for 17.6% of revenues.24-4 Although these 
high taxes cut into profits, they may encourage investment from the Indian government. As an 
investor, the government would realize returns through tax revenue, increased Indian gross 
domestic product, and particularly the humanitarian benefit of eradicating or reducing HCV.  
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24.3 Sensitivity Analysis  
As sofosbuvir sales total $1.05B over ten years, an NPV of $1.22B is indicative of a very 
profitable operation. Despite this success, it is necessary to account for changes in various factors 
that contribute to the financial performance. The following were analyzed for sensitivity: the sale 
price of sofosbuvir, the production schedule for sofosbuvir, the purchase cost of methyluridine, 
the cost of solvent waste disposal, and plant shutdown. For each analysis, NPV is calculated 
using a 15% discount rate, and the base case is as discussed above: 350 metric tons of sofosbuvir 
produced per year for 10 years, sale price of $3,000/kg or $100/treatment, net zero organic waste 
disposal costs, and methyluridine purchase price of $888/kg. Tabulated data for all figures can be 
found in Appendix L. 
24.3.1 Sofosbuvir Sale Price 
The sale price of sofosbuvir is susceptible to change for many reasons, such as 
unforeseen costs, government regulations, patent expiry, or market competition. Additionally, if 
the sale price can be decreased while preserving profitability, it would be possible to eliminate or 
at least further reduce cost barriers for HCV patients. Figure 24-2 explores the effect of sale price 
on financial performance. 
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Figure 24-2: Sensitivity of IRR and NPV to change in sale price 
 The intended sale price of sofosbuvir, $3,000/kg or $100/treatment, was varied from 
50% to 150% in increments of 10%. Break-even sale price, at which NPV is equal to zero, 
occurs at roughly $63/kg, indicating the opportunity for substantial decreases in price in 
countries of particular need or for price negotiation with national healthcare providers.  
24.3.2 Sofosbuvir Production Schedule 
The base production schedule was set to produce 10 million batches/year for 10 years to 
treat the 100 million patients in the countries included by the low-cost license. It is possible that 
Gilead decides to extend the license to countries currently excluded, such as China, to eliminate 
HCV on a global scale as well as to increase profits. If it can be shown that this facility has the 
capability to serve these additional markets, Gilead may be strongly encouraged to consider this 
option. The High-output case assumes unrestricted sales territory and production of enough 
sofosbuvir to treat all HCV patients through the end of operation. The current global population 
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affected by HCV is 130 million, and each year brings four million new diagnoses and 700,000 
deaths, for a net increase of 3.3 million patients per year.24-1, 24-2 Over the next ten years, the 
required amount of sofosbuvir rises to 163 million treatments, or 5,705 metric tons, a 63% 
increase from the base case. To account for this growth, production is ramped up linearly from 
standard capacity (350 metric tons/year) in Year 1 to 625 metric tons/year in Year 4 and 
maintained at this level through Year 10. The increase in production is accomplished by longer 
operating periods each year. 
Another scenario, the Low-output case, was constructed to model slow plant startup. 
Entry into a new market may be hindered by government regulations, vendor delays, or other 
unforeseen circumstances. In this case, production begins at 50% of initial capacity and increases 
evenly to 100% through Year 6. In each case, all sofosbuvir is sold the year after it is produced. 
The yearly output schedules are shown for each case in Figure 24-3 as a percentage of the base 
350 metric tons/year, and the IRR and NPV calculated for each case are shown in Table 24-1.  
 
Figure 24-3: Production Capacity as % of Base vs. Year in three different scenarios, where base 
production is 350 metric tons/year 
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Table 24-1 IRR and NPV for all Production Schedule Models 
Case IRR NPV 
High 66.9% $1,884 MM 
Base 67.7% $1,221 MM 
Low 64.6% $947 MM 
 
All three scenarios are highly profitable, yielding large NPV and IRR significantly higher 
than the cost of capital. While shifting to the high-output case slightly decreases IRR, the NPV 
increases by 50%. These conflicting changes occur due to the one-year delay in sales; the higher 
variable costs to ramp up production are not fully offset by the previous years’ stocks of 
sofosbuvir, and income is relatively lower in the first few years. However, the considerable 
increase in NPV from higher total sales outweighs the change in IRR, indicating the potential for 
this plant to treat the entire population of HCV patients. The low-output scenario displays both 
lower IRR and NPV but is still a highly profitable outcome.  
24.3.3 Methyluridine Purchase Price 
As discussed in Section 22, the highest individual cost incurred is the purchase price of 
the methyluridine. Synthesizing methyluridine was ruled out, as the cost of starting materials is 
only marginally lower and the requisite chemistry added an unnecessary amount of complexity 
to the operation. An increase in the price of methyluridine could drive the raw material costs 
further over the $1/g mark, cutting into the profit margin, while a decrease in price would greatly 
expand profit margin. Figure 24-4 shows how the purchase price of methyluridine affects IRR 
and NPV.  
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Figure 24-4: Sensitivity of IRR and NPV to Methyluridine Purchase Price 
While the purchase price is not prohibitive, methyluridine comprises 79% of the raw 
material costs and 31% of revenues and thus would be a primary target for cost reduction to 
increase profit. The break-even cost of methyluridine is just below $1,640/kg, a highly unlikely 
increase of 85% from the current quoted cost. Online wholesale distributors sell methyluridine 
for as low as $100/kg, albeit for batch sizes on the order of kilograms. If a bulk order contract 
could be created with one of these vendors, it would triple the IRR and double the NPV; the 
drastic increase in profit margin could allow the sale price of sofosbuvir to decrease further to 
ensure affordability. 
24.3.4 Solvent Waste Disposal Costs 
Throughout the synthesis process, organic and aqueous outlet streams are generated, 
containing organic contaminants that must be properly handled. Solvents and starting materials 
are not recycled due to FDA regulations that dictate the need for batch integrity, the ability to 
separate discrete amounts of product for testing purposes and to track contamination. Any stream 
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that has contact with the active is considered contaminated. In all three parts of the process, 
roughly 95% of the organic solvent material is removed using distillation or flash. In the base 
scenario, it is assumed that these distillate streams are pure enough to be resold, and that the 
resale value and cost to dispose of the remaining 5% of the organic solvents sum to zero. The 
calculations for these costs and resale values, along with the amount of solvent waste generated, 
are shown in Appendix N. 
Table 24-2 IRR and NPV With and Without Solvent Disposal Costs 
Solvent Disposal IRR NPV 
With Organic Solvent Resale 67.7% $1,221 MM  
Without Organic Solvent Resale 61.5% $1,119 MM  
   
The alternative is considered where the distillate streams are deemed too impure for 
resale and require paid collection. In both cases, the paid disposal of spent water-based streams is 
unavoidable for environmental purposes. Table 24-2 shows the impact on IRR and NPV of the 
waste disposal cost. The need for paid collection lowers IRR by over 6% and NPV by $102MM. 
These changes are by no means prohibitive, but waste management could be a future 
consideration to further reduce costs and boost profit. 
24.3.5 Interruption of Batch Production 
Despite various safety measures and constant supervision, there is always the possibility 
of a runaway reaction or other plant emergency. It is necessary to assess the financial impact of a 
production disturbance to determine if extra safety and damage control mechanisms need to be 
installed. A proposed disruption is a runaway reaction in Year 5 that causes the breakdown of 
units V203 and V209, duplicate 140,000 L reactors and duplicate 100,000 L runaway reaction 
vessels, respectively. It is assumed that no other equipment, materials, or staff are harmed, and 
that the vessels are replaced at their bare module costs as calculated in Section 21.  
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Table 24-3 IRR and NPV With and Without Runaway Reaction 
Batch Interruption IRR NPV 
Without 67.7% $1,221 MM  
With 67.5% $1,216 MM  
   
The disruption results in the use and repurchase of all stored sand, waste disposal of all 
materials from this batch, and a halt in production for three months awaiting the reinstallation of 
the broken vessels. Staff are paid continuously through the down time, as it is expected they 
would be reassigned to other tasks by the company. After the replacement equipment is installed, 
operations are resumed and extended to yield the target output for the year. The total expense in 
Year 5 is $12.8MM: $3MM to replace the vessels, $6MM for waste disposal and extra raw 
materials purchase, and $3MM for the additional staff wages and fixed costs. Table 24-3 shows 
the result of the runaway reaction on financial performance. The cost associated with this 
runaway reaction is more than compensated by the profit margin, as shown in the 0.2% decrease 
in IRR and $5MM decrease in NPV. Nevertheless, it is important to implement safeguards to 
prevent runaway reactions to limit dangers to the staff, equipment, and product. 
24.4 Conclusion 
Ultimately, the proposed design to produce sofosbuvir at a low cost has potential to make 
a tremendous impact on HCV and those affected. The $100MM total capital investment required 
to construct and prepare the facility can easily be financed by the company and will generate 
enough sofosbuvir to cure 75% of the global population suffering from HCV as well as an NPV 
of $1.22B and an IRR of 67.7%. Even in the more conservative cases discussed here, the project 
still meets low cost goals and stands to be highly lucrative. Profit can be used to streamline parts 
of the process previously unexplored, such as the purchase of methyluridine, and facilitate 
distribution to all target markets. 
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Section 25 - Conclusions and Recommendations 
 This report describes a commercial-scale process design for the production of sofosbuvir, 
a much-needed treatment for Hepatitis C. HCV will kill or shorten the lifespan of nearly 150 
million people worldwide over the next 25 years, assuming no intervention. The plant design is 
capable of producing enough drugs to treat all current global cases at a cost that can be readily 
afforded by patients out-of-pocket or with assistance from their local governments.  
The proposed facility requires full operation for 120 days/year, with each batch 
producing 3,500 kg of sofosbuvir. The process, with an overall yield of 41%, consists of three 
processes: 100, 200 and 300. Abiding by the timing and scheduling presented in Section 23 and 
Appendix D, 100 batches per year is projected to produce 350,000 kg per year, meeting the 
demand for 10 million patients.  
 From a financial standpoint, it is highly recommended that this project be carried out. The 
internal rate of return is greater than 67%, and the net present value is in excess of $1.2 billion. 
To compute these financial measures, we assumed a ten-year operation period. These numbers 
motivate further investigation and investment as a financially feasible design to produce a 
Hepatitis C therapeutic at an affordable price in India. The demand for this drug is very high in 
India and low-income developing countries, and this venture provides a valuable medication at 
an affordable price to patients. This financial analysis does not consider the distribution costs of 
the drug product. It is recommended that this project is conducted at an existing pharmaceutical 
facility to save on land costs and general equipment costs.      
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Appendix A – Patent Search 
Appendix A-1 Reaxys Synthesis 
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Appendix A-2 Process 100 Patent 
 
Appendix A-3 Process 200 Patent 
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Jiangsu Hanson Pharma Group Co., Ltd.; Zhu, Qiang; Liu, 
Zhaopeng; Li, Bin; Li, Yunfei; Yang, Baohai 
Patent: CN105461773 A,2016 ; 
Location in patent: Paragraph 0065; 0066; 0067; 0068; 0069;  
 
 
Translation: Example 1, Preparation of Intermediate A1 
 
40mL of dichloromethane was added into flask R1. Under N2 protection, the solvent was cooled 
to -50°C with constant stirring. Phenyl dichlorophosphate (2.31g, 11.0 mmol, 1.1 equiv.) was 
added and the mixture was stirred for 10-20 min; (S)-Isopropyl 2-aminopropanoate 
hydrochloride (1.85g, 11.0 mmol, 1.1 equiv.) was added, and N, N-diisopropyl ethylamine (2.8g, 
22.0 mmol, 2.2 equiv.) was added dropwise; once N, N-diisopropyl ethylamine was completely 
added, the temperature was raised to -10 ~ -5°C over 3-4 hours.  
In another flask R2, 2-Chloro-6-hydroxypyridine (1.29g, 10.0mmol, 1.0equiv.) and 20 ml 
dichloromethane were added. Under N2 protection, the mixture was cooled to -10 ° C with 
constant stirring. N, N-diisopropyl ethylamine (1.4g, 11.0mmol, 1.1equiv.) was added dropwise; 
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Once N,N-diisopropyl ethylamine was completely added, the temperature in R2 was gradually 
increased between -5 and 0°C over 1-2 hours.  
Once R1 reached a temperature between -10 and -5°C, the mixture in R2 was added dropwise to 
R1. While mixing, the temperature was controlled at around 0°C. Once finished, the mixture 
equilibrated to room temperature with constant stirring for 6h.  
After completion of the reaction, the organic phase was washed twice, then washed with 
saturated salt water once and dried over anhydrous sodium sulfate. The resulting substance was 
Rotor-evaporated to obtain 3.88g of a colorless oily substance, the molar yield was 97.5%. 
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Appendix A-4 Process 300 Patent 
Jiangsu Hanson Pharma Group Co., Ltd.; Zhu, Qiang; Liu, 
Zhaopeng; Li, Bin; Li, Yunfei; Yang, Baohai 
Patent: CN105461773 A,2016 ; 
Location in patent: Paragraph 0097; 0098; 0099; 0100; 
 
 
 
1, Using Intermediate A1 as the Starting Material 
In flask R1 containing 40 ml tetrahydrofuran, 2’-deoxy-2’-fluoro-2’-methyluridine (2.6g, 
10.0mmol, 1.0equiv.), intermediate A1 (7.96g, 20.0mmol, 2.0equiv.), N, N-diisopropyl 
ethylamine (DIEA, 1.95g, 15.0mmol, 1.5equiv.), and zinc chloride (2.06g, 15.0mmol, 1.5equiv.) 
were added. Under N2 protection, the mixture was heated to 55-60°C while stirring for 15-40h.  
After the reaction, the solution was washed once with 80 ml ethyl acetate and saturated 
ammonium chloride solution (40mLx1), washed once with 0.5M hydrochloric acid (40mLx1), 
washed once with Na2CO3/NaHCO3 buffer solution (40mLx1), washed once with saturated salt 
water (40mLx1), and dried over anhydrous sodium sulfate.  
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The remaining solution was rotor-evaporated leaving an oily substance, crystallize using 
acetone/dichloromethane (1/8, V/V). Yields 2.5g of Sofosbuvir product, quality yield of 96.4%. 
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Appendix B - Equipment Costing Sheets 
Appendix B-1 Pressure Vessel Calculations 
 
Reactor Vessel V102, V209 
 
 
Reaction Vessel V201, V202 
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Reaction Vessel V203 
 
   
Reaction Vessel V301 
 
 
Wash Vessel V205 
 
 
Wash Vessel V302 
 
 
Mixing Vessel V305 
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Appendix B-2 Distillation Column and Packed Column Calculations 
Distillation Columns 
 
 
 
 
Packed Columns 
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Appendix B-3 Condensers and Head Exchangers 
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Appendix C- Calculations 
Appendix C-1 Equipment Cost Calculations 
Screw Conveyer 
Cp = 80DL0.59 where D is diameter in inches and L is length in feet  
D = 20 inches, L = 30 feet. Cp = $11,902 
 
Agitator 
Turbine closed vessel 
Cp = 4105 S0.57 where S = power in horsepower 
S = 15 hp  Cp = $19,216 
 
Dryer 
Batch Tray 
Cp = 4400 A0.35 
Area = 50 ft2 
Cp = $17,301 
 
Belt Conveyer 
Cp = 24.4 WL where W = width in inches, L = length in feet 
W = 30 inches, L = 30 feet 
Cp = $21,960 
Appendix C-2 Distillation Column Sizing 
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Process 100 
 
24 inch spacing between plates 
f = 0.85 
G = 111 kg/sec vapor 
L = 119 kg/sec liquid 
Uf = C*[(rhoL-rhoG] / RhoG)^0.5 = 10.307 ft/s = 3.1 meters/s 
Rho G = 2.5 kg/m3 
Rho L = 1000 kg/m3 
C =Csb Fst Ff Fha 
Csb = 0.4 ft/s 
Flg = (L/G) (rhog/rhoL)^0.5 = (112/119)*(2.5/1000) ^0.5 = 0.047 
Fst = [(sigma)/20] ^ 0.2 = (72/20)^0.2 = 1.29 
Ff = 1 
Fha = 1 
C = 0.516 
Ad/At = 0.1  
 
Dt = [4G/(fUf * PI* (1-ad/at) * rhoG)] ^0.5= 4.613 meters = 15 feet  
H = 2 feet * 3 stages + 25 feet = 31 feet 
 
Process 300 
24 inch spacing between plates 
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f = 0.85 
G = 18 kg/s 
L = 26 kg/s 
Uf = C*[(rhoL-rhoG] / RhoG)^0.5 = 9.29 ft/s = 2.83 meter/s 
Rho G = 1.911 kg/m3 
Rho L = 689 kg/m3 
C =Csb Fst Ff Fha 
Csb = 0.38 ft/s 
Flg = (L/G) (rhog/rhoL)^0.5 = 0.076 
Fst = [(sigma)/20] ^ 0.2 = (72/20)^0.2 = 1.29 
Ff = 1 
Fha = 1 
C = 0.49 
Ad/At = 0.1 
Dt = [4G/(fUf * PI* (1-ad/at) * rhoG)] ^0.5 = 2.35 meter = 7.7 feet 
H = 2 stages * 2 feet + 25 feet = 29 feet  
 
Chiller Sizing 
1 ton  = 3.517 kW 
Propane total cooling: 
79496 kwh  
24 hour turnaround:  3312 kw = 946 tons 
Ethylene Glycol total Cooling: 
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61 kwh 
18 hour turnaround:  3.3 kw = 1 tons. Round to 10, to be reasonable 
 
Brine total cooling: 230 kwh = 65 tons 
Cost = $400/ton for chillerC-1 
 
Propane chiller  = $378,500 
Ethylene Glycol Chiller = $4000 
Brine Chiller  = $26,158 
 
 
 
 
 
 
 
 
 
 
Endnotes 
C-1: Florida Power and Light Company (2010). Water-Cooled Chillers. Retrieved from 
https://www.fpl.com/business/pdf/water-cooled-chillers-primer.pdf 
 
  
180
 
 
 
Appendix D - Project Labor and Salary Considerations 
The minimum wage in the United States is: $7.25 D-1 
The ‘minimum wage’ in India is: ~$1.00 D-2 
Therefore, the multiple for $ in US to $ in India is 0.138. 
Appendix D-1 Labor Costs in India by position on a per hour basis 
Position Average Pay in US ($/hr) 
Calculated Pay in 
India ($/hr) 
Highly trained chemical engineer $56 D-4 $8.00 
Skilled chemical operator $46 D-5 $6.50 
Skilled plant worker $24 D-3 $3.50 
Appendix D-2 Labor Costs for the Entire Project+ 
Position $/hr 
Regular 
Days 
worked 
$/hr 
OT^ OT days  
Hours 
per day 
Number of 
employees Total pay ($) 
Chemical 
Engineer 
$8.00 86 $10.00  34 8 2 $16,448  
Chemical 
operator (day 
shift) 
$6.50 86 $8.13  34 8 2 $13,367  
Plant worker 
(day) 
$3.50 86 $4.38  34 8 25 $89,984  
Chemical 
operator (night 
shift) 
$6.30* 86 $7.88  34 8 4 $25,911  
Plant worker 
(night) 
$3.30* 86 $4.13  34 8 40 $135,750  
 
*Slightly lowered the salary for night-time workers, as they will be less highly skilled, yet will 
still do similar work. 
^Calculation assumes an OT rate of 25% above baseline pay. 
+Total pay = ($/hr * Regular days worked*hours per day + OT $/hr * OT days worked*hours per 
day)*# employees 
 
Total labor costs are: $281,460 or $2,815 per batch. 
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Endnotes 
D-1: United States Department of Labor Wage and Hour Division (WHD) (2017): History of 
Federal Minimum Wage Rates Under the Fair Labor Standards Act, 1938 - 2009 
D-2: Einhorn, Bloomberg (2014): India vs. China: The Battle for Global Manufacturing 
D-3: Salary.com (2017): US Salary Information for chemical operators  
D-4: Salary.com (2017): US Salary Information for Chemical Engineers IV (Senior Chemical 
Engineer) 
D-5: Salary.com (2017): US Salary Information for Chemical Plant Superintendents and Highly 
Skilled Plant Operators 
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Appendix E - Annual Sales Projections 
Annual US Sales of sofosbuvir name brand Sovaldi are $10.3 billion. At approximately $84,000 
per treatment, the total number of treatment sales in the United States is 0.12 million, accounting 
for significant figures to remain conservative.E-1 
 
In the United States, 3.2 million people are infected with Hepatitis C, which indicates a sale of 
0.0375 treatments per person infected with Hepatitis C.E-2 
 
A key assumption made was that the new, lower price point of sofosbuvir would allow for a sales 
rate similar to that seen in the United States in the target market. At the previously determined 
multiplier, it was possible to determine the approximate annual sales.  
 
Approximately 100 million people in the developing world are infected with Hepatitis C in 
countries covered by Gilead’s low-cost license, which would reflect 5.25 million annual sales of 
the affordable treatment.E-5 At 33.6 g per treatment, annual sales would be 176,400 kg, or 176 
metric tons. The project plans to synthesize 350 metric tons of sofosbuvir each year for 10 years. 
However, our team has reasoned that the United States has a significant market saturation, with 
4-5 competitive Hepatitis C treatments on the market. Furthermore, the treatment has been on the 
market for a significant amount of time, meaning that it has acquired most of its majority 
customer share, as seen in Figure E-1, the sales adoption curve. 
 
 
Figure E-1: Sales Adoption CurveE-4 
 
Justifiably, it is possible that the US Hepatitis C drug market is in the latter stages of sales and is 
also affected by significant market saturation. Since Hepatitis C drugs are currently sold in India, 
albeit at a much more prohibitive price, our team determined that the sales curve had already 
progressed significantly in the developing world. Therefore, our team felt confident to make 
optimistic sales projections for sofosbuvir rather than over a 20-year sales cycle. Overall, we 
have projected the following sales by year, shown in Table E-1. Our team projects early and 
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rapid sales of the generic, affordable sofosbuvir, allowing for rapid and extensive market 
expansion.  
 
Appendix E-1 Production Schedules by Year+ 
Year 
High Output Base Case Low Output 
Production 
(metric tons) 
Production 
(metric tons) 
Production 
(metric tons) 
1 350 350 175 
2 442 350 210 
3 534 350 245 
4 626 350 280 
5 626 350 315 
6 626 350 350 
7 626 350 350 
8 626 350 350 
9 626 350 350 
10 626 350 350 
11 0 0 0 
+350 metric tons is 100 batches. 
 
 
Endnotes 
E-1: Pollack, New York Times (2015): Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to 
$10.3 Billion. 
E-2: Viral Hepatitis Action Coalition (2017): Hepatitis C.  
E-3: The Hindu (2016): India may soon get treatment for Hepatitis C.  
E-4: Rogers, Everett M. (1995): Diffusion of Innovations. Free Press, New York City. 
E-5: World Health Organization (2016): Hepatitis C 
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Appendix F - Energy Utilities 
Appendix F-1 Costing of Energy Utilities F-1  
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Appendix F-2 Parameters for Coolant Selection 
 
Appendix F-3 Pump Energy Utility Calculations 
BLOCK:  PUMP     MODEL: PUMP  
---------------------------- 
  INLET STREAM:          1PUMP_IN  
  OUTLET STREAM:         2PUMP_OUT  
  PROPERTY OPTION SET:   NRTL      RENON (NRTL) / IDEAL GAS                     
 
                     ***  MASS AND ENERGY BALANCE  *** 
                                   IN              OUT        RELATIVE DIFF. 
   TOTAL BALANCE 
      MOLE(KMOL/HR )            1655.19         1655.19         0.00000     
      MASS(KG/HR   )            29818.7         29818.7         0.00000     
      ENTHALPY(CAL/SEC )      -0.313852E+08   -0.313851E+08   -0.328300E-05 
 
                          ***  RESULTS  *** 
   VOLUMETRIC FLOW RATE  L/MIN                          500.000       
   PRESSURE CHANGE  BAR                                 0.30000     
   NPSH AVAILABLE   M-KGF/KG                            9.93390     
   FLUID POWER  KW                                      0.24617     
   BRAKE POWER  KW                                      0.43140     
   ELECTRICITY  KW                                      0.43140     
   HEAD DEVELOPED M-KGF/KG                              3.03056     
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Pump Stream Calculations 
Unit 
Time 
(hr) 
Flow rate 
(L/min) kW kWh 
Pump (Isopropanol to 101) 1 2200 1.514 1.514 
Pump (Thionyl Chloride to 101) 0.18 500 0.438 0.08 
Pump (101 to flash vessel) 1 2200 1.514 1.514 
Pump (Storage to 200) 1 250 0.143 0.143 
    
3.251 
     
Unit 
Time 
(hr) 
Flow rate 
(L/min) kW kWh 
Pump (DCM to 201) 3.8 500 0.438 1.664 
Pump (DIEA to 201) 1.1 100 0.143 0.157 
Pump (DCM to 202) 1.9 500 0.438 0.832 
Pump (DIEA to 202) 0.66 100 0.143 0.094 
Pump (201 to 203) 3.8 500 0.438 1.664 
Pump (202 Storage to 203) 1.9 500 0.438 0.832 
Pump (203 to Flash) 5.7 250 0.143 0.815 
Pump (Flash to wash 1.15 500 0.438 0.504 
Pump (water to Wash) 4.98 500 0.438 2.181 
Pump (wash effluent) 4.98 500 0.438 2.181 
Pump (Sodium Sulfate drying) 1.75 500 2.19 3.833 
Pump (Wash to evaporator) 1.75 500 0.438 0.767 
Pump (Evaporator to 300) 0.48 500 0.438 0.21 
    
15.735 
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Unit 
Time 
(hr) 
Flow rate 
(L/min) kW kWh 
Pump (THF to 301) 1.17 500 0.438 0.511 
Pump (DIEA to 301) 0.12 500 0.438 0.054 
Pump (301 to wash vessel) 1.25 500 0.438 0.548 
Pump (Ethyl Acetate to Wash) 1.87 1000 0.769 1.435 
Pump (NH4Cl to Wash) 0.93 1000 0.769 0.718 
Pump (0.5M HCl to Wash) 0.93 1000 0.769 0.718 
Pump (Buffer to Wash) 0.93 1000 0.769 0.718 
Pump (Salt to Wash) 0.93 1000 0.769 0.718 
Pump (Sodium sulfate drying) 2.45 1000 3.33 8.159 
Pump (Wash to waste) 4.32 1000 0.769 3.32 
Pump (Acetone to Crystallizer) 0.37 500 0.438 0.163 
Pump (DCM to crystallizer) 1.49 1000 0.769 1.147 
Pump Crystallizer Out 23.52 100 0.143 3.363 
    
21.569 
    
40.555 
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Appendix F-4 Screw Conveyor Power Requirements F-2 
 
 
 
Endnotes 
F-1: Seider, W. D., Lewin, D. R., Seader, J. D., Widagdo, S., Gani, R., & Ng, K. M. (2017). 
Product and process design principles: Synthesis, analysis and evaluation. Hoboken, NJ: 
Wiley. 
F-2: Zareiforoush H, Komarizadeh MH, Alizadeh MR, Masoomi M. Screw conveyors power and 
throughput analysis during horizontal handling of paddy grains. J Agric Sci 2010; 
2:147–57. 
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Appendix G - Import/Export 
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Appendix H - SuperPro and Gantt Charts 
Appendix H-1 Overall Gantt Chart 
 
s
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Appendix H-2 Overall Process Super Pro 
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194
 
 
 
Appendix H-3 Process 100 Super Pro 
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Appendix H-4 Process 200 Super Pro 
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Appendix H-5 Process 300 Super Pro 
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Appendix I - ASPEN Block and Stream Reports 
Appendix I-1 Thionyl Chloride Cooling - HeatEx Block Report (V101) 
BLOCK: B1        MODEL: HEATX 
----------------------------- 
 HOT SIDE: 
 --------- 
 INLET STREAM:             3 
 OUTLET STREAM:            4 
 PROPERTY OPTION SET:   IDEAL      IDEAL LIQUID / IDEAL GAS 
 COLD SIDE: 
 ---------- 
 INLET STREAM:             1 
 OUTLET STREAM:            2 
 PROPERTY OPTION SET:   IDEAL      IDEAL LIQUID / IDEAL GAS 
                   ***   MASS AND ENERGY BALANCE      *** 
                                  IN                  OUT          RELATIVE DIFF. 
 TOTAL BALANCE 
    MOLE(KMOL/HR )               945.008            945.008          0.00000 
    MASS(KG/HR   )               81900.0            81900.0          0.00000 
    ENTHALPY(CAL/SEC )         -0.230949E+08      -0.230949E+08      0.00000 
                   *** CO2 EQUIVALENT SUMMARY *** 
 FEED STREAMS CO2E            0.00000      KG/HR 
 PRODUCT STREAMS CO2E         0.00000      KG/HR 
 NET STREAMS CO2E PRODUCTION  0.00000      KG/HR 
 UTILITIES CO2E PRODUCTION    0.00000      KG/HR 
 TOTAL CO2E PRODUCTION        0.00000      KG/HR 
 
                         ***   INPUT DATA   *** 
 
FLASH SPECS FOR HOT SIDE: 
TWO    PHASE      FLASH 
MAXIMUM NO. ITERATIONS                                        30 
CONVERGENCE TOLERANCE                                          0.000100000 
 
FLASH SPECS FOR COLD SIDE: 
TWO    PHASE      FLASH 
MAXIMUM NO. ITERATIONS                                        30 
CONVERGENCE TOLERANCE                                          0.000100000 
FLOW DIRECTION AND SPECIFICATION: 
  COUNTERCURRENT   HEAT EXCHANGER 
  SPECIFIED HOT OUTLET TEMP 
  SPECIFIED VALUE                C                                0.0000 
  LMTD CORRECTION FACTOR                                          1.00000 
PRESSURE SPECIFICATION: 
  HOT SIDE PRESSURE DROP           BAR                            0.0000 
  COLD SIDE PRESSURE DROP          BAR                            0.0000 
HEAT TRANSFER COEFFICIENT SPECIFICATION: 
  HOT LIQUID    COLD LIQUID      CAL/SEC-SQCM-K                   0.0203 
  HOT 2-PHASE   COLD LIQUID      CAL/SEC-SQCM-K                   0.0203 
  HOT VAPOR     COLD LIQUID      CAL/SEC-SQCM-K                   0.0203 
  HOT LIQUID    COLD 2-PHASE     CAL/SEC-SQCM-K                   0.0203 
  HOT 2-PHASE   COLD 2-PHASE     CAL/SEC-SQCM-K                   0.0203 
  HOT VAPOR     COLD 2-PHASE     CAL/SEC-SQCM-K                   0.0203 
  HOT LIQUID    COLD VAPOR       CAL/SEC-SQCM-K                   0.0203 
  HOT 2-PHASE   COLD VAPOR       CAL/SEC-SQCM-K                   0.0203 
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  HOT VAPOR     COLD VAPOR       CAL/SEC-SQCM-K                   0.0203 
 
                     ***    OVERALL RESULTS    *** 
 
STREAMS: 
                  -------------------------------------- 
                  |                                    | 
3           ----->|                HOT                 |----->     4 
T=    2.5000D+01 |                                     |           T=    0.0000D+00 
P=    1.0000D+00 |                                     |           P=    1.0000D+00 
V=    0.0000D+00 |                                     |           V=    0.0000D+00 
                  |                                    | 
2           <-----|                COLD                |<-----     1 
T=    4.8660D+00 |                                     |           T= -1.0000D+01 
P=    1.0000D+00 |                                     |           P= 1.0000D+00 
V=    0.0000D+00 |                                     |           V= 0.0000D+00 
                  -------------------------------------- 
DUTY AND AREA: 
  CALCULATED HEAT DUTY               CAL/SEC                73571.3464 
  CALCULATED (REQUIRED) AREA         SQM                       25.0254 
  ACTUAL EXCHANGER AREA              SQM                       25.0254 
  PER CENT OVER-DESIGN                                          0.0000 
 
HEAT TRANSFER COEFFICIENT: 
  AVERAGE COEFFICIENT (DIRTY)        CAL/SEC-SQCM-K             0.0203 
  UA (DIRTY)                         CAL/SEC-K               5080.6220 
LOG-MEAN TEMPERATURE DIFFERENCE: 
  LMTD CORRECTION FACTOR                                        1.0000 
  LMTD (CORRECTED)               C                             14.4808 
  NUMBER OF SHELLS IN SERIES                                     1 
 
PRESSURE DROP: 
  HOTSIDE, TOTAL                     BAR                        0.0000 
  COLDSIDE, TOTAL                    BAR                        0.0000 
 
                         ***   ZONE RESULTS    *** 
 
TEMPERATURE LEAVING EACH ZONE: 
                                   HOT 
       ------------------------------------------------------------- 
       |                                                           | 
HOT IN  |                           LIQ                             | HOT OUT 
------> |                                                           |------> 
 25.0  |                                                           |    0.0 
       |                                                           | 
COLDOUT |                           LIQ                             | COLDIN 
<------ |                                                           |<------ 
  4.9  |                                                           | -10.0 
       |                                                           | 
       ------------------------------------------------------------- 
                                   COLD 
ZONE HEAT TRANSFER AND AREA: 
ZONE         HEAT DUTY          AREA         LMTD       AVERAGE U        UA 
             CAL/SEC            SQM           C         CAL/SEC-SQCM-K   CAL/SEC-K 
  1        73571.346           25.0254        14.4808     0.0203         5080.6220 
 
HEATX COLD-TQCU B1       TQCURV INLET 
------------------------------------- 
 PRESSURE PROFILE:      CONSTANT2 
 PRESSURE DROP:         0.0         BAR 
 PROPERTY OPTION SET:   IDEAL     IDEAL LIQUID / IDEAL GAS 
 
199
 
 
 
----------------------------------------------------- 
! DUTY       ! PRES       ! TEMP       ! VFRAC      ! 
!            !            !            !            ! 
! CAL/SEC    ! BAR        ! C          !            ! 
!            !            !            !            ! 
!============!============!============!============! 
!     0.0    !     1.0000 !     4.8660 !     0.0    ! 
! 3503.3974 !      1.0000 !     4.1632 !     0.0    ! 
! 7006.7949 !      1.0000 !     3.4598 !     0.0    ! 
! 1.0510+04 !      1.0000 !     2.7560 !     0.0    ! 
! 1.4014+04 !      1.0000 !     2.0516 !     0.0    ! 
!------------+------------+------------+------------! 
! 1.7517+04 !      1.0000 !     1.3467 !     0.0    ! 
! 2.1020+04 !      1.0000 !     0.6413 !     0.0    ! 
! 2.4524+04 !      1.0000 ! -6.4647-02 !     0.0    ! 
! 2.8027+04 !      1.0000 !    -0.7711 !     0.0    ! 
! 3.1531+04 !      1.0000 !    -1.4780 !     0.0    ! 
!------------+------------+------------+------------! 
! 3.5034+04 !      1.0000 !    -2.1855 !     0.0    ! 
! 3.8537+04 !      1.0000 !    -2.8935 !     0.0    ! 
! 4.2041+04 !      1.0000 !    -3.6019 !     0.0    ! 
! 4.5544+04 !      1.0000 !    -4.3109 !     0.0    ! 
! 4.9048+04 !      1.0000 !    -5.0203 !     0.0    ! 
!------------+------------+------------+------------! 
! 5.2551+04 !      1.0000 !    -5.7303 !     0.0    ! 
! 5.6054+04 !      1.0000 !    -6.4407 !     0.0    ! 
! 5.9558+04 !      1.0000 !    -7.1516 !     0.0    ! 
! 6.3061+04 !      1.0000 !    -7.8630 !     0.0    ! 
! 6.6565+04 !      1.0000 !    -8.5749 !     0.0    ! 
!------------+------------+------------+------------! 
! 7.0068+04 !      1.0000 !    -9.2872 !     0.0    ! 
! 7.3571+04 !      1.0000 !   -10.0000 !     0.0    ! 
 
HEATX HOT-TQCUR B1       TQCURV INLET 
------------------------------------- 
 PRESSURE PROFILE:      CONSTANT2 
 PRESSURE DROP:         0.0         BAR 
 PROPERTY OPTION SET:   IDEAL     IDEAL LIQUID / IDEAL GAS 
 
----------------------------------------------------- 
! DUTY       ! PRES       ! TEMP       ! VFRAC      ! 
!            !            !            !            ! 
! CAL/SEC    ! BAR        ! C          !            ! 
!            !            !            !            ! 
!============!============!============!============! 
!     0.0    !     1.0000 !    25.0000 !     0.0    ! 
! 3503.3974 !      1.0000 !    23.8308 !     0.0    ! 
! 7006.7949 !      1.0000 !    22.6595 !     0.0    ! 
! 1.0510+04 !      1.0000 !    21.4862 !     0.0    ! 
! 1.4014+04 !      1.0000 !    20.3107 !     0.0    ! 
!------------+------------+------------+------------! 
! 1.7517+04 !      1.0000 !    19.1331 !     0.0    ! 
! 2.1020+04 !      1.0000 !    17.9534 !     0.0    ! 
! 2.4524+04 !      1.0000 !    16.7716 !     0.0    ! 
! 2.8027+04 !      1.0000 !    15.5876 !     0.0    ! 
! 3.1531+04 !      1.0000 !    14.4015 !     0.0    ! 
!------------+------------+------------+------------! 
! 3.5034+04 !      1.0000 !    13.2133 !     0.0    ! 
! 3.8537+04 !      1.0000 !    12.0229 !     0.0    ! 
! 4.2041+04 !      1.0000 !    10.8304 !     0.0    ! 
! 4.5544+04 !      1.0000 !     9.6357 !     0.0    ! 
! 4.9048+04 !      1.0000 !     8.4389 !     0.0    ! 
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!------------+------------+------------+------------! 
! 5.2551+04 !      1.0000 !     7.2399 !     0.0    ! 
! 5.6054+04 !      1.0000 !     6.0387 !     0.0    ! 
! 5.9558+04 !      1.0000 !     4.8353 !     0.0    ! 
! 6.3061+04 !      1.0000 !     3.6298 !     0.0    ! 
! 6.6565+04 !      1.0000 !     2.4221 !     0.0    ! 
!------------+------------+------------+------------! 
! 7.0068+04 !      1.0000 !     1.2121 !     0.0    ! 
! 7.3571+04 !      1.0000 ! 3.9530-07 !      0.0    ! 
----------------------------------------------------- 
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Appendix I-2 Distillation Column - Radfrac Stream and Block Reports (V103) 
S1 S2 S3                             
------------- 
 
STREAM 
ID               S1         S2         S3              
FROM :                  ----       B1         B1     
TO   :                  B1         ----       ----      
 
SUBSTREAM: MIXED    
PHASE:                  LIQUID     LIQUID     LIQUID    
COMPONENTS: KMOL/SEC         
  ISOPR-01            0.4709     1.1491-03  0.4697      
  L-ALA-01            1.3614-03  1.3614-03  7.7991-13  
  THION-01            1.1772-02  5.6213-07  1.1771-02 
  HYDRO-01            9.1103-03  4.9487-17  9.1103-03  
  SULFU-01            9.1103-03  9.6251-13  9.1103-03 
TOTAL FLOW:      
  KMOL/SEC            0.5022     2.5111-03  0.4997   
  KG/SEC              30.7349    0.1904     30.5445    
  CUM/SEC             3.8083-02  5.0377-04  3.3599-02  
STATE VARIABLES: 
  TEMP   K            298.1500   309.7911   208.7851   
  PRES   N/SQM        1.0000+05  5332.8947  5332.8947  
  VFRAC               0.0        0.0        0.0           
  LFRAC               1.0000     1.0000     1.0000     
  SFRAC               0.0        0.0        0.0           
ENTHALPY:        
  J/KMOL             -3.1302+08 -4.1217+08 -3.2731+08 
  J/KG               -5.1149+06 -5.4354+06 -5.3549+06 
  WATT               -1.5720+08 -1.0350+06 -1.6356+08 
ENTROPY:         
  J/KMOL-K           -4.3383+05 -8.8447+05 -4.9042+05 
  J/KG-K             -7088.9766 -1.1664+04 -8023.2898 
DENSITY:         
  KMOL/CUM           13.1876     4.9847    14.8729  
  KG/CUM             807.0488   377.9916   909.0958  
AVG MW               61.1978    75.8308    61.1242    
 
                                        
BLOCK: B1        MODEL: RADFRAC 
------------------------------- 
  INLETS   - S1       STAGE   2 
  OUTLETS  - S3       STAGE   1 
             S2       STAGE   3 
 PROPERTY OPTION SET:   IDEAL         IDEAL LIQUID / IDEAL GAS 
                      ***    MASS AND ENERGY BALANCE   *** 
                                      IN               OUT          RELATIVE DIFF. 
 TOTAL BALANCE 
    MOLE(KMOL/SEC)                 0.502222         0.502222          0.00000 
    MASS(KG/SEC )                   31.5055          31.5055         0.234953E-09 
    ENTHALPY(WATT       )         -0.161346E+09    -0.161454E+09     0.673947E-03 
                   *** CO2 EQUIVALENT SUMMARY *** 
 FEED STREAMS CO2E            0.00000      KG/SEC 
 PRODUCT STREAMS CO2E         0.00000      KG/SEC 
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 NET STREAMS CO2E PRODUCTION  0.00000      KG/SEC 
 UTILITIES CO2E PRODUCTION    0.00000      KG/SEC 
 TOTAL CO2E PRODUCTION        0.00000      KG/SEC 
 
                         ********************** 
                         **** INPUT DATA **** 
                         ********************** 
 
****   INPUT PARAMETERS        **** 
 
 NUMBER OF STAGES                                               3 
 ALGORITHM OPTION                                            STANDARD 
 ABSORBER OPTION                                             NO 
 INITIALIZATION OPTION                                       STANDARD 
 HYDRAULIC PARAMETER CALCULATIONS                            NO 
 INSIDE LOOP CONVERGENCE METHOD                              BROYDEN 
 DESIGN SPECIFICATION METHOD                                 NESTED 
 MAXIMUM NO. OF OUTSIDE LOOP ITERATIONS                        25 
 MAXIMUM NO. OF INSIDE LOOP ITERATIONS                         10 
 MAXIMUM NUMBER OF FLASH ITERATIONS                            30 
 FLASH TOLERANCE                                                0.000100000 
 OUTSIDE LOOP CONVERGENCE TOLERANCE                             0.000100000 
****   COL-SPECS      **** 
 MOLAR VAPOR DIST / TOTAL DIST                                     0.0 
 MOLAR REFLUX RATIO                                                3.00000 
 BOTTOMS TO FEED RATIO                                             0.040000 
 
****      PROFILES    **** 
 P-SPEC              STAGE    1   PRES, N/SQM                5,332.89 
                             ******************* 
                             **** RESULTS **** 
                             ******************* 
 
***    COMPONENT SPLIT FRACTIONS       *** 
 
                               OUTLET STREAMS 
                               -------------- 
                S3               S2 
 COMPONENT: 
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 ISOPR-01       .98943        .10574E-01 
 L-ALA-01       .68188E-09    1.0000 
 THION-01       .99798        .20220E-02 
 
***      SUMMARY OF KEY RESULTS        *** 
 TOP STAGE TEMPERATURE                 K                         295.867 
 BOTTOM STAGE TEMPERATURE              K                         320.862 
 TOP STAGE LIQUID FLOW                 KMOL/SEC                    1.44640 
 BOTTOM STAGE LIQUID FLOW              KMOL/SEC                    0.020089 
 TOP STAGE VAPOR FLOW                  KMOL/SEC                    0.0 
 BOILUP VAPOR FLOW                     KMOL/SEC                    1.82840 
 MOLAR REFLUX RATIO                                                3.00000 
 MOLAR BOILUP RATIO                                               91.0157 
 CONDENSER DUTY (W/O SUBCOOL)          WATT                       -0.884715+08 
 REBOILER DUTY                         WATT                        0.883627+08 
 
****     MAXIMUM FINAL RELATIVE ERRORS        **** 
 DEW POINT                             0.46351E-06     STAGE=   3 
 BUBBLE POINT                          0.28072E-06     STAGE=   3 
 COMPONENT MASS BALANCE                0.32587E-07     STAGE=   2 COMP=L-ALA-01 
 ENERGY BALANCE                        0.71674E-07     STAGE=   2 
 
****      PROFILES     **** 
 
**NOTE** REPORTED VALUES FOR STAGE LIQUID AND VAPOR RATES ARE THE FLOWS 
         FROM THE STAGE INCLUDING ANY SIDE PRODUCT. 
 
                                             ENTHALPY 
STAGE TEMPERATURE     PRESSURE                J/KMOL                HEAT DUTY 
     K               N/SQM             LIQUID       VAPOR           WATT 
 
1      295.87        5332.9       -0.31626E+09 -0.26727E+09       -.88471+08 
2      296.57        5332.9       -0.31908E+09 -0.27039E+09 
3      320.86        5332.9       -0.44683E+09 -0.26935E+09        .88363+08 
 
STAGE    FLOW RATE                         FEED RATE                 PRODUCT RATE 
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         KMOL/SEC                          KMOL/SEC                   KMOL/SEC 
    LIQUID     VAPOR            LIQUID      VAPOR      MIXED      LIQUID    VAPOR 
1 1.929       0.000                       .34912-02                 0.4821 
2 1.848       1.925             0.4987 
3 0.2009E-01 1.828                                               .20089-01 
 
 ****    MASS FLOW PROFILES     **** 
 
STAGE     FLOW RATE                        FEED RATE                 PRODUCT RATE 
          KG/SEC                           KG/SEC                     KG/SEC 
     LIQUID     VAPOR           LIQUID      VAPOR      MIXED      LIQUID    VAPOR 
1   119.4      0.000                         0.2266                29.8595 
2   112.7      119.2            31.2788 
3   1.646      111.1                                                1.6459 
                    ****   MOLE-X-PROFILE    **** 
STAGE       ISOPR-01       L-ALA-01      THION-01 
   1      0.96881        0.21309E-10   0.31187E-01 
   2      0.98070        0.81508E-02   0.11150E-01 
   3      0.24848        0.75000       0.15165E-02 
                    ****    MOLE-Y-PROFILE    **** 
 
STAGE     ISOPR-01     L-ALA-01         THION-01 
  1    0.91567      0.55216E-19      0.84332E-01 
  2    0.96891      0.21205E-10      0.31095E-01 
  3    0.98874      0.22169E-08      0.11256E-01 
                    ****   K-VALUES    **** 
STAGE     ISOPR-01     L-ALA-01      THION-01 
  1    0.94514      0.25913E-08    2.7041 
  2    0.98797      0.26016E-08    2.7887 
  3     3.9791      0.29559E-08    7.4225 
                    ****   MASS-X-PROFILE   **** 
STAGE     ISOPR-01     L-ALA-01      THION-01 
  1    0.94009      0.30654E-10   0.59910E-01 
  2    0.96634      0.11907E-01   0.21751E-01 
  3    0.18225      0.81554       0.22020E-02 
                    ****   MASS-Y-PROFILE     **** 
STAGE     ISOPR-01     L-ALA-01      THION-01 
  1    0.84579      0.75613E-19   0.15421 
  2    0.94026      0.30508E-10   0.59738E-01 
  3    0.97796      0.32508E-08   0.22041E-01 
 
Appendix I-3 Flash Separation - Flash2 Stream and Block Reports (V204) 
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BLOCK:  B1       MODEL: FLASH2           
------------------------------ 
  INLET STREAM:          1        
  OUTLET VAPOR STREAM:   2        
  OUTLET LIQUID STREAM:  3        
  PROPERTY OPTION SET:   IDEAL     IDEAL LIQUID / IDEAL GAS                     
 
                     ***  MASS AND ENERGY BALANCE  *** 
                                   IN              OUT        RELATIVE DIFF. 
   TOTAL BALANCE 
      MOLE(KMOL/HR )            440.425         440.425         0.00000     
      MASS(KG/HR   )            39413.0         39413.0         0.00000     
      ENTHALPY(CAL/SEC )      -0.361206E+07   -0.303710E+07   -0.159178     
 
                     ***  CO2 EQUIVALENT SUMMARY *** 
   FEED STREAMS CO2E             310347.      KG/HR            
   PRODUCT STREAMS CO2E          310347.      KG/HR            
   NET STREAMS CO2E PRODUCTION   0.00000      KG/HR            
   UTILITIES CO2E PRODUCTION     0.00000      KG/HR            
   TOTAL CO2E PRODUCTION         0.00000      KG/HR            
 
                         ***  INPUT DATA  *** 
  TWO    PHASE  TP  FLASH 
  SPECIFIED TEMPERATURE C                                  25.0000      
  SPECIFIED PRESSURE    BAR                                 0.50000     
  MAXIMUM NO. ITERATIONS                                   30 
  CONVERGENCE TOLERANCE                                     0.000100000 
 
                          ***  RESULTS  *** 
  OUTLET TEMPERATURE    C                                    25.000     
  OUTLET PRESSURE       BAR                                 0.50000     
  HEAT DUTY             CAL/SEC                             0.57496E+06 
  VAPOR FRACTION                                            0.67805     
 
  V-L PHASE EQUILIBRIUM :  
 
     COMP              F(I)           X(I)           Y(I)           K(I)       
     DICHL-01         0.95364        0.85600         1.0000         1.1682     
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     PHENY-01         0.46362E-01    0.14400        0.23158E-08    0.16082E-07 
 
 
  1 2 3                                    
----- 
 
STREAM ID               1          2          3        
FROM :                  ----       B1         B1       
TO   :                  B1         ----       ----     
 
SUBSTREAM: MIXED    
PHASE:                  LIQUID     VAPOR      LIQUID  
COMPONENTS: KMOL/HR          
  DICHL-01             420.0057   298.6291   121.3766 
  PHENY-01              20.4189  6.9157-07    20.4189 
TOTAL FLOW:      
  KMOL/HR              440.4246   298.6291   141.7955 
  KG/HR               3.9413+04  2.5363+04  1.4050+04 
  L/MIN                500.0000  2.4676+05   181.0709 
STATE VARIABLES: 
  TEMP   C              25.0000    25.0000    25.0000 
  PRES   BAR             1.0100     0.5000     0.5000 
  VFRAC                  0.0        1.0000     0.0    
  LFRAC                  1.0000     0.0        1.0000 
  SFRAC                  0.0        0.0        0.0    
ENTHALPY:        
  CAL/MOL            -2.9525+04 -2.2815+04 -2.9059+04 
  CAL/GM              -329.9270  -268.6206  -293.2771 
  CAL/SEC            -3.6121+06 -1.8925+06 -1.1446+06 
ENTROPY:         
  CAL/MOL-K            -43.2111   -19.8744   -43.0882 
  CAL/GM-K              -0.4829    -0.2340    -0.4349 
DENSITY:         
  MOL/CC              1.4681-02  2.0170-05  1.3052-02 
  GM/CC                  1.3138  1.7131-03     1.2932 
AVG MW                  89.4886    84.9323    99.0845 
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Appendix I-4 Intermediate A1 Wash - Decanter Block Report (V205) 
BLOCK:  B1       MODEL: DECANTER         
-------------------------------- 
  INLET STREAM:          S1       
  FIRST LIQUID OUTLET:   S3       
  SECOND LIQUID OUTLET:  S2       
  PROPERTY OPTION SET:   NRTL      RENON (NRTL) / IDEAL GAS                     
 
                     ***  MASS AND ENERGY BALANCE  *** 
                                   IN              OUT        RELATIVE DIFF. 
   TOTAL BALANCE 
      MOLE(KMOL/HR )          1089.50        1089.50        0.00000     
      MASS(KG/HR   )          35627.9        35627.9        0.782301E-08 
      ENTHALPY(CAL/SEC )      -0.180794E+08  -0.180973E+08  0.987702E-03 
 
                     ***  CO2 EQUIVALENT SUMMARY *** 
   FEED STREAMS CO2E             176679.      KG/HR            
   PRODUCT STREAMS CO2E          176679.      KG/HR            
   NET STREAMS CO2E PRODUCTION -0.307765E-02  KG/HR            
   UTILITIES CO2E PRODUCTION     0.00000      KG/HR            
   TOTAL CO2E PRODUCTION       -0.307765E-02  KG/HR            
 
                         ***  INPUT DATA  *** 
 
  LIQUID-LIQUID SPLIT, TP SPECIFICATION 
  SPECIFIED TEMPERATURE               C                         25.0000      
  SPECIFIED PRESSURE                  BAR                     1.00000     
  CONVERGENCE TOLERANCE ON EQUILIBRIUM                       0.10000E-03 
  MAXIMUM NO ITERATIONS ON EQUILIBRIUM                       30 
  EQUILIBRIUM METHOD                           EQUATION-SOLVING 
  KLL COEFFICIENTS FROM                       OPTION SET OR EOS 
  KLL BASIS                                                MOLE 
  KEY COMPONENT(S):       DICHL-01  WATER                        
 
                          ***  RESULTS  *** 
 
  OUTLET TEMPERATURE      C                                  25.000     
  OUTLET PRESSURE         BAR                                1.0000     
  CALCULATED HEAT DUTY    CAL/SEC                           -17875.     
  MOLAR RATIO 1ST LIQUID / TOTAL LIQUID                     0.22190     
 
  L1-L2 PHASE EQUILIBRIUM :  
     COMP          F             X1            X2            K 
     DICHL-01   0.21947       0.98131       0.0022004     0.0022423    
     WATER      0.78053       0.018690      0.99780       53.3855   
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Appendix I-5 Flash Distillate Condenser - HeatEx Block Report (V208) 
 
BLOCK:  CONDENSE MODEL: HEATX            
----------------------------- 
  HOT SIDE: 
  --------- 
  INLET STREAM:             DCM-IN   
  OUTLET STREAM:            DCM-OUT  
  PROPERTY OPTION SET:   UNIF-LL   UNIFAC / REDLICH-KWONG                       
  COLD SIDE: 
  ---------- 
  INLET STREAM:             CW-IN    
  OUTLET STREAM:            CW-OUT   
  PROPERTY OPTION SET:   UNIF-LL   UNIFAC / REDLICH-KWONG                       
 
                     ***  MASS AND ENERGY BALANCE  *** 
                                   IN              OUT        RELATIVE DIFF. 
   TOTAL BALANCE 
      MOLE(KMOL/HR )            891.207         891.207         0.00000     
      MASS(KG/HR   )            62229.2         62229.2         0.00000     
      ENTHALPY(CAL/SEC )      -0.204374E+08   -0.204374E+08     0.00000     
 
                     ***  CO2 EQUIVALENT SUMMARY *** 
   FEED STREAMS CO2E             223424.      KG/HR            
   PRODUCT STREAMS CO2E          223424.      KG/HR            
   NET STREAMS CO2E PRODUCTION   0.00000      KG/HR            
   UTILITIES CO2E PRODUCTION     0.00000      KG/HR            
   TOTAL CO2E PRODUCTION         0.00000      KG/HR            
 
                         ***  INPUT DATA  *** 
 
  FLASH SPECS FOR HOT SIDE: 
  TWO    PHASE      FLASH 
  MAXIMUM NO. ITERATIONS                                   30 
  CONVERGENCE TOLERANCE                                     0.000100000 
 
  FLASH SPECS FOR COLD SIDE: 
  TWO    PHASE      FLASH 
  MAXIMUM NO. ITERATIONS                                   30 
  CONVERGENCE TOLERANCE                                     0.000100000 
 
  FLOW DIRECTION AND SPECIFICATION: 
    COUNTERCURRENT   HEAT EXCHANGER 
    SPECIFIED HOT VAPOR FRACTION   
    SPECIFIED VALUE                                         0.0000 
    LMTD CORRECTION FACTOR                                  1.00000 
 
  PRESSURE SPECIFICATION: 
    HOT  SIDE PRESSURE DROP        BAR                      0.0000 
    COLD SIDE PRESSURE DROP        BAR                      0.0000 
 
  HEAT TRANSFER COEFFICIENT SPECIFICATION: 
    HOT LIQUID    COLD LIQUID      CAL/SEC-SQCM-K           0.0203 
    HOT 2-PHASE   COLD LIQUID      CAL/SEC-SQCM-K           0.0203 
    HOT VAPOR     COLD LIQUID      CAL/SEC-SQCM-K           0.0203 
    HOT LIQUID    COLD 2-PHASE     CAL/SEC-SQCM-K           0.0203 
    HOT 2-PHASE   COLD 2-PHASE     CAL/SEC-SQCM-K           0.0203 
    HOT VAPOR     COLD 2-PHASE     CAL/SEC-SQCM-K           0.0203 
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    HOT LIQUID    COLD VAPOR       CAL/SEC-SQCM-K           0.0203 
    HOT 2-PHASE   COLD VAPOR       CAL/SEC-SQCM-K           0.0203 
    HOT VAPOR     COLD VAPOR       CAL/SEC-SQCM-K           0.0203 
 
                       ***  OVERALL RESULTS  *** 
 
  STREAMS: 
                  -------------------------------------- 
                  |                                    | 
  DCM-IN    ----->|                HOT                 |-----> DCM-OUT  
  T=  2.5000D+01  |                                    |       T=  2.1161D+01 
  P=  5.0000D-01  |                                    |       P=  5.0000D-01 
  V=  1.0000D+00  |                                    |       V=  0.0000D+00 
                  |                                    | 
  CW-OUT    <-----|                COLD                |<----- CW-IN    
  T=  2.1609D+01  |                                    |       T= -9.0000D+01 
  P=  1.0132D+00  |                                    |       P=  1.0132D+00 
  V=  0.0000D+00  |                                    |       V=  0.0000D+00 
                  -------------------------------------- 
 
  DUTY AND AREA: 
    CALCULATED HEAT DUTY           CAL/SEC             590551.3185 
    CALCULATED (REQUIRED) AREA     SQM                    149.8232 
    ACTUAL EXCHANGER AREA          SQM                    149.8232 
    PER CENT OVER-DESIGN                                    0.0000 
 
  HEAT TRANSFER COEFFICIENT: 
    AVERAGE COEFFICIENT (DIRTY)    CAL/SEC-SQCM-K           0.0203 
    UA (DIRTY)                     CAL/SEC-K            30416.9486 
 
  LOG-MEAN TEMPERATURE DIFFERENCE: 
    LMTD CORRECTION FACTOR                                  1.0000 
    LMTD (CORRECTED)               C                       19.4152 
    NUMBER OF SHELLS IN SERIES                               1 
 
  PRESSURE DROP: 
    HOTSIDE, TOTAL                 BAR                      0.0000 
    COLDSIDE, TOTAL                BAR                      0.0000 
 
                       ***  ZONE RESULTS  *** 
 
  TEMPERATURE LEAVING EACH ZONE: 
 
                                    HOT  
        ------------------------------------------------------------- 
        |                             |                             | 
HOT IN  |             VAP             |             COND            | HOT OUT  
------> |                             |                             |------> 
  25.0  |                         21.2|                             |   21.2 
        |                             |                             | 
COLDOUT |             LIQ             |             LIQ             | COLDIN   
<------ |                             |                             |<------ 
  21.6  |                         20.9|                             |  -90.0 
        |                             |                             | 
        ------------------------------------------------------------- 
                                    COLD 
 
  ZONE HEAT TRANSFER AND AREA: 
 
  ZONE       HEAT DUTY       AREA       LMTD       AVERAGE U       UA 
             CAL/SEC         SQM         C         CAL/SEC-SQCM-K  CAL/SEC-K        
    1       3967.806        12.3106       1.5876     0.0203        2499.2784 
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    2     586583.512       137.5126      21.0112     0.0203       27917.6703 
 
HEATX COLD-TQCU CONDENSE TQCURV INLET    
------------------------------------- 
  PRESSURE PROFILE:      CONSTANT2    
  PRESSURE DROP:         0.0         BAR              
  PROPERTY OPTION SET:   UNIF-LL   UNIFAC / REDLICH-KWONG                       
 
----------------------------------------------------- 
!  DUTY      !  PRES      !  TEMP      !  VFRAC     ! 
!            !            !            !            ! 
!            !            !            !            ! 
!            !            !            !            ! 
!  CAL/SEC   !  BAR       !  C         !            ! 
!            !            !            !            ! 
!============!============!============!============! 
!     0.0    !     1.0133 !    21.6091 !     0.0    ! 
!  3967.8059 !     1.0133 !    20.8978 !     0.0    ! 
!  2.8121+04 !     1.0133 !    16.5543 !     0.0    ! 
!  5.6243+04 !     1.0133 !    11.4688 !     0.0    ! 
!  8.4364+04 !     1.0133 !     6.3536 !     0.0    ! 
!------------+------------+------------+------------! 
!  1.1249+05 !     1.0133 !     1.2095 !     0.0    ! 
!  1.4061+05 !     1.0133 !    -3.9621 !     0.0    ! 
!  1.6873+05 !     1.0133 !    -9.1602 !     0.0    ! 
!  1.9685+05 !     1.0133 !   -14.3835 !     0.0    ! 
!  2.2497+05 !     1.0133 !   -19.6331 !     0.0    ! 
!------------+------------+------------+------------! 
!  2.5309+05 !     1.0133 !   -24.9093 !     0.0    ! 
!  2.8121+05 !     1.0133 !   -30.2117 !     0.0    ! 
!  3.0934+05 !     1.0133 !   -35.5395 !     0.0    ! 
!  3.3746+05 !     1.0133 !   -40.8920 !     0.0    ! 
!  3.6558+05 !     1.0133 !   -46.2682 !     0.0    ! 
!------------+------------+------------+------------! 
!  3.9370+05 !     1.0133 !   -51.6674 !     0.0    ! 
!  4.2182+05 !     1.0133 !   -57.0882 !     0.0    ! 
!  4.4994+05 !     1.0133 !   -62.5297 !     0.0    ! 
!  4.7807+05 !     1.0133 !   -67.9905 !     0.0    ! 
!  5.0619+05 !     1.0133 !   -73.4693 !     0.0    ! 
!------------+------------+------------+------------! 
!  5.3431+05 !     1.0133 !   -78.9648 !     0.0    ! 
!  5.6243+05 !     1.0133 !   -84.4755 !     0.0    ! 
!  5.9055+05 !     1.0133 !   -90.0000 !     0.0    ! 
----------------------------------------------------- 
 
HEATX HOT-TQCUR CONDENSE TQCURV INLET    
------------------------------------- 
  PRESSURE PROFILE:      CONSTANT2    
  PRESSURE DROP:         0.0         BAR              
  PROPERTY OPTION SET:   UNIF-LL   UNIFAC / REDLICH-KWONG                       
 
----------------------------------------------------- 
!  DUTY      !  PRES      !  TEMP      !  VFRAC     ! 
!            !            !            !            ! 
!            !            !            !            ! 
!            !            !            !            ! 
!  CAL/SEC   !  BAR       !  C         !            ! 
!            !            !            !            ! 
!============!============!============!============! 
!     0.0    !     0.5000 !    25.0000 !     1.0000 ! 
!  3967.8059 !     0.5000 !    21.1608 ! DEW>1.0000 ! 
!  2.8121+04 !     0.5000 !    21.1608 !     0.9588 ! 
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!  5.6243+04 !     0.5000 !    21.1608 !     0.9109 ! 
!  8.4364+04 !     0.5000 !    21.1608 !     0.8629 ! 
!------------+------------+------------+------------! 
!  1.1249+05 !     0.5000 !    21.1608 !     0.8150 ! 
!  1.4061+05 !     0.5000 !    21.1608 !     0.7671 ! 
!  1.6873+05 !     0.5000 !    21.1608 !     0.7191 ! 
!  1.9685+05 !     0.5000 !    21.1608 !     0.6712 ! 
!  2.2497+05 !     0.5000 !    21.1608 !     0.6232 ! 
!------------+------------+------------+------------! 
!  2.5309+05 !     0.5000 !    21.1608 !     0.5753 ! 
!  2.8121+05 !     0.5000 !    21.1608 !     0.5274 ! 
!  3.0934+05 !     0.5000 !    21.1608 !     0.4794 ! 
!  3.3746+05 !     0.5000 !    21.1608 !     0.4315 ! 
!  3.6558+05 !     0.5000 !    21.1608 !     0.3835 ! 
!------------+------------+------------+------------! 
!  3.9370+05 !     0.5000 !    21.1608 !     0.3356 ! 
!  4.2182+05 !     0.5000 !    21.1608 !     0.2876 ! 
!  4.4994+05 !     0.5000 !    21.1608 !     0.2397 ! 
!  4.7807+05 !     0.5000 !    21.1608 !     0.1918 ! 
!  5.0619+05 !     0.5000 !    21.1608 !     0.1438 ! 
!------------+------------+------------+------------! 
!  5.3431+05 !     0.5000 !    21.1608 !  9.5882-02 ! 
!  5.6243+05 !     0.5000 !    21.1608 !  4.7941-02 ! 
!  5.9055+05 !     0.5000 !    21.1608 !     0.0    ! 
----------------------------------------------------- 
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Appendix I-6 Solvent Removal Distillation Column - Radfrac Block Report (V304) 
BLOCK:  VOLRED   MODEL: RADFRAC          
------------------------------- 
   INLETS   - DRYWASH  STAGE   1 
   OUTLETS  - SOLV     STAGE   1 
              CONC     STAGE   2 
  PROPERTY OPTION SET:   IDEAL     IDEAL LIQUID / IDEAL 
GAS                     
 
                     ***  MASS AND ENERGY BALANCE  *** 
                                   IN              OUT        RELATIVE DIFF. 
   TOTAL BALANCE 
      MOLE(KMOL/HR )            302.660         302.660        0.187812E-15 
      MASS(KG/HR   )            25633.6         25633.6        0.152100E-06 
      ENTHALPY(CAL/SEC )      -0.786110E+07   -0.786975E+07    0.109857E-02 
 
                     ***  CO2 EQUIVALENT SUMMARY *** 
   FEED STREAMS CO2E             23853.1      KG/HR            
   PRODUCT STREAMS CO2E          23853.2      KG/HR            
   NET STREAMS CO2E PRODUCTION  0.108865      KG/HR            
   UTILITIES CO2E PRODUCTION     0.00000      KG/HR            
   TOTAL CO2E PRODUCTION        0.108865      KG/HR            
 
 
 
                        ********************** 
                        ****  INPUT DATA  **** 
                        ********************** 
 
  ****   INPUT PARAMETERS   **** 
 
   NUMBER OF STAGES                                         2 
   ALGORITHM OPTION                                      STANDARD     
   ABSORBER OPTION                                       NO       
   INITIALIZATION OPTION                                 STANDARD     
   HYDRAULIC PARAMETER CALCULATIONS                      NO       
   INSIDE LOOP CONVERGENCE METHOD                        BROYDEN  
   DESIGN SPECIFICATION METHOD                           NESTED   
   MAXIMUM NO. OF OUTSIDE LOOP ITERATIONS                  25 
   MAXIMUM NO. OF INSIDE LOOP ITERATIONS                   10 
   MAXIMUM NUMBER OF FLASH ITERATIONS                      30 
   FLASH TOLERANCE                                          0.000100000 
   OUTSIDE LOOP CONVERGENCE TOLERANCE                       0.000100000 
 
  ****   COL-SPECS   **** 
 
   MOLAR VAPOR DIST / TOTAL DIST                            0.0         
   MOLAR REFLUX RATIO                                       3.00000     
   MASS BOTTOMS TO FEED RATIO                               0.085000    
 
  ****    PROFILES   **** 
 
   P-SPEC          STAGE   1  PRES, ATM                     0.15791     
 
                         ******************* 
                         ****  RESULTS  **** 
                         ******************* 
 
 
  ***   COMPONENT SPLIT FRACTIONS   *** 
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                            OUTLET STREAMS  
                            -------------- 
                 SOLV         CONC     
   COMPONENT: 
   L-ALA-01    .25001       .74999     
   ETHYL-01    .93884       .61157E-01 
   TETRA-01    .96139       .38613E-01 
   DICHL-01    .98454       .15460E-01 
 
 
  ***    SUMMARY OF KEY RESULTS    *** 
 
   TOP STAGE TEMPERATURE          K                       293.902       
   BOTTOM STAGE TEMPERATURE       K                       310.795       
   TOP STAGE LIQUID FLOW          KMOL/HR                 832.839       
   BOTTOM STAGE LIQUID FLOW       KMOL/HR                  25.0473      
   TOP STAGE VAPOR FLOW           KMOL/HR                   0.0         
   BOILUP VAPOR FLOW              KMOL/HR                 807.792       
   MOLAR REFLUX RATIO                                       3.00000     
   MOLAR BOILUP RATIO                                      32.2506      
   CONDENSER DUTY (W/O SUBCOOL)   CAL/SEC          -1,946,020.          
   REBOILER DUTY                  CAL/SEC           1,937,370.          
 
  ****   MAXIMUM FINAL RELATIVE ERRORS   **** 
 
   DEW POINT                       0.71594E-04  STAGE=  2 
   BUBBLE POINT                    0.31367E-05  STAGE=  2 
   COMPONENT MASS BALANCE          0.67813E-04  STAGE=  2 COMP=L-ALA-01 
   ENERGY BALANCE                  0.79773E-05  STAGE=  2 
 
 
  ****    PROFILES   **** 
 
  **NOTE** REPORTED VALUES FOR STAGE LIQUID AND VAPOR RATES ARE THE FLOWS 
           FROM THE STAGE INCLUDING ANY SIDE PRODUCT. 
 
                                         ENTHALPY 
STAGE TEMPERATURE   PRESSURE             CAL/MOL            HEAT DUTY 
      K             ATM            LIQUID       VAPOR        CAL/SEC  
 
  1   293.90       0.15791       -92288.      -62787.      -.19460+07 
  2   310.80       0.15791      -0.10822E+06  -83160.       .19374+07 
 
STAGE     FLOW RATE                  FEED RATE               PRODUCT RATE 
           KMOL/HR                    KMOL/HR                  KMOL/HR  
      LIQUID     VAPOR       LIQUID    VAPOR    MIXED      LIQUID    VAPOR 
  1  1110.      0.000       298.1608    4.4996             277.6131           
  2  25.05      807.8                                       25.0473           
 
   ****  MASS FLOW PROFILES  **** 
 
STAGE     FLOW RATE                  FEED RATE               PRODUCT RATE 
           KG/HR                      KG/HR                    KG/HR    
      LIQUID     VAPOR       LIQUID    VAPOR    MIXED      LIQUID    VAPOR 
  1 0.9382E+05  0.000      .25258+05  375.2479            .23455+05           
  2  2179.     0.6819E+05                                 2178.8540           
 
                        ****   MOLE-X-PROFILE     **** 
  STAGE     L-ALA-01      ETHYL-01      TETRA-01      DICHL-01 
     1    0.12214E-01   0.66905       0.20425       0.11448     
     2    0.40610       0.48305       0.90923E-01   0.19925E-01 
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                        ****   MOLE-Y-PROFILE     **** 
  STAGE     L-ALA-01      ETHYL-01      TETRA-01      DICHL-01 
     1    0.10430E-10   0.42076       0.22746       0.35178     
     2    0.38046E-09   0.67482       0.20776       0.11742     
 
                        ****   K-VALUES           **** 
  STAGE     L-ALA-01      ETHYL-01      TETRA-01      DICHL-01 
     1    0.85397E-09   0.62889        1.1137        3.0727     
     2    0.93671E-09    1.3970        2.2850        5.8927     
 
                        ****   MASS-X-PROFILE     **** 
  STAGE     L-ALA-01      ETHYL-01      TETRA-01      DICHL-01 
     1    0.12880E-01   0.69771       0.17432       0.11509     
     2    0.41592       0.48925       0.75368E-01   0.19454E-01 
 
                        ****   MASS-Y-PROFILE     **** 
  STAGE     L-ALA-01      ETHYL-01      TETRA-01      DICHL-01 
     1    0.11148E-10   0.44477       0.19678       0.35845     
     2    0.40158E-09   0.70437       0.17748       0.11814    
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Appendix J - Solubility from EMAJ-1 
 
 
 
Endnotes  
J-1: European Medicines Agency (2016). Committee for Medicinal Products for Human Use 
(CHMP) Assessment report: Epclusa EMA/399285/2016. Retrieved from 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Public_assessment_report/human/004210/WC500211152.pdf.  
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Appendix K - Molecule Costing Spreadsheet 
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Appendix L - Tabulated Data for Profitability Analysis 
Appendix L-1 Input Summary 
General Information               
 
Process Title: Sofosbuvir Production 
     
 
Product: Sofosbuvir 
      
 
Plant Site Location: India 
      
 
Site Factor: 1.00 
      
 
Operating Hours 
per Year: 2880 
      
 
Operating Day s 
Per Year: 120 
      
 
Operating Factor: 0.3288 
      
         
         
Product Information               
This Process will Yield 
       
  
122 kg of Sofosbuv ir per hour 
   
  
2,917 kg of Sofosbuv ir per day 
    
  
350,000 kg of Sofosbuv ir per y ear 
   
         
 
Price $3,000.00  /kg 
     
         
Chronology               
  
Distribution of Production  Sale Depreciation Product Price 
 
Year Action Permanent Investment Capacity Capacity 5 y ear MACRS  
 
0 Production 100% 100.0% 0.0% 20.00% $3,000.00   
1 Production 0% 100.0% 100.0% 32.00% $3,000.00   
2 Production 0% 100.0% 100.0% 19.20% $3,000.00   
3 Production 0% 100.0% 100.0% 11.52% $3,000.00   
4 Production 0% 100.0% 100.0% 11.52% $3,000.00   
5 Production 6% 100.0% 100.0% 5.76% $3,000.00   
6 Production 0% 100.0% 100.0% 
 
$3,000.00   
7 Production 0% 100.0% 100.0% 
 
$3,000.00   
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8 Production 0% 100.0% 100.0% 
 
$3,000.00   
9 Production 0% 100.0% 100.0% 
 
$3,000.00   
10 Production 0% 0.0% 100.0% 
 
$3,000.00   
                  
Equipment Costs               
         
Equipment Description 
     
Bare Module Cost 
         
Agitator 
  
Process Machinery 
  
$345,600 
 
Centrifugal Pumps 
 
Process Machinery 
  
$693,000 
 
Ethy lene Gly col Chiller 
 
Process Machinery 
  
$12,840 
 
Heat Ex changer 
 
Process Machinery 
  
$114,437 
 
100,000L Reaction Vessel Process Machinery 
  
$1,574,144 
 
Distillation Column 
 
Process Machinery 
  
$1,039,168 
 
85,000 L Reaction Vessel 
 
Process Machinery 
  
$1,482,624 
 
85,000L Reaction Vessel 
 
Process Machinery 
  
$741,312 
 
140,000L Reaction Vessel Process Machinery 
  
$1,847,872 
 
Flash Vessel 
 
Process Machinery 
  
$457,600 
 
400,000 L Wash Vessel 
 
Process Machinery 
  
$1,501,760 
 
Packed Bed Dry ing Vessel Process Machinery 
  
$299,936 
 
Condenser (Heat Ex changer) Process Machinery 
  
$213,975 
 
100,000L Runaway Reaction Vessel Process Machinery 
  
$1,574,144 
 
Brine Chiller 
 
Process Machinery 
  
$83,054 
 
Propane Chiller 
 
Process Machinery 
  
$100,172 
 
120,000L Reactor 
 
Process Machinery 
  
$804,960 
 
192,000L Wash Vessel 
 
Process Machinery 
  
$2,113,280 
 
Packed Bed Dry ing Vessel Process Machinery 
  
$200,096 
 
Distillation Column 
 
Process Machinery 
  
$572,832 
 
160,000L Mix ing Vessel 
 
Process Machinery 
  
$986,752 
 
Cry stallization Unit 
 
Process Machinery 
  
$1,545,000 
 
Dry ing Unit 
 
Process Machinery 
  
$35,638 
 
Belt Conv eyer 
 
Process Machinery 
  
$35,420 
 
Screw  Conveyer 
 
Process Machinery 
  
$94,800 
 
Sprinkler
s 
  
Other Equipment 
  
$516,810 
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Coolants 
  
Other Equipment 
  
$577,000 
 
         
Total 
      
$19,564,226 
 
         
Raw Materials               
 
Raw Material: Unit: Required Ratio: 
  
Cost of Raw Material: 
1 Materials 100 kg 1 kg per kg of Sofosbuv ir 
 
$34.710 per kg 
2 Materials 200 kg 1 kg per kg of Sofosbuv ir 
 
$81.91 per kg 
3 Materials 300 kg 1 kg per kg of Sofosbuv ir 
 
$982.50 per kg 
4 Sand kg 1 kg per kg of Sofosbuv ir 
 
$1.30 per kg 
5 Nitrogen kg 1 kg per kg of Sofosbuv ir 
 
$4.69 per kg 
6 Ribav irin kg 1 kg per kg of Sofosbuv ir 
 
$65.14 per kg 
 
Total Weighted Av erage:         $1170.250 per kg of Sofosbuv ir 
         
Byproducts               
 
Byproduct: Unit: Ratio to Product 
  
Byproduct Selling Price 
 
Total Weighted Av erage: 
    
$0.00 per kg of Sofosbuv ir 
         
Utilities                 
 
Utility: Unit: Required Ratio 
  
Utility Cost 
 
1 Heating unit 1 unit per kg of Sofosbuv ir 
 
$1.950 per unit 
2 Cooling unit 1 unit per kg of Sofosbuv ir 
 
$4.890 per unit 
3 Transport unit 1 unit per kg of Sofosbuv ir 
 
$9.000E-04 per unit 
4 Stirring unit 1 unit per kg of Sofosbuv ir 
 
$0.020 per unit 
5 Waste Disposal unit 1 unit per kg of Sofosbuv ir 
 
$17.640 per unit 
6 Leasing Costs unit 1 unit per kg of Sofosbuv ir 
 
$0.456 per unit 
7 Formulation unit 1 unit per kg of Sofosbuv ir 
 
$239.04 per unit 
 
Total Weighted Av erage:         $263.999 per kg of Sofosbuv ir 
         
Variable Costs               
 
General Expenses: 
      
   
Selling / Transfer 
Ex penses: 3.00% 
 
of Sales 
  
   
Direct Research: 0.00% 
 
of Sales 
  
   
Allocated Research: 0.00% 
 
of Sales 
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Administrativ e 
Ex pense: 2.00% 
 
of Sales 
  
   
Management Incentiv e 
Compensation: 1.25% 
 
of Sales 
  
         
Working Capital               
         
 
Accounts Receivable  30 
 
Days 
  
 
Cash Reserves (excluding Raw 
Materials)  30 
 
Days 
  
 
Accounts Pay able  30 
 
Days 
  
 
Sofosbuv ir Inventory  4 
 
Days 
  
 
Raw  Materials  2 
 
Days 
  
         
         
Total Permanent Investment             
         
   
Cost of Site 
Preparations: 5.00% 
 
of Total Bare Module Costs 
   
Cost of Serv ice 
Facilities: 5.00% 
 
of Total Bare Module Costs 
   
Allocated Costs for 
utility  plants and related 
facilities: $0  
    
   
Cost of Contingencies 
and Contractor Fees: 18.00% 
 
of Direct Permanent Investment 
   
Cost of Land: 2.00% 
 
of Total Depreciable Capital 
   
Cost of Roy alties: $0  
    
   
Cost of Plant Start-Up: 2.00% 
 
of Total Depreciable Capital 
         
         
Fixed Costs               
 
Operations 
       
   
Operators per Shift: 4 
 
(assuming 1 shifts) 
 
   
Direct Wages and 
Benefits: $34  
 
/operator hour 
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Direct Salaries and 
Benefits: 15% 
 
of Direct Wages and Benefits 
   
Operating Supplies and 
Serv ices: 6% 
 
of Direct Wages and Benefits 
   
Technical Assistance to 
Manufacturing: $0.00 
 
per year, for each Operator per Shift 
   
Control Laboratory : $0.00 
 
per year, for each Operator per Shift 
         
 
Maintenance 
      
   
Wages and Benefits: 4.50% 
 
of Total Depreciable Capital 
   
Salaries and Benefits: 25% 
 
of Maintenance Wages and Benefits 
   
Materials and Serv ices: 100% 
 
of Maintenance Wages and Benefits 
   
Maintenance Ov erhead: 5% 
 
of Maintenance Wages and Benefits 
         
 
Operating Overhead 
      
         
   
General Plant 
Ov erhead: 7.10% 
 
of Maintenance and Operations Wages and Benefits 
   
Mechanical Department 
Serv ices: 2.40% 
 
of Maintenance and Operations Wages and Benefits 
   
Employ ee Relations 
Department: 5.90% 
 
of Maintenance and Operations Wages and Benefits 
   
Business Services: 7.40% 
 
of Maintenance and Operations Wages and Benefits 
         
         
 
Property Taxes and Insurance 
     
   
Property  Taxes and 
Insurance: 2% 
 
of Total Depreciable Capital 
         
 
Straight Line Depreciation 
      
 
Direct Plant: 8.00% of Total Depreciable Capital, less 1.18 times the Allocated Costs  
 
      
for Utility Plants and Related Facilities 
 
Allocated Plant: 6.00% of 1.18 times the Allocated Costs for Utility Plants and Related Facilities 
         
 
Other Annual Expenses 
      
   
Rental Fees (Office and 
Laboratory  Space): $0 
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Licensing Fees: $0 
    
   
Miscellaneous: $0 
    
         
 
Depletion Allowance 
      
   
Annual Depletion 
Allow ance: $0 
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Appendix L-2 Cost Summary 
 
Variable Cost Summary               
 
Variable Costs at 100% Capacity: 
     
         
 
General Expenses 
      
         
  
Selling / Transfer Ex penses: 
  
 $31,500,000  
  
  
Direct Research: 
  
 $-  
  
  
Allocated Research: 
  
 $-  
  
  
Administrativ e Expense: 
  
 $21,000,000  
  
  
Management Incentiv e Compensation: 
 
 $13,125,000  
  
         
 
Total General Expenses 
   
 $65,625,000  
  
         
 
Raw Materials $1,170.25 per kg of Sofosbuv ir $409,587,493  
  
         
 
Byproducts 
 
$0.00 per kg of Sofosbuv ir $0  
  
         
 
Utilities 
 
$264.00 per kg of Sofosbuv ir $92,399,577  
  
         
 
Total Variable Costs 
   
 $567,612,070  
  
         
Fixed Cost Summary               
         
         
 
Operations 
       
         
  
Direct Wages and Benefits 
  
 $281,500  
  
  
Direct Salaries and Benefits 
  
 $42,225  
  
  
Operating Supplies and Serv ices 
  
 $16,890  
  
  
Technical Assistance to Manufacturing 
 
 $-    
  
  
Control Laboratory  
  
 $-    
  
         
  
Total Operations 
  
 $340,615  
  
         
 
Maintenance 
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Wages and Benefits 
  
 $1,142,746  
  
  
Salaries and Benefits 
  
 $285,687  
  
  
Materials and Serv ices 
  
 $1,142,746  
  
  
Maintenance Ov erhead 
  
 $57,137  
  
         
  
Total Maintenance 
  
 $2,628,317  
  
         
 
Operating Overhead 
      
         
  
General Plant Ov erhead: 
  
 $124,403  
  
  
Mechanical Department Services: 
  
 $42,052  
  
  
Employ ee Relations Department: 
  
 $103,377  
  
  
Business Services: 
  
 $129,660  
  
         
  
Total Operating Overhead 
  
 $399,492  
  
         
 
Property Taxes and Insurance 
     
         
  
Property  Taxes and Insurance: 
  
 $507,887  
  
         
 
Other Annual Expenses 
      
         
  
Rental Fees (Office and Laboratory  Space): 
 
 $-    
  
  
Licensing Fees: 
  
 $-    
  
  
Miscellaneous: 
  
 $-    
  
         
  
Total Other Annual Expenses 
  
 $-    
  
         
 
Total Fixed Costs 
   
 $3,876,311  
  
         
Investment Summary               
         
Total Bare Module Costs: 
       
 
Fabricated Equipment 
   
 $-    
  
 
Process Machinery 
   
 $18,470,416  
  
 
Spares 
    
 $-    
  
 
Storage 
    
 $-    
  
 
Other Equipment 
   
 $1,093,810  
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Catalysts 
    
 $-    
  
 
Computers, Software, Etc. 
   
 $-    
  
         
 
Total Bare Module Costs: 
    
 $19,564,226  
 
         
Direct Permanent Investment 
      
         
 
Cost of Site Preparations: 
   
 $978,211  
  
 
Cost of Service Facilities: 
   
 $978,211  
  
 
Allocated Costs for utility plants and related facilities: 
 
 $-    
  
         
 
Direct Permanent Investment 
   
 $21,520,649  
 
         
         
Total Depreciable Capital 
       
         
 
Cost of Contingencies & Contractor Fees 
  
 $3,873,717  
  
         
         
 
Total Depreciable Capital 
    
 $25,394,365  
 
         
Total Permanent Investment 
      
         
 
Cost of Land: 
   
 $507,887  
  
 
Cost of Royalties: 
   
 $-    
  
 
Cost of Plant Start-Up: 
   
 $507,887  
  
         
 
Total Permanent Investment - Unadjusted 
   
 $26,410,140  
 
 
Site Factor 
     
1.00 
 
 
Total Permanent Investment 
   
 $26,410,140  
 
         
         
Working Capital               
         
      
-1 0 1 
   
Accounts Receivable 
  
 $86,301,370   $-     $-    
   
Cash Reserves 
  
 $7,913,087   $-     $-    
   
Accounts Pay able 
  
 $(41,259,211)  $-     $-    
   
Sofosbuv ir Inventory 
  
 $11,506,849   $-     $-    
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Raw  Materials 
  
 $2,244,315   $-     $-    
   
Total 
  
 $66,706,410   $-     $-    
         
   
Present Value at 15% 
  
 $76,712,371   $-     $-    
         
 
Total Capital Investment 
    
 $103,122,511  
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Appendix L-3 Sensitivity Tables 
Table L-1 Sensitivity of IRR and NPV to Sofosbuvir Sale Price 
 
Sofosbuvir price/kg IRR NPV 
$1,500  -2.90% ($343MM) 
$1,800  13.5% ($30MM) 
$2,100  28.5% $283MM 
$2,400  42.5% $596MM 
$2,700  55.5% $908MM 
$3,000  67.7% $1,221MM 
$3,300  79.2% $1,534MM 
$3,600  90.0% $1,847MM 
$3,900  100% $2,160MM 
$4,200  110% $2,473MM 
$4,500  119% $2,785MM 
 
Table L-2 Sensitivity of IRR and NPV to Sofosbuvir Production Schedule 
Sofosbuvir Production Schedule IRR NPV 
High 66.9% $1,884MM 
Base 67.7% $1,222MM 
Low 64.6% $947MM 
 
 
Table L-3 Sensitivity of IRR and NPV to Methyluridine Purchase Price  
Methyluridine price/kg IRR NPV 
$100 206%  $2,505MM  
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$200 178%  $2,342MM  
$300 154%  $2,179MM  
$400 134%  $2,016MM  
$500 117%  $1,853MM  
$600 102%  $1,690MM  
$700 88.5%  $1,527MM  
$800 76.9%  $1,365MM  
$888 67.7% $1,222MM 
$900 66.5%  $1,202MM  
$1,000 57.2%  $1,039MM  
$1,100 48.9%  $877MM  
$1,200 41.3%  $714MM  
$1,300 34.4%  $551MM  
$1,400 28.1%  $388MM  
$1,500 22.3%  $225MM  
$1,600 16.9%  $62MM  
$1,700 12.0%  ($100MM) 
 
Table L-4 Sensitivity of IRR and NPV to Solvent Waste Disposal Cost  
Solvent Disposal IRR NPV 
With Organic Solvent Resale 67.7% $1,221  
Without Organic Solvent Resale 61.5% $1,118  
 
Table L-5 IRR and NPV with and without Runaway Reaction 
Batch Interruption IRR NPV 
Without 67.7% $1,221 MM  
With 67.5% $1,216 MM  
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Appendix M - MSDS Sheets 
Appendix M-1 MSDS of Starting Materials 
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Appendix M-2 MSDS of Solvents, Catalysts, and Wash Salts 
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Appendix N - Waste Disposal Costs 
Appendix N-1 Solvent Waste Costs 
Solvent Process Contaminants Purity 
Quantity 
per batch 
(L) 
Quantity 
per batch 
(gal) 
Cost 
($/gal) 
Waste Cost 
per batch 
IPA 100 
Thionyl chloride, L-
alanine, HCl, L-alanine 
isopropyl ester 
95% 130,000 34,342 $1.60  $54,948  
DCM 200 
DIEA, phenyl 
dichlorophosphate, L-
alanine isopropyl ester, 2-
chloro-6-hydroxypyridine 
92% 170,000 44,909 $1.60  $71,855  
Sodium 
Sulfate 
200 
DIEA, phenyl 
dichlorophosphate, L-
alanine isopropyl ester, 2-
chloro-6-hydroxypyridine 
99% 8* 8* $100*  $800  
Water 200 
DIEA, phenyl 
dichlorophosphate, L-
alanine isopropyl ester, 2-
chloro-6-hydroxypyridine 
90% 200,000 52,834 $0.55  $29,059  
THF 300 
A1, DIEA, Zinc Chloride, 
Methyluridine 
82-90% 60,000 15,850 $1.60  $25,361  
Ethyl 
Acetate 
300 
THF, A1, DIEA, Zinc 
Chloride, Methyluridine 
90-95% 110,000 29,059 $1.60  $46,494  
DCM 300 Acetone 85% 63,000 16,643 $1.60  $26,629  
Sodium 
Sulfate 
300 HCl, Buffer Solution, 
Sodium Carbonate, NH4Cl 
99% 8.7* 8.7* $100*  $870  
Water 300 
HCl, Buffer Solution, 
Sodium Carbonate, NH4Cl 
90% 225,000 59,439 $0.55  $32,691  
Cost of disposal of only 
organic solvents  $61,750 
Cost of disposal of only 
organic solvents 
 ($226,956) 
Paid disposal of all 
solvents  
 ($288,706) 
Disposal of 
contaminated 5%  of 
organics 
 ($11,348) 
*Quantities for Sodium Sulfate are reported in yd3, and Costs for Sodium Sulfate are reported in $/yd3, as per the 
figures provided by the industrial consultants. 
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Appendix N-2 Organic Solvent Resale Values 
Solvent Process Contaminants Purity Quantity per 
Batch (L) 
Resale Value 
($/kg) 
Resale Value 
per batch 
IPA 100 Thionyl chloride, L-alanine, 
HCl, L-alanine isopropyl ester 
95%  130,000  $0.05 $4,630  
DCM 200 
DIEA, phenyl 
dichlorophosphate, L-alanine 
isopropyl ester, 2-chloro-6-
hydroxypyridine 
92%  170,000  $0.02 $4,805  
THF 300 
A1, DIEA, Zinc Chloride, 
Methyluridine 
82-90%  60,000  $0.09 $4,534  
Ethyl 
Acetate 
300 THF, A1, DIEA, Zinc 
Chloride, Methyluridine 
90-95%  110,000  $0.02 $1,480  
DCM 300 Acetone 85%  63,000  0.02 $178  
Total Resale Value  $15,627 
Resale Value of 
95%  Pure Solvents 
 $14,845 
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